#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Neurofunctional Differences Related to Methamphetamine and Sexual Cues in Men With Shorter and Longer Term Abstinence Methamphetamine Dependence
#Text=Abstract
#Text=Background
#Text=Stimulant use and sexual behaviors have been linked in behavioral and epidemiological studies.
1-1	0-15	Neurofunctional	_
1-2	16-27	Differences	_
1-3	28-35	Related	_
1-4	36-38	to	_
1-5	39-54	Methamphetamine	_
1-6	55-58	and	_
1-7	59-65	Sexual	_
1-8	66-70	Cues	_
1-9	71-73	in	_
1-10	74-77	Men	_
1-11	78-82	With	_
1-12	83-90	Shorter	_
1-13	91-94	and	_
1-14	95-101	Longer	_
1-15	102-106	Term	_
1-16	107-117	Abstinence	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[1]
1-17	118-133	Methamphetamine	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[1]
1-18	134-144	Dependence	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[1]
1-19	145-153	Abstract	_
1-20	154-164	Background	_
1-21	165-174	Stimulant	_
1-22	175-178	use	_
1-23	179-182	and	_
1-24	183-189	sexual	_
1-25	190-199	behaviors	_
1-26	200-204	have	_
1-27	205-209	been	_
1-28	210-216	linked	_
1-29	217-219	in	_
1-30	220-230	behavioral	_
1-31	231-234	and	_
1-32	235-250	epidemiological	_
1-33	251-258	studies	_
1-34	258-259	.	_

#Text=Although methamphetamine-related neurofunctional differences have been investigated, few studies have examined neural responses to drug and sexual cues with respect to shorter or longer term methamphetamine abstinence in individuals with methamphetamine dependence.
2-1	260-268	Although	_
2-2	269-292	methamphetamine-related	_
2-3	293-308	neurofunctional	_
2-4	309-320	differences	_
2-5	321-325	have	_
2-6	326-330	been	_
2-7	331-343	investigated	_
2-8	343-344	,	_
2-9	345-348	few	_
2-10	349-356	studies	_
2-11	357-361	have	_
2-12	362-370	examined	_
2-13	371-377	neural	_
2-14	378-387	responses	_
2-15	388-390	to	_
2-16	391-395	drug	_
2-17	396-399	and	_
2-18	400-406	sexual	_
2-19	407-411	cues	_
2-20	412-416	with	_
2-21	417-424	respect	_
2-22	425-427	to	_
2-23	428-435	shorter	_
2-24	436-438	or	_
2-25	439-445	longer	_
2-26	446-450	term	_
2-27	451-466	methamphetamine	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[2]
2-28	467-477	abstinence	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[2]
2-29	478-480	in	_
2-30	481-492	individuals	_
2-31	493-497	with	_
2-32	498-513	methamphetamine	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[3]
2-33	514-524	dependence	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[3]
2-34	524-525	.	_

#Text=Methods
#Text=Forty-nine men with shorter term methamphetamine abstinence, 50 men with longer term methamphetamine abstinence, and 47 non–drug-using healthy comparison men completed a functional magnetic resonance imaging cue-reactivity task consisting of methamphetamine, sexual, and neutral visual cues.
3-1	526-533	Methods	_
3-2	534-544	Forty-nine	_
3-3	545-548	men	_
3-4	549-553	with	_
3-5	554-561	shorter	_
3-6	562-566	term	_
3-7	567-582	methamphetamine	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[4]
3-8	583-593	abstinence	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[4]
3-9	593-594	,	_
3-10	595-597	50	_
3-11	598-601	men	_
3-12	602-606	with	_
3-13	607-613	longer	_
3-14	614-618	term	_
3-15	619-634	methamphetamine	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[5]
3-16	635-645	abstinence	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[5]
3-17	645-646	,	_
3-18	647-650	and	_
3-19	651-653	47	_
3-20	654-668	non–drug-using	_
3-21	669-676	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[6]
3-22	677-687	comparison	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[6]
3-23	688-691	men	_
3-24	692-701	completed	_
3-25	702-703	a	_
3-26	704-714	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[7]
3-27	715-723	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[7]
3-28	724-733	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[7]
3-29	734-741	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[7]
3-30	742-756	cue-reactivity	_
3-31	757-761	task	_
3-32	762-772	consisting	_
3-33	773-775	of	_
3-34	776-791	methamphetamine	_
3-35	791-792	,	_
3-36	793-799	sexual	_
3-37	799-800	,	_
3-38	801-804	and	_
3-39	805-812	neutral	_
3-40	813-819	visual	_
3-41	820-824	cues	_
3-42	824-825	.	_

#Text=Results
#Text=Region-of-interest analyses revealed greater methamphetamine cue–related activation in shorter term methamphetamine abstinence and longer term methamphetamine abstinence individuals relative to healthy comparison men in the ventromedial prefrontal cortex.
4-1	826-833	Results	_
4-2	834-852	Region-of-interest	_
4-3	853-861	analyses	_
4-4	862-870	revealed	_
4-5	871-878	greater	_
4-6	879-894	methamphetamine	_
4-7	895-906	cue–related	_
4-8	907-917	activation	_
4-9	918-920	in	_
4-10	921-928	shorter	_
4-11	929-933	term	_
4-12	934-949	methamphetamine	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[8]
4-13	950-960	abstinence	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[8]
4-14	961-964	and	_
4-15	965-971	longer	_
4-16	972-976	term	_
4-17	977-992	methamphetamine	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[9]
4-18	993-1003	abstinence	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[9]
4-19	1004-1015	individuals	_
4-20	1016-1024	relative	_
4-21	1025-1027	to	_
4-22	1028-1035	healthy	_
4-23	1036-1046	comparison	_
4-24	1047-1050	men	_
4-25	1051-1053	in	_
4-26	1054-1057	the	_
4-27	1058-1070	ventromedial	_
4-28	1071-1081	prefrontal	_
4-29	1082-1088	cortex	_
4-30	1088-1089	.	_

#Text=A significant interaction of group and condition in the anterior insula was found.
5-1	1090-1091	A	_
5-2	1092-1103	significant	_
5-3	1104-1115	interaction	_
5-4	1116-1118	of	_
5-5	1119-1124	group	_
5-6	1125-1128	and	_
5-7	1129-1138	condition	_
5-8	1139-1141	in	_
5-9	1142-1145	the	_
5-10	1146-1154	anterior	_
5-11	1155-1161	insula	_
5-12	1162-1165	was	_
5-13	1166-1171	found	_
5-14	1171-1172	.	_

#Text=Relative to healthy comparison participants, both shorter term methamphetamine abstinence and longer term methamphetamine abstinence groups displayed greater sexual cue–related anterior insula activation relative to methamphetamine cues and neutral cues, but there were no differences between shorter term methamphetamine abstinence and longer term methamphetamine abstinence groups in anterior insula responses.
6-1	1173-1181	Relative	_
6-2	1182-1184	to	_
6-3	1185-1192	healthy	_
6-4	1193-1203	comparison	_
6-5	1204-1216	participants	_
6-6	1216-1217	,	_
6-7	1218-1222	both	_
6-8	1223-1230	shorter	_
6-9	1231-1235	term	_
6-10	1236-1251	methamphetamine	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[10]
6-11	1252-1262	abstinence	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[10]
6-12	1263-1266	and	_
6-13	1267-1273	longer	_
6-14	1274-1278	term	_
6-15	1279-1294	methamphetamine	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[11]
6-16	1295-1305	abstinence	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[11]
6-17	1306-1312	groups	_
6-18	1313-1322	displayed	_
6-19	1323-1330	greater	_
6-20	1331-1337	sexual	_
6-21	1338-1349	cue–related	_
6-22	1350-1358	anterior	_
6-23	1359-1365	insula	_
6-24	1366-1376	activation	_
6-25	1377-1385	relative	_
6-26	1386-1388	to	_
6-27	1389-1404	methamphetamine	_
6-28	1405-1409	cues	_
6-29	1410-1413	and	_
6-30	1414-1421	neutral	_
6-31	1422-1426	cues	_
6-32	1426-1427	,	_
6-33	1428-1431	but	_
6-34	1432-1437	there	_
6-35	1438-1442	were	_
6-36	1443-1445	no	_
6-37	1446-1457	differences	_
6-38	1458-1465	between	_
6-39	1466-1473	shorter	_
6-40	1474-1478	term	_
6-41	1479-1494	methamphetamine	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[12]
6-42	1495-1505	abstinence	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[12]
6-43	1506-1509	and	_
6-44	1510-1516	longer	_
6-45	1517-1521	term	_
6-46	1522-1537	methamphetamine	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[13]
6-47	1538-1548	abstinence	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[13]
6-48	1549-1555	groups	_
6-49	1556-1558	in	_
6-50	1559-1567	anterior	_
6-51	1568-1574	insula	_
6-52	1575-1584	responses	_
6-53	1584-1585	.	_

#Text=Subsequent whole-brain analyses indicated a group-by-condition interaction with longer term methamphetamine abstinence participants showing greater sexual-related activation in the left superior frontal cortex relative to healthy comparison men.
7-1	1586-1596	Subsequent	_
7-2	1597-1608	whole-brain	_
7-3	1609-1617	analyses	_
7-4	1618-1627	indicated	_
7-5	1628-1629	a	_
7-6	1630-1648	group-by-condition	_
7-7	1649-1660	interaction	_
7-8	1661-1665	with	_
7-9	1666-1672	longer	_
7-10	1673-1677	term	_
7-11	1678-1693	methamphetamine	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[14]
7-12	1694-1704	abstinence	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[14]
7-13	1705-1717	participants	_
7-14	1718-1725	showing	_
7-15	1726-1733	greater	_
7-16	1734-1748	sexual-related	_
7-17	1749-1759	activation	_
7-18	1760-1762	in	_
7-19	1763-1766	the	_
7-20	1767-1771	left	_
7-21	1772-1780	superior	_
7-22	1781-1788	frontal	_
7-23	1789-1795	cortex	_
7-24	1796-1804	relative	_
7-25	1805-1807	to	_
7-26	1808-1815	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[15]
7-27	1816-1826	comparison	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[15]
7-28	1827-1830	men	_
7-29	1830-1831	.	_

#Text=Shorter term methamphetamine abstinence participants showed greater superior frontal cortex activation to sexual relative to neutral cues, and longer term methamphetamine abstinence participants showed greater superior frontal cortex activation to sexual relative to neutral and methamphetamine cues.
8-1	1832-1839	Shorter	_
8-2	1840-1844	term	_
8-3	1845-1860	methamphetamine	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[16]
8-4	1861-1871	abstinence	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[16]
8-5	1872-1884	participants	_
8-6	1885-1891	showed	_
8-7	1892-1899	greater	_
8-8	1900-1908	superior	_
8-9	1909-1916	frontal	_
8-10	1917-1923	cortex	_
8-11	1924-1934	activation	_
8-12	1935-1937	to	_
8-13	1938-1944	sexual	_
8-14	1945-1953	relative	_
8-15	1954-1956	to	_
8-16	1957-1964	neutral	_
8-17	1965-1969	cues	_
8-18	1969-1970	,	_
8-19	1971-1974	and	_
8-20	1975-1981	longer	_
8-21	1982-1986	term	_
8-22	1987-2002	methamphetamine	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[17]
8-23	2003-2013	abstinence	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[17]
8-24	2014-2026	participants	_
8-25	2027-2033	showed	_
8-26	2034-2041	greater	_
8-27	2042-2050	superior	_
8-28	2051-2058	frontal	_
8-29	2059-2065	cortex	_
8-30	2066-2076	activation	_
8-31	2077-2079	to	_
8-32	2080-2086	sexual	_
8-33	2087-2095	relative	_
8-34	2096-2098	to	_
8-35	2099-2106	neutral	_
8-36	2107-2110	and	_
8-37	2111-2126	methamphetamine	_
8-38	2127-2131	cues	_
8-39	2131-2132	.	_

#Text=Conclusions
#Text=The findings suggest that abstinence from methamphetamine may alter how individuals respond to drug and sexual cues and thus may influence drug use and sexual behaviors.
9-1	2133-2144	Conclusions	_
9-2	2145-2148	The	_
9-3	2149-2157	findings	_
9-4	2158-2165	suggest	_
9-5	2166-2170	that	_
9-6	2171-2181	abstinence	_
9-7	2182-2186	from	_
9-8	2187-2202	methamphetamine	_
9-9	2203-2206	may	_
9-10	2207-2212	alter	_
9-11	2213-2216	how	_
9-12	2217-2228	individuals	_
9-13	2229-2236	respond	_
9-14	2237-2239	to	_
9-15	2240-2244	drug	_
9-16	2245-2248	and	_
9-17	2249-2255	sexual	_
9-18	2256-2260	cues	_
9-19	2261-2264	and	_
9-20	2265-2269	thus	_
9-21	2270-2273	may	_
9-22	2274-2283	influence	_
9-23	2284-2288	drug	_
9-24	2289-2292	use	_
9-25	2293-2296	and	_
9-26	2297-2303	sexual	_
9-27	2304-2313	behaviors	_
9-28	2313-2314	.	_

#Text=Given the use of methamphetamine for sexual purposes and responses to natural vs drug rewards for addiction recovery, the findings may have particular clinical relevance.
10-1	2315-2320	Given	_
10-2	2321-2324	the	_
10-3	2325-2328	use	_
10-4	2329-2331	of	_
10-5	2332-2347	methamphetamine	_
10-6	2348-2351	for	_
10-7	2352-2358	sexual	_
10-8	2359-2367	purposes	_
10-9	2368-2371	and	_
10-10	2372-2381	responses	_
10-11	2382-2384	to	_
10-12	2385-2392	natural	_
10-13	2393-2395	vs	_
10-14	2396-2400	drug	_
10-15	2401-2408	rewards	_
10-16	2409-2412	for	_
10-17	2413-2422	addiction	_
10-18	2423-2431	recovery	_
10-19	2431-2432	,	_
10-20	2433-2436	the	_
10-21	2437-2445	findings	_
10-22	2446-2449	may	_
10-23	2450-2454	have	_
10-24	2455-2465	particular	_
10-25	2466-2474	clinical	_
10-26	2475-2484	relevance	_
10-27	2484-2485	.	_

#Text=Significance Statement
#Text=Methamphetamine use and sexual behaviors are related, but neural responses to drug and sexual cues with respect to shorter or longer term methamphetamine abstinence in individuals with methamphetamine dependence are unclear.
11-1	2486-2498	Significance	_
11-2	2499-2508	Statement	_
11-3	2509-2524	Methamphetamine	_
11-4	2525-2528	use	_
11-5	2529-2532	and	_
11-6	2533-2539	sexual	_
11-7	2540-2549	behaviors	_
11-8	2550-2553	are	_
11-9	2554-2561	related	_
11-10	2561-2562	,	_
11-11	2563-2566	but	_
11-12	2567-2573	neural	_
11-13	2574-2583	responses	_
11-14	2584-2586	to	_
11-15	2587-2591	drug	_
11-16	2592-2595	and	_
11-17	2596-2602	sexual	_
11-18	2603-2607	cues	_
11-19	2608-2612	with	_
11-20	2613-2620	respect	_
11-21	2621-2623	to	_
11-22	2624-2631	shorter	_
11-23	2632-2634	or	_
11-24	2635-2641	longer	_
11-25	2642-2646	term	_
11-26	2647-2662	methamphetamine	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[18]
11-27	2663-2673	abstinence	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[18]
11-28	2674-2676	in	_
11-29	2677-2688	individuals	_
11-30	2689-2693	with	_
11-31	2694-2709	methamphetamine	_
11-32	2710-2720	dependence	_
11-33	2721-2724	are	_
11-34	2725-2732	unclear	_
11-35	2732-2733	.	_

#Text=Relatively greater methamphetamine cue–related activation in the ventromedial prefrontal cortex was found in men with shorter and longer term methamphetamine abstinence compared with healthy comparison men.
12-1	2734-2744	Relatively	_
12-2	2745-2752	greater	_
12-3	2753-2768	methamphetamine	_
12-4	2769-2780	cue–related	_
12-5	2781-2791	activation	_
12-6	2792-2794	in	_
12-7	2795-2798	the	_
12-8	2799-2811	ventromedial	_
12-9	2812-2822	prefrontal	_
12-10	2823-2829	cortex	_
12-11	2830-2833	was	_
12-12	2834-2839	found	_
12-13	2840-2842	in	_
12-14	2843-2846	men	_
12-15	2847-2851	with	_
12-16	2852-2859	shorter	_
12-17	2860-2863	and	_
12-18	2864-2870	longer	_
12-19	2871-2875	term	_
12-20	2876-2891	methamphetamine	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[19]
12-21	2892-2902	abstinence	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[19]
12-22	2903-2911	compared	_
12-23	2912-2916	with	_
12-24	2917-2924	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[20]
12-25	2925-2935	comparison	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[20]
12-26	2936-2939	men	_
12-27	2939-2940	.	_

#Text=Greater sexual cue–related anterior insula activation relative to methamphetamine cues and neutral cues was found in men with shorter and longer term methamphetamine abstinence compared with healthy comparison men.
13-1	2941-2948	Greater	_
13-2	2949-2955	sexual	_
13-3	2956-2967	cue–related	_
13-4	2968-2976	anterior	_
13-5	2977-2983	insula	_
13-6	2984-2994	activation	_
13-7	2995-3003	relative	_
13-8	3004-3006	to	_
13-9	3007-3022	methamphetamine	_
13-10	3023-3027	cues	_
13-11	3028-3031	and	_
13-12	3032-3039	neutral	_
13-13	3040-3044	cues	_
13-14	3045-3048	was	_
13-15	3049-3054	found	_
13-16	3055-3057	in	_
13-17	3058-3061	men	_
13-18	3062-3066	with	_
13-19	3067-3074	shorter	_
13-20	3075-3078	and	_
13-21	3079-3085	longer	_
13-22	3086-3090	term	_
13-23	3091-3106	methamphetamine	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[21]
13-24	3107-3117	abstinence	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[21]
13-25	3118-3126	compared	_
13-26	3127-3131	with	_
13-27	3132-3139	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[22]
13-28	3140-3150	comparison	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[22]
13-29	3151-3154	men	_
13-30	3154-3155	.	_

#Text=Relatively greater sexual cue–related activation in the left superior frontal cortex was also found in men with longer term methamphetamine abstinence compared with healthy comparison men.
14-1	3156-3166	Relatively	_
14-2	3167-3174	greater	_
14-3	3175-3181	sexual	_
14-4	3182-3193	cue–related	_
14-5	3194-3204	activation	_
14-6	3205-3207	in	_
14-7	3208-3211	the	_
14-8	3212-3216	left	_
14-9	3217-3225	superior	_
14-10	3226-3233	frontal	_
14-11	3234-3240	cortex	_
14-12	3241-3244	was	_
14-13	3245-3249	also	_
14-14	3250-3255	found	_
14-15	3256-3258	in	_
14-16	3259-3262	men	_
14-17	3263-3267	with	_
14-18	3268-3274	longer	_
14-19	3275-3279	term	_
14-20	3280-3295	methamphetamine	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[23]
14-21	3296-3306	abstinence	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[23]
14-22	3307-3315	compared	_
14-23	3316-3320	with	_
14-24	3321-3328	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[24]
14-25	3329-3339	comparison	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[24]
14-26	3340-3343	men	_
14-27	3343-3344	.	_

#Text=Abstinence from methamphetamine may alter how individuals respond to drug and sexual cues and may thus influence drug use and sexual behaviors.
15-1	3345-3355	Abstinence	_
15-2	3356-3360	from	_
15-3	3361-3376	methamphetamine	_
15-4	3377-3380	may	_
15-5	3381-3386	alter	_
15-6	3387-3390	how	_
15-7	3391-3402	individuals	_
15-8	3403-3410	respond	_
15-9	3411-3413	to	_
15-10	3414-3418	drug	_
15-11	3419-3422	and	_
15-12	3423-3429	sexual	_
15-13	3430-3434	cues	_
15-14	3435-3438	and	_
15-15	3439-3442	may	_
15-16	3443-3447	thus	_
15-17	3448-3457	influence	_
15-18	3458-3462	drug	_
15-19	3463-3466	use	_
15-20	3467-3470	and	_
15-21	3471-3477	sexual	_
15-22	3478-3487	behaviors	_
15-23	3487-3488	.	_

#Text=Introduction
#Text=Methamphetamine is a psychostimulant that is widely abused and linked to serious public health problems globally.
16-1	3489-3501	Introduction	_
16-2	3502-3517	Methamphetamine	_
16-3	3518-3520	is	_
16-4	3521-3522	a	_
16-5	3523-3538	psychostimulant	_
16-6	3539-3543	that	_
16-7	3544-3546	is	_
16-8	3547-3553	widely	_
16-9	3554-3560	abused	_
16-10	3561-3564	and	_
16-11	3565-3571	linked	_
16-12	3572-3574	to	_
16-13	3575-3582	serious	_
16-14	3583-3589	public	_
16-15	3590-3596	health	_
16-16	3597-3605	problems	_
16-17	3606-3614	globally	_
16-18	3614-3615	.	_

#Text=Methamphetamine use has been associated with sexual activity, as methamphetamine may enhance sexual self-confidence, diminish sexual inhibitions, and increase sexual desire, arousal, and pleasure and delay orgasm both in humans and animal models.
17-1	3616-3631	Methamphetamine	_
17-2	3632-3635	use	_
17-3	3636-3639	has	_
17-4	3640-3644	been	_
17-5	3645-3655	associated	_
17-6	3656-3660	with	_
17-7	3661-3667	sexual	_
17-8	3668-3676	activity	_
17-9	3676-3677	,	_
17-10	3678-3680	as	_
17-11	3681-3696	methamphetamine	_
17-12	3697-3700	may	_
17-13	3701-3708	enhance	_
17-14	3709-3715	sexual	_
17-15	3716-3731	self-confidence	_
17-16	3731-3732	,	_
17-17	3733-3741	diminish	_
17-18	3742-3748	sexual	_
17-19	3749-3760	inhibitions	_
17-20	3760-3761	,	_
17-21	3762-3765	and	_
17-22	3766-3774	increase	_
17-23	3775-3781	sexual	_
17-24	3782-3788	desire	_
17-25	3788-3789	,	_
17-26	3790-3797	arousal	_
17-27	3797-3798	,	_
17-28	3799-3802	and	_
17-29	3803-3811	pleasure	_
17-30	3812-3815	and	_
17-31	3816-3821	delay	_
17-32	3822-3828	orgasm	_
17-33	3829-3833	both	_
17-34	3834-3836	in	_
17-35	3837-3843	humans	_
17-36	3844-3847	and	_
17-37	3848-3854	animal	_
17-38	3855-3861	models	_
17-39	3861-3862	.	_

#Text=Some individuals who use methamphetamine have reported that sexual enhancement was the primary motivation for their drug use.
18-1	3863-3867	Some	_
18-2	3868-3879	individuals	_
18-3	3880-3883	who	_
18-4	3884-3887	use	_
18-5	3888-3903	methamphetamine	_
18-6	3904-3908	have	_
18-7	3909-3917	reported	_
18-8	3918-3922	that	_
18-9	3923-3929	sexual	_
18-10	3930-3941	enhancement	_
18-11	3942-3945	was	_
18-12	3946-3949	the	_
18-13	3950-3957	primary	_
18-14	3958-3968	motivation	_
18-15	3969-3972	for	_
18-16	3973-3978	their	_
18-17	3979-3983	drug	_
18-18	3984-3987	use	_
18-19	3987-3988	.	_

#Text=Animal studies have found that methamphetamine activates the same cells in reward systems as sexual behavior, which in turn suggests that methamphetamine may influence compulsive sexual behaviors.
19-1	3989-3995	Animal	_
19-2	3996-4003	studies	_
19-3	4004-4008	have	_
19-4	4009-4014	found	_
19-5	4015-4019	that	_
19-6	4020-4035	methamphetamine	_
19-7	4036-4045	activates	_
19-8	4046-4049	the	_
19-9	4050-4054	same	_
19-10	4055-4060	cells	_
19-11	4061-4063	in	_
19-12	4064-4070	reward	_
19-13	4071-4078	systems	_
19-14	4079-4081	as	_
19-15	4082-4088	sexual	_
19-16	4089-4097	behavior	_
19-17	4097-4098	,	_
19-18	4099-4104	which	_
19-19	4105-4107	in	_
19-20	4108-4112	turn	_
19-21	4113-4121	suggests	_
19-22	4122-4126	that	_
19-23	4127-4142	methamphetamine	_
19-24	4143-4146	may	_
19-25	4147-4156	influence	_
19-26	4157-4167	compulsive	_
19-27	4168-4174	sexual	_
19-28	4175-4184	behaviors	_
19-29	4184-4185	.	_

#Text=Multiple addiction studies have focused on dopamine-related reward systems involving the ventral striatum.
20-1	4186-4194	Multiple	_
20-2	4195-4204	addiction	_
20-3	4205-4212	studies	_
20-4	4213-4217	have	_
20-5	4218-4225	focused	_
20-6	4226-4228	on	_
20-7	4229-4245	dopamine-related	_
20-8	4246-4252	reward	_
20-9	4253-4260	systems	_
20-10	4261-4270	involving	_
20-11	4271-4274	the	_
20-12	4275-4282	ventral	_
20-13	4283-4291	striatum	_
20-14	4291-4292	.	_

#Text=The ventral striatum may be activated by methamphetamine or cocaine administration in humans and animals.
21-1	4293-4296	The	_
21-2	4297-4304	ventral	_
21-3	4305-4313	striatum	_
21-4	4314-4317	may	_
21-5	4318-4320	be	_
21-6	4321-4330	activated	_
21-7	4331-4333	by	_
21-8	4334-4349	methamphetamine	_
21-9	4350-4352	or	_
21-10	4353-4360	cocaine	_
21-11	4361-4375	administration	_
21-12	4376-4378	in	_
21-13	4379-4385	humans	_
21-14	4386-4389	and	_
21-15	4390-4397	animals	_
21-16	4397-4398	.	_

#Text=The ventral striatum receives projections of midbrain dopaminergic neurons and has been implicated in reward-based learning and drug-associated conditioned reinforcement learning; thus, it may mediate the rewarding effects of drugs.
22-1	4399-4402	The	_
22-2	4403-4410	ventral	_
22-3	4411-4419	striatum	_
22-4	4420-4428	receives	_
22-5	4429-4440	projections	_
22-6	4441-4443	of	_
22-7	4444-4452	midbrain	_
22-8	4453-4465	dopaminergic	_
22-9	4466-4473	neurons	_
22-10	4474-4477	and	_
22-11	4478-4481	has	_
22-12	4482-4486	been	_
22-13	4487-4497	implicated	_
22-14	4498-4500	in	_
22-15	4501-4513	reward-based	_
22-16	4514-4522	learning	_
22-17	4523-4526	and	_
22-18	4527-4542	drug-associated	_
22-19	4543-4554	conditioned	_
22-20	4555-4568	reinforcement	_
22-21	4569-4577	learning	_
22-22	4577-4578	;	_
22-23	4579-4583	thus	_
22-24	4583-4584	,	_
22-25	4585-4587	it	_
22-26	4588-4591	may	_
22-27	4592-4599	mediate	_
22-28	4600-4603	the	_
22-29	4604-4613	rewarding	_
22-30	4614-4621	effects	_
22-31	4622-4624	of	_
22-32	4625-4630	drugs	_
22-33	4630-4631	.	_

#Text=However, the transition from voluntary drug-taking to compulsive drug-seeking may be the result of dynamic shifts from ventral to dorsal striatal involvement.
23-1	4632-4639	However	_
23-2	4639-4640	,	_
23-3	4641-4644	the	_
23-4	4645-4655	transition	_
23-5	4656-4660	from	_
23-6	4661-4670	voluntary	_
23-7	4671-4682	drug-taking	_
23-8	4683-4685	to	_
23-9	4686-4696	compulsive	_
23-10	4697-4709	drug-seeking	_
23-11	4710-4713	may	_
23-12	4714-4716	be	_
23-13	4717-4720	the	_
23-14	4721-4727	result	_
23-15	4728-4730	of	_
23-16	4731-4738	dynamic	_
23-17	4739-4745	shifts	_
23-18	4746-4750	from	_
23-19	4751-4758	ventral	_
23-20	4759-4761	to	_
23-21	4762-4768	dorsal	_
23-22	4769-4777	striatal	_
23-23	4778-4789	involvement	_
23-24	4789-4790	.	_

#Text=For example, chronic stimulant use may shift activation from the ventral to dorsal striatum during drug seeking.
24-1	4791-4794	For	_
24-2	4795-4802	example	_
24-3	4802-4803	,	_
24-4	4804-4811	chronic	_
24-5	4812-4821	stimulant	_
24-6	4822-4825	use	_
24-7	4826-4829	may	_
24-8	4830-4835	shift	_
24-9	4836-4846	activation	_
24-10	4847-4851	from	_
24-11	4852-4855	the	_
24-12	4856-4863	ventral	_
24-13	4864-4866	to	_
24-14	4867-4873	dorsal	_
24-15	4874-4882	striatum	_
24-16	4883-4889	during	_
24-17	4890-4894	drug	_
24-18	4895-4902	seeking	_
24-19	4902-4903	.	_

#Text=As such, different stages of addiction and abstinence may be linked to differences in striatal correlates of reward processing.
25-1	4904-4906	As	_
25-2	4907-4911	such	_
25-3	4911-4912	,	_
25-4	4913-4922	different	_
25-5	4923-4929	stages	_
25-6	4930-4932	of	_
25-7	4933-4942	addiction	_
25-8	4943-4946	and	_
25-9	4947-4957	abstinence	_
25-10	4958-4961	may	_
25-11	4962-4964	be	_
25-12	4965-4971	linked	_
25-13	4972-4974	to	_
25-14	4975-4986	differences	_
25-15	4987-4989	in	_
25-16	4990-4998	striatal	_
25-17	4999-5009	correlates	_
25-18	5010-5012	of	_
25-19	5013-5019	reward	_
25-20	5020-5030	processing	_
25-21	5030-5031	.	_

#Text=However, dopamine-related processes in the striatum may be insufficient to account fully for addiction processes, and other brain regions implicated in reward processing and behavioral control, including the prefrontal cortex (PFC), are important to consider.
26-1	5032-5039	However	_
26-2	5039-5040	,	_
26-3	5041-5057	dopamine-related	_
26-4	5058-5067	processes	_
26-5	5068-5070	in	_
26-6	5071-5074	the	_
26-7	5075-5083	striatum	_
26-8	5084-5087	may	_
26-9	5088-5090	be	_
26-10	5091-5103	insufficient	_
26-11	5104-5106	to	_
26-12	5107-5114	account	_
26-13	5115-5120	fully	_
26-14	5121-5124	for	_
26-15	5125-5134	addiction	_
26-16	5135-5144	processes	_
26-17	5144-5145	,	_
26-18	5146-5149	and	_
26-19	5150-5155	other	_
26-20	5156-5161	brain	_
26-21	5162-5169	regions	_
26-22	5170-5180	implicated	_
26-23	5181-5183	in	_
26-24	5184-5190	reward	_
26-25	5191-5201	processing	_
26-26	5202-5205	and	_
26-27	5206-5216	behavioral	_
26-28	5217-5224	control	_
26-29	5224-5225	,	_
26-30	5226-5235	including	_
26-31	5236-5239	the	_
26-32	5240-5250	prefrontal	_
26-33	5251-5257	cortex	_
26-34	5258-5259	(	_
26-35	5259-5262	PFC	_
26-36	5262-5263	)	_
26-37	5263-5264	,	_
26-38	5265-5268	are	_
26-39	5269-5278	important	_
26-40	5279-5281	to	_
26-41	5282-5290	consider	_
26-42	5290-5291	.	_

#Text=Within the PFC, the ventromedial PFC (vmPFC) may contribute importantly to reward processing and the development of addictions, as this region engages in emotional processes, stress reactivity, and attentional processes underlying goal-directed behaviors and decision-making.
27-1	5292-5298	Within	_
27-2	5299-5302	the	_
27-3	5303-5306	PFC	_
27-4	5306-5307	,	_
27-5	5308-5311	the	_
27-6	5312-5324	ventromedial	_
27-7	5325-5328	PFC	_
27-8	5329-5330	(	_
27-9	5330-5335	vmPFC	_
27-10	5335-5336	)	_
27-11	5337-5340	may	_
27-12	5341-5351	contribute	_
27-13	5352-5363	importantly	_
27-14	5364-5366	to	_
27-15	5367-5373	reward	_
27-16	5374-5384	processing	_
27-17	5385-5388	and	_
27-18	5389-5392	the	_
27-19	5393-5404	development	_
27-20	5405-5407	of	_
27-21	5408-5418	addictions	_
27-22	5418-5419	,	_
27-23	5420-5422	as	_
27-24	5423-5427	this	_
27-25	5428-5434	region	_
27-26	5435-5442	engages	_
27-27	5443-5445	in	_
27-28	5446-5455	emotional	_
27-29	5456-5465	processes	_
27-30	5465-5466	,	_
27-31	5467-5473	stress	_
27-32	5474-5484	reactivity	_
27-33	5484-5485	,	_
27-34	5486-5489	and	_
27-35	5490-5501	attentional	_
27-36	5502-5511	processes	_
27-37	5512-5522	underlying	_
27-38	5523-5536	goal-directed	_
27-39	5537-5546	behaviors	_
27-40	5547-5550	and	_
27-41	5551-5566	decision-making	_
27-42	5566-5567	.	_

#Text=Damage to the vmPFC has been associated with blunted emotional reactivity, poorly modulated emotional reactions, disadvantageous social decision-making, impaired goal-directed behaviors, and lack of insight.
28-1	5568-5574	Damage	_
28-2	5575-5577	to	_
28-3	5578-5581	the	_
28-4	5582-5587	vmPFC	_
28-5	5588-5591	has	_
28-6	5592-5596	been	_
28-7	5597-5607	associated	_
28-8	5608-5612	with	_
28-9	5613-5620	blunted	_
28-10	5621-5630	emotional	_
28-11	5631-5641	reactivity	_
28-12	5641-5642	,	_
28-13	5643-5649	poorly	_
28-14	5650-5659	modulated	_
28-15	5660-5669	emotional	_
28-16	5670-5679	reactions	_
28-17	5679-5680	,	_
28-18	5681-5696	disadvantageous	_
28-19	5697-5703	social	_
28-20	5704-5719	decision-making	_
28-21	5719-5720	,	_
28-22	5721-5729	impaired	_
28-23	5730-5743	goal-directed	_
28-24	5744-5753	behaviors	_
28-25	5753-5754	,	_
28-26	5755-5758	and	_
28-27	5759-5763	lack	_
28-28	5764-5766	of	_
28-29	5767-5774	insight	_
28-30	5774-5775	.	_

#Text=Individuals with substance dependence show similar behaviors to patients with bilateral vmPFC lesions, which suggests vmPFC dysfunction in substance dependence.
29-1	5776-5787	Individuals	_
29-2	5788-5792	with	_
29-3	5793-5802	substance	_
29-4	5803-5813	dependence	_
29-5	5814-5818	show	_
29-6	5819-5826	similar	_
29-7	5827-5836	behaviors	_
29-8	5837-5839	to	_
29-9	5840-5848	patients	_
29-10	5849-5853	with	_
29-11	5854-5863	bilateral	_
29-12	5864-5869	vmPFC	_
29-13	5870-5877	lesions	_
29-14	5877-5878	,	_
29-15	5879-5884	which	_
29-16	5885-5893	suggests	_
29-17	5894-5899	vmPFC	_
29-18	5900-5911	dysfunction	_
29-19	5912-5914	in	_
29-20	5915-5924	substance	_
29-21	5925-5935	dependence	_
29-22	5935-5936	.	_

#Text=The anterior insula is another crucial region to consider, as it is implicated in both drug and non-drug craving.
30-1	5938-5941	The	_
30-2	5942-5950	anterior	_
30-3	5951-5957	insula	_
30-4	5958-5960	is	_
30-5	5961-5968	another	_
30-6	5969-5976	crucial	_
30-7	5977-5983	region	_
30-8	5984-5986	to	_
30-9	5987-5995	consider	_
30-10	5995-5996	,	_
30-11	5997-5999	as	_
30-12	6000-6002	it	_
30-13	6003-6005	is	_
30-14	6006-6016	implicated	_
30-15	6017-6019	in	_
30-16	6020-6024	both	_
30-17	6025-6029	drug	_
30-18	6030-6033	and	_
30-19	6034-6042	non-drug	_
30-20	6043-6050	craving	_
30-21	6050-6051	.	_

#Text=As the anterior insula has been implicated in motivation, executive functioning, interoceptive awareness, and decision-making processes, abnormalities in anterior insula function may promote addictive behaviors.
31-1	6052-6054	As	_
31-2	6055-6058	the	_
31-3	6059-6067	anterior	_
31-4	6068-6074	insula	_
31-5	6075-6078	has	_
31-6	6079-6083	been	_
31-7	6084-6094	implicated	_
31-8	6095-6097	in	_
31-9	6098-6108	motivation	_
31-10	6108-6109	,	_
31-11	6110-6119	executive	_
31-12	6120-6131	functioning	_
31-13	6131-6132	,	_
31-14	6133-6146	interoceptive	_
31-15	6147-6156	awareness	_
31-16	6156-6157	,	_
31-17	6158-6161	and	_
31-18	6162-6177	decision-making	_
31-19	6178-6187	processes	_
31-20	6187-6188	,	_
31-21	6189-6202	abnormalities	_
31-22	6203-6205	in	_
31-23	6206-6214	anterior	_
31-24	6215-6221	insula	_
31-25	6222-6230	function	_
31-26	6231-6234	may	_
31-27	6235-6242	promote	_
31-28	6243-6252	addictive	_
31-29	6253-6262	behaviors	_
31-30	6262-6263	.	_

#Text=Moreover, the relationship between cue-elicited anterior insula activation and treatment outcome has been shown in prior fMRI studies.
32-1	6264-6272	Moreover	_
32-2	6272-6273	,	_
32-3	6274-6277	the	_
32-4	6278-6290	relationship	_
32-5	6291-6298	between	_
32-6	6299-6311	cue-elicited	_
32-7	6312-6320	anterior	_
32-8	6321-6327	insula	_
32-9	6328-6338	activation	_
32-10	6339-6342	and	_
32-11	6343-6352	treatment	_
32-12	6353-6360	outcome	_
32-13	6361-6364	has	_
32-14	6365-6369	been	_
32-15	6370-6375	shown	_
32-16	6376-6378	in	_
32-17	6379-6384	prior	_
32-18	6385-6389	fMRI	_
32-19	6390-6397	studies	_
32-20	6397-6398	.	_

#Text=Janes et al. found that cue-elicited bilateral anterior insula activation may reflect potentiated relapse vulnerability in treated, abstinent smokers, and suggest that insula activation may help identify individuals vulnerable to engaging in addictive disorders.
33-1	6399-6404	Janes	_
33-2	6405-6407	et	_
33-3	6408-6410	al	_
33-4	6410-6411	.	_
33-5	6412-6417	found	_
33-6	6418-6422	that	_
33-7	6423-6435	cue-elicited	_
33-8	6436-6445	bilateral	_
33-9	6446-6454	anterior	_
33-10	6455-6461	insula	_
33-11	6462-6472	activation	_
33-12	6473-6476	may	_
33-13	6477-6484	reflect	_
33-14	6485-6496	potentiated	_
33-15	6497-6504	relapse	_
33-16	6505-6518	vulnerability	_
33-17	6519-6521	in	_
33-18	6522-6529	treated	_
33-19	6529-6530	,	_
33-20	6531-6540	abstinent	_
33-21	6541-6548	smokers	_
33-22	6548-6549	,	_
33-23	6550-6553	and	_
33-24	6554-6561	suggest	_
33-25	6562-6566	that	_
33-26	6567-6573	insula	_
33-27	6574-6584	activation	_
33-28	6585-6588	may	_
33-29	6589-6593	help	_
33-30	6594-6602	identify	_
33-31	6603-6614	individuals	_
33-32	6615-6625	vulnerable	_
33-33	6626-6628	to	_
33-34	6629-6637	engaging	_
33-35	6638-6640	in	_
33-36	6641-6650	addictive	_
33-37	6651-6660	disorders	_
33-38	6660-6661	.	_

#Text=According to the impaired response inhibition and salience attribution (iRISA) model of addiction, disrupted PFC function could lead to increased salience of drugs and drug-related cues, decreased sensitivity to non-drug cues, and fewer tendencies to inhibit maladaptive behaviors.
34-1	6662-6671	According	_
34-2	6672-6674	to	_
34-3	6675-6678	the	_
34-4	6679-6687	impaired	_
34-5	6688-6696	response	_
34-6	6697-6707	inhibition	_
34-7	6708-6711	and	_
34-8	6712-6720	salience	_
34-9	6721-6732	attribution	_
34-10	6733-6734	(	_
34-11	6734-6739	iRISA	_
34-12	6739-6740	)	_
34-13	6741-6746	model	_
34-14	6747-6749	of	_
34-15	6750-6759	addiction	_
34-16	6759-6760	,	_
34-17	6761-6770	disrupted	_
34-18	6771-6774	PFC	_
34-19	6775-6783	function	_
34-20	6784-6789	could	_
34-21	6790-6794	lead	_
34-22	6795-6797	to	_
34-23	6798-6807	increased	_
34-24	6808-6816	salience	_
34-25	6817-6819	of	_
34-26	6820-6825	drugs	_
34-27	6826-6829	and	_
34-28	6830-6842	drug-related	_
34-29	6843-6847	cues	_
34-30	6847-6848	,	_
34-31	6849-6858	decreased	_
34-32	6859-6870	sensitivity	_
34-33	6871-6873	to	_
34-34	6874-6882	non-drug	_
34-35	6883-6887	cues	_
34-36	6887-6888	,	_
34-37	6889-6892	and	_
34-38	6893-6898	fewer	_
34-39	6899-6909	tendencies	_
34-40	6910-6912	to	_
34-41	6913-6920	inhibit	_
34-42	6921-6932	maladaptive	_
34-43	6933-6942	behaviors	_
34-44	6942-6943	.	_

#Text=Enhanced PFC drug-related cue activation has been reported after short-term abstinence (up to a mean of 8 days) in studies of tobacco smoking.
35-1	6944-6952	Enhanced	_
35-2	6953-6956	PFC	_
35-3	6957-6969	drug-related	_
35-4	6970-6973	cue	_
35-5	6974-6984	activation	_
35-6	6985-6988	has	_
35-7	6989-6993	been	_
35-8	6994-7002	reported	_
35-9	7003-7008	after	_
35-10	7009-7019	short-term	_
35-11	7020-7030	abstinence	_
35-12	7031-7032	(	_
35-13	7032-7034	up	_
35-14	7035-7037	to	_
35-15	7038-7039	a	_
35-16	7040-7044	mean	_
35-17	7045-7047	of	_
35-18	7048-7049	8	_
35-19	7050-7054	days	_
35-20	7054-7055	)	_
35-21	7056-7058	in	_
35-22	7059-7066	studies	_
35-23	7067-7069	of	_
35-24	7070-7077	tobacco	_
35-25	7078-7085	smoking	_
35-26	7085-7086	.	_

#Text=However, it was proposed in the iRISA model that in early abstinence, the sensitivity of the PFC to non-drug–related rewards may be markedly attenuated, leading to impaired inhibitory control in individuals with drug use disorders and promoting relapse.
36-1	7087-7094	However	_
36-2	7094-7095	,	_
36-3	7096-7098	it	_
36-4	7099-7102	was	_
36-5	7103-7111	proposed	_
36-6	7112-7114	in	_
36-7	7115-7118	the	_
36-8	7119-7124	iRISA	_
36-9	7125-7130	model	_
36-10	7131-7135	that	_
36-11	7136-7138	in	_
36-12	7139-7144	early	_
36-13	7145-7155	abstinence	_
36-14	7155-7156	,	_
36-15	7157-7160	the	_
36-16	7161-7172	sensitivity	_
36-17	7173-7175	of	_
36-18	7176-7179	the	_
36-19	7180-7183	PFC	_
36-20	7184-7186	to	_
36-21	7187-7203	non-drug–related	_
36-22	7204-7211	rewards	_
36-23	7212-7215	may	_
36-24	7216-7218	be	_
36-25	7219-7227	markedly	_
36-26	7228-7238	attenuated	_
36-27	7238-7239	,	_
36-28	7240-7247	leading	_
36-29	7248-7250	to	_
36-30	7251-7259	impaired	_
36-31	7260-7270	inhibitory	_
36-32	7271-7278	control	_
36-33	7279-7281	in	_
36-34	7282-7293	individuals	_
36-35	7294-7298	with	_
36-36	7299-7303	drug	_
36-37	7304-7307	use	_
36-38	7308-7317	disorders	_
36-39	7318-7321	and	_
36-40	7322-7331	promoting	_
36-41	7332-7339	relapse	_
36-42	7339-7340	.	_

#Text=As a result, drug seeking and drug taking may become main motivational drives relative to others during early abstinence.
37-1	7341-7343	As	_
37-2	7344-7345	a	_
37-3	7346-7352	result	_
37-4	7352-7353	,	_
37-5	7354-7358	drug	_
37-6	7359-7366	seeking	_
37-7	7367-7370	and	_
37-8	7371-7375	drug	_
37-9	7376-7382	taking	_
37-10	7383-7386	may	_
37-11	7387-7393	become	_
37-12	7394-7398	main	_
37-13	7399-7411	motivational	_
37-14	7412-7418	drives	_
37-15	7419-7427	relative	_
37-16	7428-7430	to	_
37-17	7431-7437	others	_
37-18	7438-7444	during	_
37-19	7445-7450	early	_
37-20	7451-7461	abstinence	_
37-21	7461-7462	.	_

#Text=However, studies investigating the impact of abstinence on PFC cue reactivity on exposure to drug, drug-related, or non-drug–related cues are limited.
38-1	7463-7470	However	_
38-2	7470-7471	,	_
38-3	7472-7479	studies	_
38-4	7480-7493	investigating	_
38-5	7494-7497	the	_
38-6	7498-7504	impact	_
38-7	7505-7507	of	_
38-8	7508-7518	abstinence	_
38-9	7519-7521	on	_
38-10	7522-7525	PFC	_
38-11	7526-7529	cue	_
38-12	7530-7540	reactivity	_
38-13	7541-7543	on	_
38-14	7544-7552	exposure	_
38-15	7553-7555	to	_
38-16	7556-7560	drug	_
38-17	7560-7561	,	_
38-18	7562-7574	drug-related	_
38-19	7574-7575	,	_
38-20	7576-7578	or	_
38-21	7579-7595	non-drug–related	_
38-22	7596-7600	cues	_
38-23	7601-7604	are	_
38-24	7605-7612	limited	_
38-25	7612-7613	.	_

#Text=The evidence that methamphetamine may increase sexual desire and heighten sexual rewards may be contrary to the iRISA model.
39-1	7614-7617	The	_
39-2	7618-7626	evidence	_
39-3	7627-7631	that	_
39-4	7632-7647	methamphetamine	_
39-5	7648-7651	may	_
39-6	7652-7660	increase	_
39-7	7661-7667	sexual	_
39-8	7668-7674	desire	_
39-9	7675-7678	and	_
39-10	7679-7687	heighten	_
39-11	7688-7694	sexual	_
39-12	7695-7702	rewards	_
39-13	7703-7706	may	_
39-14	7707-7709	be	_
39-15	7710-7718	contrary	_
39-16	7719-7721	to	_
39-17	7722-7725	the	_
39-18	7726-7731	iRISA	_
39-19	7732-7737	model	_
39-20	7737-7738	.	_

#Text=Moreover, although sexual pleasure and orgasm may be significantly impaired after chronic drug use and abstinence, sexual desire and arousal may not be similarly impacted.
40-1	7739-7747	Moreover	_
40-2	7747-7748	,	_
40-3	7749-7757	although	_
40-4	7758-7764	sexual	_
40-5	7765-7773	pleasure	_
40-6	7774-7777	and	_
40-7	7778-7784	orgasm	_
40-8	7785-7788	may	_
40-9	7789-7791	be	_
40-10	7792-7805	significantly	_
40-11	7806-7814	impaired	_
40-12	7815-7820	after	_
40-13	7821-7828	chronic	_
40-14	7829-7833	drug	_
40-15	7834-7837	use	_
40-16	7838-7841	and	_
40-17	7842-7852	abstinence	_
40-18	7852-7853	,	_
40-19	7854-7860	sexual	_
40-20	7861-7867	desire	_
40-21	7868-7871	and	_
40-22	7872-7879	arousal	_
40-23	7880-7883	may	_
40-24	7884-7887	not	_
40-25	7888-7890	be	_
40-26	7891-7900	similarly	_
40-27	7901-7909	impacted	_
40-28	7909-7910	.	_

#Text=Thus, investigating how individuals with methamphetamine dependence respond to sexual cues at various stages of abstinence is important from theoretical and clinical perspectives.
41-1	7911-7915	Thus	_
41-2	7915-7916	,	_
41-3	7917-7930	investigating	_
41-4	7931-7934	how	_
41-5	7935-7946	individuals	_
41-6	7947-7951	with	_
41-7	7952-7967	methamphetamine	_
41-8	7968-7978	dependence	_
41-9	7979-7986	respond	_
41-10	7987-7989	to	_
41-11	7990-7996	sexual	_
41-12	7997-8001	cues	_
41-13	8002-8004	at	_
41-14	8005-8012	various	_
41-15	8013-8019	stages	_
41-16	8020-8022	of	_
41-17	8023-8033	abstinence	_
41-18	8034-8036	is	_
41-19	8037-8046	important	_
41-20	8047-8051	from	_
41-21	8052-8063	theoretical	_
41-22	8064-8067	and	_
41-23	8068-8076	clinical	_
41-24	8077-8089	perspectives	_
41-25	8089-8090	.	_

#Text=Changes in brain systems associated with chronic methamphetamine use may be difficult to reverse merely through drug termination.
42-1	8091-8098	Changes	_
42-2	8099-8101	in	_
42-3	8102-8107	brain	_
42-4	8108-8115	systems	_
42-5	8116-8126	associated	_
42-6	8127-8131	with	_
42-7	8132-8139	chronic	_
42-8	8140-8155	methamphetamine	_
42-9	8156-8159	use	_
42-10	8160-8163	may	_
42-11	8164-8166	be	_
42-12	8167-8176	difficult	_
42-13	8177-8179	to	_
42-14	8180-8187	reverse	_
42-15	8188-8194	merely	_
42-16	8195-8202	through	_
42-17	8203-8207	drug	_
42-18	8208-8219	termination	_
42-19	8219-8220	.	_

#Text=Vulnerabilities to relapse may persist in relationship to drug cues or drug-use motivations (e.g., to enhance sexual pleasure and performance) after years of abstinence.
43-1	8221-8236	Vulnerabilities	_
43-2	8237-8239	to	_
43-3	8240-8247	relapse	_
43-4	8248-8251	may	_
43-5	8252-8259	persist	_
43-6	8260-8262	in	_
43-7	8263-8275	relationship	_
43-8	8276-8278	to	_
43-9	8279-8283	drug	_
43-10	8284-8288	cues	_
43-11	8289-8291	or	_
43-12	8292-8300	drug-use	_
43-13	8301-8312	motivations	_
43-14	8313-8314	(	_
43-15	8314-8317	e.g	_
43-16	8317-8318	.	_
43-17	8318-8319	,	_
43-18	8320-8322	to	_
43-19	8323-8330	enhance	_
43-20	8331-8337	sexual	_
43-21	8338-8346	pleasure	_
43-22	8347-8350	and	_
43-23	8351-8362	performance	_
43-24	8362-8363	)	_
43-25	8364-8369	after	_
43-26	8370-8375	years	_
43-27	8376-8378	of	_
43-28	8379-8389	abstinence	_
43-29	8389-8390	.	_

#Text=Furthermore, self-reported impulsivity may increase when abstaining from methamphetamine, potentially promoting relapse.
44-1	8391-8402	Furthermore	_
44-2	8402-8403	,	_
44-3	8404-8417	self-reported	_
44-4	8418-8429	impulsivity	_
44-5	8430-8433	may	_
44-6	8434-8442	increase	_
44-7	8443-8447	when	_
44-8	8448-8458	abstaining	_
44-9	8459-8463	from	_
44-10	8464-8479	methamphetamine	_
44-11	8479-8480	,	_
44-12	8481-8492	potentially	_
44-13	8493-8502	promoting	_
44-14	8503-8510	relapse	_
44-15	8510-8511	.	_

#Text=While some drug-related brain alterations may be reversed or partially recovered with increasing abstinence (e.g., longer term abstinence [12–17 months] vs shorter term abstinence [<6 months], understanding neural responses at varying stages of abstinence may provide insight into potential risks for relapse or engagement in other risky behaviors.
45-1	8512-8517	While	_
45-2	8518-8522	some	_
45-3	8523-8535	drug-related	_
45-4	8536-8541	brain	_
45-5	8542-8553	alterations	_
45-6	8554-8557	may	_
45-7	8558-8560	be	_
45-8	8561-8569	reversed	_
45-9	8570-8572	or	_
45-10	8573-8582	partially	_
45-11	8583-8592	recovered	_
45-12	8593-8597	with	_
45-13	8598-8608	increasing	_
45-14	8609-8619	abstinence	_
45-15	8620-8621	(	_
45-16	8621-8624	e.g	_
45-17	8624-8625	.	_
45-18	8625-8626	,	_
45-19	8627-8633	longer	_
45-20	8634-8638	term	_
45-21	8639-8649	abstinence	_
45-22	8650-8651	[	_
45-23	8651-8653	12	_
45-24	8653-8654	–	_
45-25	8654-8656	17	_
45-26	8657-8663	months	_
45-27	8663-8664	]	_
45-28	8665-8667	vs	_
45-29	8668-8675	shorter	_
45-30	8676-8680	term	_
45-31	8681-8691	abstinence	_
45-32	8692-8693	[	_
45-33	8693-8694	<	_
45-34	8694-8695	6	_
45-35	8696-8702	months	_
45-36	8702-8703	]	_
45-37	8703-8704	,	_
45-38	8705-8718	understanding	_
45-39	8719-8725	neural	_
45-40	8726-8735	responses	_
45-41	8736-8738	at	_
45-42	8739-8746	varying	_
45-43	8747-8753	stages	_
45-44	8754-8756	of	_
45-45	8757-8767	abstinence	_
45-46	8768-8771	may	_
45-47	8772-8779	provide	_
45-48	8780-8787	insight	_
45-49	8788-8792	into	_
45-50	8793-8802	potential	_
45-51	8803-8808	risks	_
45-52	8809-8812	for	_
45-53	8813-8820	relapse	_
45-54	8821-8823	or	_
45-55	8824-8834	engagement	_
45-56	8835-8837	in	_
45-57	8838-8843	other	_
45-58	8844-8849	risky	_
45-59	8850-8859	behaviors	_
45-60	8859-8860	.	_

#Text=However, human studies investigating functional responses to cues relating to drug or sexual cues at various stages of abstinence in chronic methamphetamine dependence are lacking.
46-1	8861-8868	However	_
46-2	8868-8869	,	_
46-3	8870-8875	human	_
46-4	8876-8883	studies	_
46-5	8884-8897	investigating	_
46-6	8898-8908	functional	_
46-7	8909-8918	responses	_
46-8	8919-8921	to	_
46-9	8922-8926	cues	_
46-10	8927-8935	relating	_
46-11	8936-8938	to	_
46-12	8939-8943	drug	_
46-13	8944-8946	or	_
46-14	8947-8953	sexual	_
46-15	8954-8958	cues	_
46-16	8959-8961	at	_
46-17	8962-8969	various	_
46-18	8970-8976	stages	_
46-19	8977-8979	of	_
46-20	8980-8990	abstinence	_
46-21	8991-8993	in	_
46-22	8994-9001	chronic	_
46-23	9002-9017	methamphetamine	_
46-24	9018-9028	dependence	_
46-25	9029-9032	are	_
46-26	9033-9040	lacking	_
46-27	9040-9041	.	_

#Text=In this investigation, we employed a functional magnetic resonance imaging (fMRI) cue-reactivity task involving methamphetamine, sexual, and neutral cues to examine neural differences between 2 groups of men with varying degrees of methamphetamine abstinence (shorter term methamphetamine abstinence [STMA] and longer term methamphetamine abstinence [LTMA]) and relative to a group of healthy comparison (HC) men.
47-1	9042-9044	In	_
47-2	9045-9049	this	_
47-3	9050-9063	investigation	_
47-4	9063-9064	,	_
47-5	9065-9067	we	_
47-6	9068-9076	employed	_
47-7	9077-9078	a	_
47-8	9079-9089	functional	_
47-9	9090-9098	magnetic	_
47-10	9099-9108	resonance	_
47-11	9109-9116	imaging	_
47-12	9117-9118	(	_
47-13	9118-9122	fMRI	_
47-14	9122-9123	)	_
47-15	9124-9138	cue-reactivity	_
47-16	9139-9143	task	_
47-17	9144-9153	involving	_
47-18	9154-9169	methamphetamine	_
47-19	9169-9170	,	_
47-20	9171-9177	sexual	_
47-21	9177-9178	,	_
47-22	9179-9182	and	_
47-23	9183-9190	neutral	_
47-24	9191-9195	cues	_
47-25	9196-9198	to	_
47-26	9199-9206	examine	_
47-27	9207-9213	neural	_
47-28	9214-9225	differences	_
47-29	9226-9233	between	_
47-30	9234-9235	2	_
47-31	9236-9242	groups	_
47-32	9243-9245	of	_
47-33	9246-9249	men	_
47-34	9250-9254	with	_
47-35	9255-9262	varying	_
47-36	9263-9270	degrees	_
47-37	9271-9273	of	_
47-38	9274-9289	methamphetamine	_
47-39	9290-9300	abstinence	_
47-40	9301-9302	(	_
47-41	9302-9309	shorter	_
47-42	9310-9314	term	_
47-43	9315-9330	methamphetamine	_
47-44	9331-9341	abstinence	_
47-45	9342-9343	[	_
47-46	9343-9347	STMA	_
47-47	9347-9348	]	_
47-48	9349-9352	and	_
47-49	9353-9359	longer	_
47-50	9360-9364	term	_
47-51	9365-9380	methamphetamine	_
47-52	9381-9391	abstinence	_
47-53	9392-9393	[	_
47-54	9393-9397	LTMA	_
47-55	9397-9398	]	_
47-56	9398-9399	)	_
47-57	9400-9403	and	_
47-58	9404-9412	relative	_
47-59	9413-9415	to	_
47-60	9416-9417	a	_
47-61	9418-9423	group	_
47-62	9424-9426	of	_
47-63	9427-9434	healthy	_
47-64	9435-9445	comparison	_
47-65	9446-9447	(	_
47-66	9447-9449	HC	_
47-67	9449-9450	)	_
47-68	9451-9454	men	_
47-69	9454-9455	.	_

#Text=We investigated 3 primary hypotheses.
48-1	9456-9458	We	_
48-2	9459-9471	investigated	_
48-3	9472-9473	3	_
48-4	9474-9481	primary	_
48-5	9482-9492	hypotheses	_
48-6	9492-9493	.	_

#Text=First, consistent with addiction relapse theories, we hypothesized that when exposed to methamphetamine cues, both STMA and LTMA groups would exhibit increased activation in the ventral striatum, dorsal striatum, vmPFC, and anterior insula compared with HC participants.
49-1	9494-9499	First	_
49-2	9499-9500	,	_
49-3	9501-9511	consistent	_
49-4	9512-9516	with	_
49-5	9517-9526	addiction	_
49-6	9527-9534	relapse	_
49-7	9535-9543	theories	_
49-8	9543-9544	,	_
49-9	9545-9547	we	_
49-10	9548-9560	hypothesized	_
49-11	9561-9565	that	_
49-12	9566-9570	when	_
49-13	9571-9578	exposed	_
49-14	9579-9581	to	_
49-15	9582-9597	methamphetamine	_
49-16	9598-9602	cues	_
49-17	9602-9603	,	_
49-18	9604-9608	both	_
49-19	9609-9613	STMA	_
49-20	9614-9617	and	_
49-21	9618-9622	LTMA	_
49-22	9623-9629	groups	_
49-23	9630-9635	would	_
49-24	9636-9643	exhibit	_
49-25	9644-9653	increased	_
49-26	9654-9664	activation	_
49-27	9665-9667	in	_
49-28	9668-9671	the	_
49-29	9672-9679	ventral	_
49-30	9680-9688	striatum	_
49-31	9688-9689	,	_
49-32	9690-9696	dorsal	_
49-33	9697-9705	striatum	_
49-34	9705-9706	,	_
49-35	9707-9712	vmPFC	_
49-36	9712-9713	,	_
49-37	9714-9717	and	_
49-38	9718-9726	anterior	_
49-39	9727-9733	insula	_
49-40	9734-9742	compared	_
49-41	9743-9747	with	_
49-42	9748-9750	HC	_
49-43	9751-9763	participants	_
49-44	9763-9764	.	_

#Text=Second, consistent with evidence of increased sexual motivations associated with methamphetamine use, we hypothesized that both STMA and LTMA groups relative to HC participants would exhibit relatively increased activation in the ventral striatum, dorsal striatum, vmPFC, and anterior insula when exposed to sexual cues.
50-1	9765-9771	Second	_
50-2	9771-9772	,	_
50-3	9773-9783	consistent	_
50-4	9784-9788	with	_
50-5	9789-9797	evidence	_
50-6	9798-9800	of	_
50-7	9801-9810	increased	_
50-8	9811-9817	sexual	_
50-9	9818-9829	motivations	_
50-10	9830-9840	associated	_
50-11	9841-9845	with	_
50-12	9846-9861	methamphetamine	_
50-13	9862-9865	use	_
50-14	9865-9866	,	_
50-15	9867-9869	we	_
50-16	9870-9882	hypothesized	_
50-17	9883-9887	that	_
50-18	9888-9892	both	_
50-19	9893-9897	STMA	_
50-20	9898-9901	and	_
50-21	9902-9906	LTMA	_
50-22	9907-9913	groups	_
50-23	9914-9922	relative	_
50-24	9923-9925	to	_
50-25	9926-9928	HC	_
50-26	9929-9941	participants	_
50-27	9942-9947	would	_
50-28	9948-9955	exhibit	_
50-29	9956-9966	relatively	_
50-30	9967-9976	increased	_
50-31	9977-9987	activation	_
50-32	9988-9990	in	_
50-33	9991-9994	the	_
50-34	9995-10002	ventral	_
50-35	10003-10011	striatum	_
50-36	10011-10012	,	_
50-37	10013-10019	dorsal	_
50-38	10020-10028	striatum	_
50-39	10028-10029	,	_
50-40	10030-10035	vmPFC	_
50-41	10035-10036	,	_
50-42	10037-10040	and	_
50-43	10041-10049	anterior	_
50-44	10050-10056	insula	_
50-45	10057-10061	when	_
50-46	10062-10069	exposed	_
50-47	10070-10072	to	_
50-48	10073-10079	sexual	_
50-49	10080-10084	cues	_
50-50	10084-10085	.	_

#Text=Third, if protracted abstinence may be associated with recovery of functioning in these regions, we hypothesized that there was the possibility that the brain activation in the ventral striatum, dorsal striatum, vmPFC, and anterior insula in the LTMA groups would be approximating more close than the brain activation in HC participants when exposed to both methamphetamine and sexual cues and would exhibit relatively decreased activation compared with the STMA group.
51-1	10086-10091	Third	_
51-2	10091-10092	,	_
51-3	10093-10095	if	_
51-4	10096-10106	protracted	_
51-5	10107-10117	abstinence	_
51-6	10118-10121	may	_
51-7	10122-10124	be	_
51-8	10125-10135	associated	_
51-9	10136-10140	with	_
51-10	10141-10149	recovery	_
51-11	10150-10152	of	_
51-12	10153-10164	functioning	_
51-13	10165-10167	in	_
51-14	10168-10173	these	_
51-15	10174-10181	regions	_
51-16	10181-10182	,	_
51-17	10183-10185	we	_
51-18	10186-10198	hypothesized	_
51-19	10199-10203	that	_
51-20	10204-10209	there	_
51-21	10210-10213	was	_
51-22	10214-10217	the	_
51-23	10218-10229	possibility	_
51-24	10230-10234	that	_
51-25	10235-10238	the	_
51-26	10239-10244	brain	_
51-27	10245-10255	activation	_
51-28	10256-10258	in	_
51-29	10259-10262	the	_
51-30	10263-10270	ventral	_
51-31	10271-10279	striatum	_
51-32	10279-10280	,	_
51-33	10281-10287	dorsal	_
51-34	10288-10296	striatum	_
51-35	10296-10297	,	_
51-36	10298-10303	vmPFC	_
51-37	10303-10304	,	_
51-38	10305-10308	and	_
51-39	10309-10317	anterior	_
51-40	10318-10324	insula	_
51-41	10325-10327	in	_
51-42	10328-10331	the	_
51-43	10332-10336	LTMA	_
51-44	10337-10343	groups	_
51-45	10344-10349	would	_
51-46	10350-10352	be	_
51-47	10353-10366	approximating	_
51-48	10367-10371	more	_
51-49	10372-10377	close	_
51-50	10378-10382	than	_
51-51	10383-10386	the	_
51-52	10387-10392	brain	_
51-53	10393-10403	activation	_
51-54	10404-10406	in	_
51-55	10407-10409	HC	_
51-56	10410-10422	participants	_
51-57	10423-10427	when	_
51-58	10428-10435	exposed	_
51-59	10436-10438	to	_
51-60	10439-10443	both	_
51-61	10444-10459	methamphetamine	_
51-62	10460-10463	and	_
51-63	10464-10470	sexual	_
51-64	10471-10475	cues	_
51-65	10476-10479	and	_
51-66	10480-10485	would	_
51-67	10486-10493	exhibit	_
51-68	10494-10504	relatively	_
51-69	10505-10514	decreased	_
51-70	10515-10525	activation	_
51-71	10526-10534	compared	_
51-72	10535-10539	with	_
51-73	10540-10543	the	_
51-74	10544-10548	STMA	_
51-75	10549-10554	group	_
51-76	10554-10555	.	_

#Text=Subsequent whole-brain analyses were performed to investigate potential functional alterations between groups beyond regions of interest.
52-1	10556-10566	Subsequent	_
52-2	10567-10578	whole-brain	_
52-3	10579-10587	analyses	_
52-4	10588-10592	were	_
52-5	10593-10602	performed	_
52-6	10603-10605	to	_
52-7	10606-10617	investigate	_
52-8	10618-10627	potential	_
52-9	10628-10638	functional	_
52-10	10639-10650	alterations	_
52-11	10651-10658	between	_
52-12	10659-10665	groups	_
52-13	10666-10672	beyond	_
52-14	10673-10680	regions	_
52-15	10681-10683	of	_
52-16	10684-10692	interest	_
52-17	10692-10693	.	_

#Text=Finally, as engagement in both stimulant use and risky sexual behaviors has been associated with impulsivity, we explored relationships between regional activations and baseline methamphetamine use and impulsivity in STMA and LTMA participants.
53-1	10694-10701	Finally	_
53-2	10701-10702	,	_
53-3	10703-10705	as	_
53-4	10706-10716	engagement	_
53-5	10717-10719	in	_
53-6	10720-10724	both	_
53-7	10725-10734	stimulant	_
53-8	10735-10738	use	_
53-9	10739-10742	and	_
53-10	10743-10748	risky	_
53-11	10749-10755	sexual	_
53-12	10756-10765	behaviors	_
53-13	10766-10769	has	_
53-14	10770-10774	been	_
53-15	10775-10785	associated	_
53-16	10786-10790	with	_
53-17	10791-10802	impulsivity	_
53-18	10802-10803	,	_
53-19	10804-10806	we	_
53-20	10807-10815	explored	_
53-21	10816-10829	relationships	_
53-22	10830-10837	between	_
53-23	10838-10846	regional	_
53-24	10847-10858	activations	_
53-25	10859-10862	and	_
53-26	10863-10871	baseline	_
53-27	10872-10887	methamphetamine	_
53-28	10888-10891	use	_
53-29	10892-10895	and	_
53-30	10896-10907	impulsivity	_
53-31	10908-10910	in	_
53-32	10911-10915	STMA	_
53-33	10916-10919	and	_
53-34	10920-10924	LTMA	_
53-35	10925-10937	participants	_
53-36	10937-10938	.	_

#Text=Methods
#Text=Participants
#Text=Participants were 146 men aged 19–45 years recruited from Hunan Province, China.
54-1	10939-10946	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod
54-2	10947-10959	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
54-3	10960-10972	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
54-4	10973-10977	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
54-5	10978-10981	146	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
54-6	10982-10985	men	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
54-7	10986-10990	aged	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
54-8	10991-10993	19	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
54-9	10993-10994	–	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
54-10	10994-10996	45	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
54-11	10997-11002	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
54-12	11003-11012	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
54-13	11013-11017	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
54-14	11018-11023	Hunan	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
54-15	11024-11032	Province	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
54-16	11032-11033	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
54-17	11034-11039	China	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
54-18	11039-11040	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]

#Text=Individuals with a period of methamphetamine use more than 18 months before entering treatment and meeting the diagnosis criteria of methamphetamine dependence as determined by the Chinese version of the Structured Clinical Interview for Diagnosis and Statistical Manual of Mental Disorders were divided into 2 subsamples.
55-1	11041-11052	Individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
55-2	11053-11057	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
55-3	11058-11059	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
55-4	11060-11066	period	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
55-5	11067-11069	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
55-6	11070-11085	methamphetamine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
55-7	11086-11089	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
55-8	11090-11094	more	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
55-9	11095-11099	than	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
55-10	11100-11102	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
55-11	11103-11109	months	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
55-12	11110-11116	before	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
55-13	11117-11125	entering	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
55-14	11126-11135	treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
55-15	11136-11139	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
55-16	11140-11147	meeting	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
55-17	11148-11151	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
55-18	11152-11161	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
55-19	11162-11170	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
55-20	11171-11173	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
55-21	11174-11189	methamphetamine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[26]
55-22	11190-11200	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[26]
55-23	11201-11203	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
55-24	11204-11214	determined	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
55-25	11215-11217	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
55-26	11218-11221	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
55-27	11222-11229	Chinese	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
55-28	11230-11237	version	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
55-29	11238-11240	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
55-30	11241-11244	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
55-31	11245-11255	Structured	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[27]
55-32	11256-11264	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[27]
55-33	11265-11274	Interview	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[27]
55-34	11275-11278	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[27]
55-35	11279-11288	Diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[27]
55-36	11289-11292	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
55-37	11293-11304	Statistical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
55-38	11305-11311	Manual	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
55-39	11312-11314	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
55-40	11315-11321	Mental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
55-41	11322-11331	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
55-42	11332-11336	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
55-43	11337-11344	divided	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
55-44	11345-11349	into	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
55-45	11350-11351	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
55-46	11352-11362	subsamples	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
55-47	11362-11363	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]

#Text=The LTMA (n = 50) sample was a convenience sample that was recruited from individuals scheduled for release from the Pingtang Isolated Compulsory Drug Rehabilitation Center, and the STMA (n = 49) sample was recruited from the Kangda Voluntary Drug Rehabilitation Center.
56-1	11364-11367	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
56-2	11368-11372	LTMA	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
56-3	11373-11374	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
56-4	11374-11375	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
56-5	11376-11377	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
56-6	11378-11380	50	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
56-7	11380-11381	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
56-8	11382-11388	sample	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
56-9	11389-11392	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
56-10	11393-11394	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
56-11	11395-11406	convenience	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
56-12	11407-11413	sample	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
56-13	11414-11418	that	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
56-14	11419-11422	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
56-15	11423-11432	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
56-16	11433-11437	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
56-17	11438-11449	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
56-18	11450-11459	scheduled	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
56-19	11460-11463	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
56-20	11464-11471	release	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
56-21	11472-11476	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
56-22	11477-11480	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
56-23	11481-11489	Pingtang	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
56-24	11490-11498	Isolated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
56-25	11499-11509	Compulsory	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
56-26	11510-11514	Drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
56-27	11515-11529	Rehabilitation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
56-28	11530-11536	Center	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
56-29	11536-11537	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
56-30	11538-11541	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
56-31	11542-11545	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
56-32	11546-11550	STMA	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
56-33	11551-11552	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
56-34	11552-11553	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
56-35	11554-11555	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
56-36	11556-11558	49	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
56-37	11558-11559	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
56-38	11560-11566	sample	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
56-39	11567-11570	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
56-40	11571-11580	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
56-41	11581-11585	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
56-42	11586-11589	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
56-43	11590-11596	Kangda	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
56-44	11597-11606	Voluntary	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
56-45	11607-11611	Drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
56-46	11612-11626	Rehabilitation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
56-47	11627-11633	Center	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
56-48	11633-11634	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]

#Text=The HC group (n = 47) was recruited from the local community.
57-1	11635-11638	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
57-2	11639-11641	HC	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[28]
57-3	11642-11647	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
57-4	11648-11649	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
57-5	11649-11650	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
57-6	11651-11652	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
57-7	11653-11655	47	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
57-8	11655-11656	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
57-9	11657-11660	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
57-10	11661-11670	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
57-11	11671-11675	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
57-12	11676-11679	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
57-13	11680-11685	local	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
57-14	11686-11695	community	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
57-15	11695-11696	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]

#Text=Individuals were excluded for meeting criteria for Structured Clinical Interview for Diagnosis and Statistical Manual of Mental Disorders dependence on a substance other than nicotine (or for the methamphetamine groups, methamphetamine); the presence or history of a psychiatric disorder or general medical illness (e.g., cardiovascular disease, high blood pressure); a history of brain injury or loss consciousness of 10 minutes or more; left-handedness; and any contraindications of MRI scanning.
58-1	11697-11708	Individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-2	11709-11713	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-3	11714-11722	excluded	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-4	11723-11726	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-5	11727-11734	meeting	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-6	11735-11743	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-7	11744-11747	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-8	11748-11758	Structured	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[29]
58-9	11759-11767	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[29]
58-10	11768-11777	Interview	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[29]
58-11	11778-11781	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[29]
58-12	11782-11791	Diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[29]
58-13	11792-11795	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-14	11796-11807	Statistical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-15	11808-11814	Manual	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-16	11815-11817	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-17	11818-11824	Mental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-18	11825-11834	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-19	11835-11845	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-20	11846-11848	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-21	11849-11850	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-22	11851-11860	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-23	11861-11866	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-24	11867-11871	than	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-25	11872-11880	nicotine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-26	11881-11882	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-27	11882-11884	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-28	11885-11888	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-29	11889-11892	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-30	11893-11908	methamphetamine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-31	11909-11915	groups	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-32	11915-11916	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-33	11917-11932	methamphetamine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-34	11932-11933	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-35	11933-11934	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-36	11935-11938	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-37	11939-11947	presence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-38	11948-11950	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-39	11951-11958	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-40	11959-11961	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-41	11962-11963	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-42	11964-11975	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-43	11976-11984	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-44	11985-11987	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-45	11988-11995	general	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-46	11996-12003	medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-47	12004-12011	illness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-48	12012-12013	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-49	12013-12016	e.g	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-50	12016-12017	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-51	12017-12018	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-52	12019-12033	cardiovascular	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-53	12034-12041	disease	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-54	12041-12042	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-55	12043-12047	high	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-56	12048-12053	blood	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-57	12054-12062	pressure	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-58	12062-12063	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-59	12063-12064	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-60	12065-12066	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-61	12067-12074	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-62	12075-12077	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-63	12078-12083	brain	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-64	12084-12090	injury	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-65	12091-12093	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-66	12094-12098	loss	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-67	12099-12112	consciousness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-68	12113-12115	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-69	12116-12118	10	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-70	12119-12126	minutes	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-71	12127-12129	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-72	12130-12134	more	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-73	12134-12135	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-74	12136-12151	left-handedness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-75	12151-12152	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-76	12153-12156	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-77	12157-12160	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-78	12161-12178	contraindications	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-79	12179-12181	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-80	12182-12185	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[30]
58-81	12186-12194	scanning	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
58-82	12194-12195	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]

#Text=All participants reported not having consumed alcohol or any other psychoactive substances for at least 48 hours before scanning, with corroborating information obtained from the doctors caring for the LTMA and STMA participants (as they were inpatients).
59-1	12196-12199	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
59-2	12200-12212	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
59-3	12213-12221	reported	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
59-4	12222-12225	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
59-5	12226-12232	having	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
59-6	12233-12241	consumed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
59-7	12242-12249	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
59-8	12250-12252	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
59-9	12253-12256	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
59-10	12257-12262	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
59-11	12263-12275	psychoactive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
59-12	12276-12286	substances	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
59-13	12287-12290	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
59-14	12291-12293	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
59-15	12294-12299	least	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
59-16	12300-12302	48	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
59-17	12303-12308	hours	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
59-18	12309-12315	before	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
59-19	12316-12324	scanning	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
59-20	12324-12325	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
59-21	12326-12330	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
59-22	12331-12344	corroborating	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
59-23	12345-12356	information	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
59-24	12357-12365	obtained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
59-25	12366-12370	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
59-26	12371-12374	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
59-27	12375-12382	doctors	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
59-28	12383-12389	caring	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
59-29	12390-12393	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
59-30	12394-12397	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
59-31	12398-12402	LTMA	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
59-32	12403-12406	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
59-33	12407-12411	STMA	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
59-34	12412-12424	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
59-35	12425-12426	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
59-36	12426-12428	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
59-37	12429-12433	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
59-38	12434-12438	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
59-39	12439-12449	inpatients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
59-40	12449-12450	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
59-41	12450-12451	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]

#Text=The final participant sample of 146 individuals represents a total enrollment of 162 males, 155 of whom completed fMRI procedures, and the exclusion of 9 individuals for excessive head motion.
60-1	12452-12455	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
60-2	12456-12461	final	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
60-3	12462-12473	participant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
60-4	12474-12480	sample	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
60-5	12481-12483	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
60-6	12484-12487	146	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
60-7	12488-12499	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
60-8	12500-12510	represents	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
60-9	12511-12512	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
60-10	12513-12518	total	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
60-11	12519-12529	enrollment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
60-12	12530-12532	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
60-13	12533-12536	162	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
60-14	12537-12542	males	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
60-15	12542-12543	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
60-16	12544-12547	155	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
60-17	12548-12550	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
60-18	12551-12555	whom	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
60-19	12556-12565	completed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
60-20	12566-12570	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[31]
60-21	12571-12581	procedures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
60-22	12581-12582	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
60-23	12583-12586	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
60-24	12587-12590	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
60-25	12591-12600	exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
60-26	12601-12603	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
60-27	12604-12605	9	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
60-28	12606-12617	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
60-29	12618-12621	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
60-30	12622-12631	excessive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
60-31	12632-12636	head	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
60-32	12637-12643	motion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
60-33	12643-12644	.	_

#Text=A portion of the LTMA (n = 28) and HC (n = 27) was included in a previous report.
61-1	12645-12646	A	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
61-2	12647-12654	portion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
61-3	12655-12657	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
61-4	12658-12661	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
61-5	12662-12666	LTMA	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]|http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[33]
61-6	12667-12668	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
61-7	12668-12669	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
61-8	12670-12671	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
61-9	12672-12674	28	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
61-10	12674-12675	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
61-11	12676-12679	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
61-12	12680-12682	HC	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[34]
61-13	12683-12684	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
61-14	12684-12685	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
61-15	12686-12687	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
61-16	12688-12690	27	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
61-17	12690-12691	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
61-18	12692-12695	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
61-19	12696-12704	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
61-20	12705-12707	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
61-21	12708-12709	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
61-22	12710-12718	previous	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
61-23	12719-12725	report	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
61-24	12725-12726	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]

#Text=All participants completed the Barratt Impulsiveness Scale (Chinese version).
62-1	12727-12730	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
62-2	12731-12743	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
62-3	12744-12753	completed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
62-4	12754-12757	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
62-5	12758-12765	Barratt	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
62-6	12766-12779	Impulsiveness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
62-7	12780-12785	Scale	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
62-8	12786-12787	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
62-9	12787-12794	Chinese	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
62-10	12795-12802	version	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
62-11	12802-12803	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
62-12	12803-12804	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]

#Text=This study was approved by the ethical review board of the Second Xiangya Hospital of Central South University, which evaluated the study specifically related to participation of incarcerated individuals and conditions for use of incarcerated individuals in research were met.
63-1	12805-12809	This	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
63-2	12810-12815	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
63-3	12816-12819	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
63-4	12820-12828	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
63-5	12829-12831	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
63-6	12832-12835	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
63-7	12836-12843	ethical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
63-8	12844-12850	review	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
63-9	12851-12856	board	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
63-10	12857-12859	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
63-11	12860-12863	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
63-12	12864-12870	Second	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
63-13	12871-12878	Xiangya	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
63-14	12879-12887	Hospital	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
63-15	12888-12890	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
63-16	12891-12898	Central	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
63-17	12899-12904	South	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
63-18	12905-12915	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
63-19	12915-12916	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
63-20	12917-12922	which	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
63-21	12923-12932	evaluated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
63-22	12933-12936	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
63-23	12937-12942	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
63-24	12943-12955	specifically	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
63-25	12956-12963	related	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
63-26	12964-12966	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
63-27	12967-12980	participation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
63-28	12981-12983	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
63-29	12984-12996	incarcerated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
63-30	12997-13008	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
63-31	13009-13012	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
63-32	13013-13023	conditions	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
63-33	13024-13027	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
63-34	13028-13031	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
63-35	13032-13034	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
63-36	13035-13047	incarcerated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
63-37	13048-13059	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
63-38	13060-13062	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
63-39	13063-13071	research	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
63-40	13072-13076	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
63-41	13077-13080	met	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
63-42	13080-13081	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]

#Text=Participants from the compulsory and voluntary drug rehabilitation centers could decline involvement in the study if they had any concerns, and all participants provided voluntary written informed consent.
64-1	13082-13094	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
64-2	13095-13099	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
64-3	13100-13103	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
64-4	13104-13114	compulsory	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
64-5	13115-13118	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
64-6	13119-13128	voluntary	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
64-7	13129-13133	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
64-8	13134-13148	rehabilitation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
64-9	13149-13156	centers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
64-10	13157-13162	could	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
64-11	13163-13170	decline	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
64-12	13171-13182	involvement	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
64-13	13183-13185	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
64-14	13186-13189	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
64-15	13190-13195	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
64-16	13196-13198	if	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
64-17	13199-13203	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
64-18	13204-13207	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
64-19	13208-13211	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
64-20	13212-13220	concerns	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
64-21	13220-13221	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
64-22	13222-13225	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
64-23	13226-13229	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
64-24	13230-13242	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
64-25	13243-13251	provided	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
64-26	13252-13261	voluntary	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
64-27	13262-13269	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
64-28	13270-13278	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
64-29	13279-13286	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
64-30	13286-13287	.	_

#Text=Cue-Reactivity Task
#Text=The details for image selection and task design have been described previously.
65-1	13288-13302	Cue-Reactivity	_
65-2	13303-13307	Task	_
65-3	13309-13312	The	_
65-4	13313-13320	details	_
65-5	13321-13324	for	_
65-6	13325-13330	image	_
65-7	13331-13340	selection	_
65-8	13341-13344	and	_
65-9	13345-13349	task	_
65-10	13350-13356	design	_
65-11	13357-13361	have	_
65-12	13362-13366	been	_
65-13	13367-13376	described	_
65-14	13377-13387	previously	_
65-15	13387-13388	.	_

#Text=Briefly, the 450-second cue-reactivity task consisted of 6 epochs, each containing three 20-second blocks (methamphetamine, sexual, and neutral images; Figure 1) and one 15-second rest (crosshair).
66-1	13389-13396	Briefly	_
66-2	13396-13397	,	_
66-3	13398-13401	the	_
66-4	13402-13405	450	_
66-5	13405-13406	-	_
66-6	13406-13412	second	_
66-7	13413-13427	cue-reactivity	_
66-8	13428-13432	task	_
66-9	13433-13442	consisted	_
66-10	13443-13445	of	_
66-11	13446-13447	6	_
66-12	13448-13454	epochs	_
66-13	13454-13455	,	_
66-14	13456-13460	each	_
66-15	13461-13471	containing	_
66-16	13472-13477	three	_
66-17	13478-13480	20	_
66-18	13480-13481	-	_
66-19	13481-13487	second	_
66-20	13488-13494	blocks	_
66-21	13495-13496	(	_
66-22	13496-13511	methamphetamine	_
66-23	13511-13512	,	_
66-24	13513-13519	sexual	_
66-25	13519-13520	,	_
66-26	13521-13524	and	_
66-27	13525-13532	neutral	_
66-28	13533-13539	images	_
66-29	13539-13540	;	_
66-30	13541-13547	Figure	_
66-31	13548-13549	1	_
66-32	13549-13550	)	_
66-33	13551-13554	and	_
66-34	13555-13558	one	_
66-35	13559-13561	15	_
66-36	13561-13562	-	_
66-37	13562-13568	second	_
66-38	13569-13573	rest	_
66-39	13574-13575	(	_
66-40	13575-13584	crosshair	_
66-41	13584-13585	)	_
66-42	13585-13586	.	_

#Text=The methamphetamine cue-related images were the images of methamphetamine itself, people who were smoking methamphetamine, or the instruments they used to smoke methamphetamine.
67-1	13587-13590	The	_
67-2	13591-13606	methamphetamine	_
67-3	13607-13618	cue-related	_
67-4	13619-13625	images	_
67-5	13626-13630	were	_
67-6	13631-13634	the	_
67-7	13635-13641	images	_
67-8	13642-13644	of	_
67-9	13645-13660	methamphetamine	_
67-10	13661-13667	itself	_
67-11	13667-13668	,	_
67-12	13669-13675	people	_
67-13	13676-13679	who	_
67-14	13680-13684	were	_
67-15	13685-13692	smoking	_
67-16	13693-13708	methamphetamine	_
67-17	13708-13709	,	_
67-18	13710-13712	or	_
67-19	13713-13716	the	_
67-20	13717-13728	instruments	_
67-21	13729-13733	they	_
67-22	13734-13738	used	_
67-23	13739-13741	to	_
67-24	13742-13747	smoke	_
67-25	13748-13763	methamphetamine	_
67-26	13763-13764	.	_

#Text=Each block contained 5 unique images presented for 3 seconds with a 1-second inter-stimulus interval.
68-1	13765-13769	Each	_
68-2	13770-13775	block	_
68-3	13776-13785	contained	_
68-4	13786-13787	5	_
68-5	13788-13794	unique	_
68-6	13795-13801	images	_
68-7	13802-13811	presented	_
68-8	13812-13815	for	_
68-9	13816-13817	3	_
68-10	13818-13825	seconds	_
68-11	13826-13830	with	_
68-12	13831-13832	a	_
68-13	13833-13834	1	_
68-14	13834-13835	-	_
68-15	13835-13841	second	_
68-16	13842-13856	inter-stimulus	_
68-17	13857-13865	interval	_
68-18	13865-13866	.	_

#Text=Thus, a total 30 images of each cue condition (i.e., methamphetamine, sexual, and neutral) were presented during the fMRI scan.
69-1	13867-13871	Thus	_
69-2	13871-13872	,	_
69-3	13873-13874	a	_
69-4	13875-13880	total	_
69-5	13881-13883	30	_
69-6	13884-13890	images	_
69-7	13891-13893	of	_
69-8	13894-13898	each	_
69-9	13899-13902	cue	_
69-10	13903-13912	condition	_
69-11	13913-13914	(	_
69-12	13914-13917	i.e	_
69-13	13917-13918	.	_
69-14	13918-13919	,	_
69-15	13920-13935	methamphetamine	_
69-16	13935-13936	,	_
69-17	13937-13943	sexual	_
69-18	13943-13944	,	_
69-19	13945-13948	and	_
69-20	13949-13956	neutral	_
69-21	13956-13957	)	_
69-22	13958-13962	were	_
69-23	13963-13972	presented	_
69-24	13973-13979	during	_
69-25	13980-13983	the	_
69-26	13984-13988	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
69-27	13989-13993	scan	_
69-28	13993-13994	.	_

#Text=The order of the images and the blocks within epochs were all presented pseudo-randomly to control for order effects across participants.
70-1	13995-13998	The	_
70-2	13999-14004	order	_
70-3	14005-14007	of	_
70-4	14008-14011	the	_
70-5	14012-14018	images	_
70-6	14019-14022	and	_
70-7	14023-14026	the	_
70-8	14027-14033	blocks	_
70-9	14034-14040	within	_
70-10	14041-14047	epochs	_
70-11	14048-14052	were	_
70-12	14053-14056	all	_
70-13	14057-14066	presented	_
70-14	14067-14082	pseudo-randomly	_
70-15	14083-14085	to	_
70-16	14086-14093	control	_
70-17	14094-14097	for	_
70-18	14098-14103	order	_
70-19	14104-14111	effects	_
70-20	14112-14118	across	_
70-21	14119-14131	participants	_
70-22	14131-14132	.	_

#Text=Images of representative methamphetamine, sexual, and neutral cues, and the crosshair of the cue-reactivity task.
#Text=fMRI Acquisition and Analysis
#Text=Images were obtained using a 3.0-T Siemens scanner (Allegra; Siemens Medical System, Erlangen, Germany) equipped with a standard 20-channel head coil.
71-1	14133-14139	Images	_
71-2	14140-14142	of	_
71-3	14143-14157	representative	_
71-4	14158-14173	methamphetamine	_
71-5	14173-14174	,	_
71-6	14175-14181	sexual	_
71-7	14181-14182	,	_
71-8	14183-14186	and	_
71-9	14187-14194	neutral	_
71-10	14195-14199	cues	_
71-11	14199-14200	,	_
71-12	14201-14204	and	_
71-13	14205-14208	the	_
71-14	14209-14218	crosshair	_
71-15	14219-14221	of	_
71-16	14222-14225	the	_
71-17	14226-14240	cue-reactivity	_
71-18	14241-14245	task	_
71-19	14245-14246	.	_
71-20	14247-14251	fMRI	_
71-21	14252-14263	Acquisition	_
71-22	14264-14267	and	_
71-23	14268-14276	Analysis	_
71-24	14277-14283	Images	_
71-25	14284-14288	were	_
71-26	14289-14297	obtained	_
71-27	14298-14303	using	_
71-28	14304-14305	a	_
71-29	14306-14309	3.0	_
71-30	14309-14310	-	_
71-31	14310-14311	T	_
71-32	14312-14319	Siemens	_
71-33	14320-14327	scanner	_
71-34	14328-14329	(	_
71-35	14329-14336	Allegra	_
71-36	14336-14337	;	_
71-37	14338-14345	Siemens	_
71-38	14346-14353	Medical	_
71-39	14354-14360	System	_
71-40	14360-14361	,	_
71-41	14362-14370	Erlangen	_
71-42	14370-14371	,	_
71-43	14372-14379	Germany	_
71-44	14379-14380	)	_
71-45	14381-14389	equipped	_
71-46	14390-14394	with	_
71-47	14395-14396	a	_
71-48	14397-14405	standard	_
71-49	14406-14408	20	_
71-50	14408-14409	-	_
71-51	14409-14416	channel	_
71-52	14417-14421	head	_
71-53	14422-14426	coil	_
71-54	14426-14427	.	_

#Text=Blood oxygen-level–dependent data were acquired with an echo-planar imaging sequence: repetition time (TR) = 2000 milliseconds, echo time (TE) = 30 milliseconds, flip = 80°, field of view = 220 × 220 mm, voxel size = 3.4 × 3.4 × 4.0 mm, slice thickness = 4 mm, gap = 1 mm, number of slices = 36.
72-1	14428-14433	Blood	_
72-2	14434-14456	oxygen-level–dependent	_
72-3	14457-14461	data	_
72-4	14462-14466	were	_
72-5	14467-14475	acquired	_
72-6	14476-14480	with	_
72-7	14481-14483	an	_
72-8	14484-14495	echo-planar	_
72-9	14496-14503	imaging	_
72-10	14504-14512	sequence	_
72-11	14512-14513	:	_
72-12	14514-14524	repetition	_
72-13	14525-14529	time	_
72-14	14530-14531	(	_
72-15	14531-14533	TR	_
72-16	14533-14534	)	_
72-17	14535-14536	=	_
72-18	14537-14541	2000	_
72-19	14542-14554	milliseconds	_
72-20	14554-14555	,	_
72-21	14556-14560	echo	_
72-22	14561-14565	time	_
72-23	14566-14567	(	_
72-24	14567-14569	TE	_
72-25	14569-14570	)	_
72-26	14571-14572	=	_
72-27	14573-14575	30	_
72-28	14576-14588	milliseconds	_
72-29	14588-14589	,	_
72-30	14590-14594	flip	_
72-31	14595-14596	=	_
72-32	14597-14599	80	_
72-33	14599-14600	°	_
72-34	14600-14601	,	_
72-35	14602-14607	field	_
72-36	14608-14610	of	_
72-37	14611-14615	view	_
72-38	14616-14617	=	_
72-39	14618-14621	220	_
72-40	14622-14623	×	_
72-41	14624-14627	220	_
72-42	14628-14630	mm	_
72-43	14630-14631	,	_
72-44	14632-14637	voxel	_
72-45	14638-14642	size	_
72-46	14643-14644	=	_
72-47	14645-14648	3.4	_
72-48	14649-14650	×	_
72-49	14651-14654	3.4	_
72-50	14655-14656	×	_
72-51	14657-14660	4.0	_
72-52	14661-14663	mm	_
72-53	14663-14664	,	_
72-54	14665-14670	slice	_
72-55	14671-14680	thickness	_
72-56	14681-14682	=	_
72-57	14683-14684	4	_
72-58	14685-14687	mm	_
72-59	14687-14688	,	_
72-60	14689-14692	gap	_
72-61	14693-14694	=	_
72-62	14695-14696	1	_
72-63	14697-14699	mm	_
72-64	14699-14700	,	_
72-65	14701-14707	number	_
72-66	14708-14710	of	_
72-67	14711-14717	slices	_
72-68	14718-14719	=	_
72-69	14720-14722	36	_
72-70	14722-14723	.	_

#Text=The first 5 volumes (10 seconds) were removed from analyses to enable the signal to achieve steady-state equilibrium.
73-1	14724-14727	The	_
73-2	14728-14733	first	_
73-3	14734-14735	5	_
73-4	14736-14743	volumes	_
73-5	14744-14745	(	_
73-6	14745-14747	10	_
73-7	14748-14755	seconds	_
73-8	14755-14756	)	_
73-9	14757-14761	were	_
73-10	14762-14769	removed	_
73-11	14770-14774	from	_
73-12	14775-14783	analyses	_
73-13	14784-14786	to	_
73-14	14787-14793	enable	_
73-15	14794-14797	the	_
73-16	14798-14804	signal	_
73-17	14805-14807	to	_
73-18	14808-14815	achieve	_
73-19	14816-14828	steady-state	_
73-20	14829-14840	equilibrium	_
73-21	14840-14841	.	_

#Text=Image analysis was performed using the Statistical Parametric Mapping 12 software package (SPM12, http://www.fil.ion.ucl.ac.uk/spm/).
74-1	14842-14847	Image	_
74-2	14848-14856	analysis	_
74-3	14857-14860	was	_
74-4	14861-14870	performed	_
74-5	14871-14876	using	_
74-6	14877-14880	the	_
74-7	14881-14892	Statistical	_
74-8	14893-14903	Parametric	_
74-9	14904-14911	Mapping	_
74-10	14912-14914	12	_
74-11	14915-14923	software	_
74-12	14924-14931	package	_
74-13	14932-14933	(	_
74-14	14933-14938	SPM12	_
74-15	14938-14939	,	_
74-16	14940-14944	http	_
74-17	14944-14945	:	_
74-18	14945-14946	/	_
74-19	14946-14947	/	_
74-20	14947-14968	www.fil.ion.ucl.ac.uk	_
74-21	14968-14969	/	_
74-22	14969-14972	spm	_
74-23	14972-14973	/	_
74-24	14973-14974	)	_
74-25	14974-14975	.	_

#Text=Functional images were realigned to the first volume of each session individually, normalized spatially into Montreal Neurological Institute template standardized space (resampling into 3 × 3 × 3 mm3 voxels), and smoothed with an 8-mm full-width-at-half-maximum Gaussian filter.
75-1	14976-14986	Functional	_
75-2	14987-14993	images	_
75-3	14994-14998	were	_
75-4	14999-15008	realigned	_
75-5	15009-15011	to	_
75-6	15012-15015	the	_
75-7	15016-15021	first	_
75-8	15022-15028	volume	_
75-9	15029-15031	of	_
75-10	15032-15036	each	_
75-11	15037-15044	session	_
75-12	15045-15057	individually	_
75-13	15057-15058	,	_
75-14	15059-15069	normalized	_
75-15	15070-15079	spatially	_
75-16	15080-15084	into	_
75-17	15085-15093	Montreal	_
75-18	15094-15106	Neurological	_
75-19	15107-15116	Institute	_
75-20	15117-15125	template	_
75-21	15126-15138	standardized	_
75-22	15139-15144	space	_
75-23	15145-15146	(	_
75-24	15146-15156	resampling	_
75-25	15157-15161	into	_
75-26	15162-15163	3	_
75-27	15164-15165	×	_
75-28	15166-15167	3	_
75-29	15168-15169	×	_
75-30	15170-15171	3	_
75-31	15172-15175	mm3	_
75-32	15176-15182	voxels	_
75-33	15182-15183	)	_
75-34	15183-15184	,	_
75-35	15185-15188	and	_
75-36	15189-15197	smoothed	_
75-37	15198-15202	with	_
75-38	15203-15205	an	_
75-39	15206-15207	8	_
75-40	15207-15208	-	_
75-41	15208-15210	mm	_
75-42	15211-15237	full-width-at-half-maximum	_
75-43	15238-15246	Gaussian	_
75-44	15247-15253	filter	_
75-45	15253-15254	.	_

#Text=Participants (n = 9) were excluded from further analyses due to head motion in excess of 3 mm and/or 3°.
76-1	15255-15267	Participants	_
76-2	15268-15269	(	_
76-3	15269-15270	n	_
76-4	15271-15272	=	_
76-5	15273-15274	9	_
76-6	15274-15275	)	_
76-7	15276-15280	were	_
76-8	15281-15289	excluded	_
76-9	15290-15294	from	_
76-10	15295-15302	further	_
76-11	15303-15311	analyses	_
76-12	15312-15315	due	_
76-13	15316-15318	to	_
76-14	15319-15323	head	_
76-15	15324-15330	motion	_
76-16	15331-15333	in	_
76-17	15334-15340	excess	_
76-18	15341-15343	of	_
76-19	15344-15345	3	_
76-20	15346-15348	mm	_
76-21	15349-15352	and	_
76-22	15352-15353	/	_
76-23	15353-15355	or	_
76-24	15356-15357	3	_
76-25	15357-15358	°	_
76-26	15358-15359	.	_

#Text=A general linear model was used to conduct a functional data analysis.
77-1	15360-15361	A	_
77-2	15362-15369	general	_
77-3	15370-15376	linear	_
77-4	15377-15382	model	_
77-5	15383-15386	was	_
77-6	15387-15391	used	_
77-7	15392-15394	to	_
77-8	15395-15402	conduct	_
77-9	15403-15404	a	_
77-10	15405-15415	functional	_
77-11	15416-15420	data	_
77-12	15421-15429	analysis	_
77-13	15429-15430	.	_

#Text=First-level models included each series of five 3-second pictures (1-second inter-stimulus interval) modeled as 20-second blocks by condition (methamphetamine, sexual, and neutral) and the 6 motion parameters as regressors.
78-1	15431-15442	First-level	_
78-2	15443-15449	models	_
78-3	15450-15458	included	_
78-4	15459-15463	each	_
78-5	15464-15470	series	_
78-6	15471-15473	of	_
78-7	15474-15478	five	_
78-8	15479-15480	3	_
78-9	15480-15481	-	_
78-10	15481-15487	second	_
78-11	15488-15496	pictures	_
78-12	15497-15498	(	_
78-13	15498-15499	1	_
78-14	15499-15500	-	_
78-15	15500-15506	second	_
78-16	15507-15521	inter-stimulus	_
78-17	15522-15530	interval	_
78-18	15530-15531	)	_
78-19	15532-15539	modeled	_
78-20	15540-15542	as	_
78-21	15543-15545	20	_
78-22	15545-15546	-	_
78-23	15546-15552	second	_
78-24	15553-15559	blocks	_
78-25	15560-15562	by	_
78-26	15563-15572	condition	_
78-27	15573-15574	(	_
78-28	15574-15589	methamphetamine	_
78-29	15589-15590	,	_
78-30	15591-15597	sexual	_
78-31	15597-15598	,	_
78-32	15599-15602	and	_
78-33	15603-15610	neutral	_
78-34	15610-15611	)	_
78-35	15612-15615	and	_
78-36	15616-15619	the	_
78-37	15620-15621	6	_
78-38	15622-15628	motion	_
78-39	15629-15639	parameters	_
78-40	15640-15642	as	_
78-41	15643-15653	regressors	_
78-42	15653-15654	.	_

#Text=Given that prior findings showed no lateralized effects in cue reactivity in these regions, bilateral region-of-interest (ROI) was used in ROI analyses.
79-1	15655-15660	Given	_
79-2	15661-15665	that	_
79-3	15666-15671	prior	_
79-4	15672-15680	findings	_
79-5	15681-15687	showed	_
79-6	15688-15690	no	_
79-7	15691-15702	lateralized	_
79-8	15703-15710	effects	_
79-9	15711-15713	in	_
79-10	15714-15717	cue	_
79-11	15718-15728	reactivity	_
79-12	15729-15731	in	_
79-13	15732-15737	these	_
79-14	15738-15745	regions	_
79-15	15745-15746	,	_
79-16	15747-15756	bilateral	_
79-17	15757-15775	region-of-interest	_
79-18	15776-15777	(	_
79-19	15777-15780	ROI	_
79-20	15780-15781	)	_
79-21	15782-15785	was	_
79-22	15786-15790	used	_
79-23	15791-15793	in	_
79-24	15794-15797	ROI	_
79-25	15798-15806	analyses	_
79-26	15806-15807	.	_

#Text=Bilateral ROIs were created using labeled regions of the Neuromorphometrics atlas (www.neuromorphometrics.com) for the ventral striatum using the accumbens area, for the dorsal striatum using the putamen and the caudate nucleus, for the vmPFC using the medial frontal cortex, and for the anterior insula using the anterior insula (supplemental Figure 1).
80-1	15808-15817	Bilateral	_
80-2	15818-15822	ROIs	_
80-3	15823-15827	were	_
80-4	15828-15835	created	_
80-5	15836-15841	using	_
80-6	15842-15849	labeled	_
80-7	15850-15857	regions	_
80-8	15858-15860	of	_
80-9	15861-15864	the	_
80-10	15865-15883	Neuromorphometrics	_
80-11	15884-15889	atlas	_
80-12	15890-15891	(	_
80-13	15891-15917	www.neuromorphometrics.com	_
80-14	15917-15918	)	_
80-15	15919-15922	for	_
80-16	15923-15926	the	_
80-17	15927-15934	ventral	_
80-18	15935-15943	striatum	_
80-19	15944-15949	using	_
80-20	15950-15953	the	_
80-21	15954-15963	accumbens	_
80-22	15964-15968	area	_
80-23	15968-15969	,	_
80-24	15970-15973	for	_
80-25	15974-15977	the	_
80-26	15978-15984	dorsal	_
80-27	15985-15993	striatum	_
80-28	15994-15999	using	_
80-29	16000-16003	the	_
80-30	16004-16011	putamen	_
80-31	16012-16015	and	_
80-32	16016-16019	the	_
80-33	16020-16027	caudate	_
80-34	16028-16035	nucleus	_
80-35	16035-16036	,	_
80-36	16037-16040	for	_
80-37	16041-16044	the	_
80-38	16045-16050	vmPFC	_
80-39	16051-16056	using	_
80-40	16057-16060	the	_
80-41	16061-16067	medial	_
80-42	16068-16075	frontal	_
80-43	16076-16082	cortex	_
80-44	16082-16083	,	_
80-45	16084-16087	and	_
80-46	16088-16091	for	_
80-47	16092-16095	the	_
80-48	16096-16104	anterior	_
80-49	16105-16111	insula	_
80-50	16112-16117	using	_
80-51	16118-16121	the	_
80-52	16122-16130	anterior	_
80-53	16131-16137	insula	_
80-54	16138-16139	(	_
80-55	16139-16151	supplemental	_
80-56	16152-16158	Figure	_
80-57	16159-16160	1	_
80-58	16160-16161	)	_
80-59	16161-16162	.	_

#Text=For whole-brain analyses, a cluster-level familywise-error correction threshold of P < .05 was applied to the voxel-level uncorrected threshold of P < .01.
81-1	16163-16166	For	_
81-2	16167-16178	whole-brain	_
81-3	16179-16187	analyses	_
81-4	16187-16188	,	_
81-5	16189-16190	a	_
81-6	16191-16204	cluster-level	_
81-7	16205-16221	familywise-error	_
81-8	16222-16232	correction	_
81-9	16233-16242	threshold	_
81-10	16243-16245	of	_
81-11	16246-16247	P	_
81-12	16248-16249	<	_
81-13	16250-16253	.05	_
81-14	16254-16257	was	_
81-15	16258-16265	applied	_
81-16	16266-16268	to	_
81-17	16269-16272	the	_
81-18	16273-16284	voxel-level	_
81-19	16285-16296	uncorrected	_
81-20	16297-16306	threshold	_
81-21	16307-16309	of	_
81-22	16310-16311	P	_
81-23	16312-16313	<	_
81-24	16314-16317	.01	_
81-25	16317-16318	.	_

#Text=Individual average parameter estimates within ROIs and whole brain–identified clusters were extracted for statistical analyses.
82-1	16319-16329	Individual	_
82-2	16330-16337	average	_
82-3	16338-16347	parameter	_
82-4	16348-16357	estimates	_
82-5	16358-16364	within	_
82-6	16365-16369	ROIs	_
82-7	16370-16373	and	_
82-8	16374-16379	whole	_
82-9	16380-16396	brain–identified	_
82-10	16397-16405	clusters	_
82-11	16406-16410	were	_
82-12	16411-16420	extracted	_
82-13	16421-16424	for	_
82-14	16425-16436	statistical	_
82-15	16437-16445	analyses	_
82-16	16445-16446	.	_

#Text=Statistical Analysis
#Text=Group-level ROI and whole-brain analyses were performed using 3 × 3 mixed-effects ANOVA with group (STMA, LTMA, HC) as a between-subjects factor, condition (methamphetamine, sexual, and neutral) as a within-subjects factor, and subject as a random-effects factor.
83-1	16447-16458	Statistical	_
83-2	16459-16467	Analysis	_
83-3	16468-16479	Group-level	_
83-4	16480-16483	ROI	_
83-5	16484-16487	and	_
83-6	16488-16499	whole-brain	_
83-7	16500-16508	analyses	_
83-8	16509-16513	were	_
83-9	16514-16523	performed	_
83-10	16524-16529	using	_
83-11	16530-16531	3	_
83-12	16532-16533	×	_
83-13	16534-16535	3	_
83-14	16536-16549	mixed-effects	_
83-15	16550-16555	ANOVA	_
83-16	16556-16560	with	_
83-17	16561-16566	group	_
83-18	16567-16568	(	_
83-19	16568-16572	STMA	_
83-20	16572-16573	,	_
83-21	16574-16578	LTMA	_
83-22	16578-16579	,	_
83-23	16580-16582	HC	_
83-24	16582-16583	)	_
83-25	16584-16586	as	_
83-26	16587-16588	a	_
83-27	16589-16605	between-subjects	_
83-28	16606-16612	factor	_
83-29	16612-16613	,	_
83-30	16614-16623	condition	_
83-31	16624-16625	(	_
83-32	16625-16640	methamphetamine	_
83-33	16640-16641	,	_
83-34	16642-16648	sexual	_
83-35	16648-16649	,	_
83-36	16650-16653	and	_
83-37	16654-16661	neutral	_
83-38	16661-16662	)	_
83-39	16663-16665	as	_
83-40	16666-16667	a	_
83-41	16668-16683	within-subjects	_
83-42	16684-16690	factor	_
83-43	16690-16691	,	_
83-44	16692-16695	and	_
83-45	16696-16703	subject	_
83-46	16704-16706	as	_
83-47	16707-16708	a	_
83-48	16709-16723	random-effects	_
83-49	16724-16730	factor	_
83-50	16730-16731	.	_

#Text=ROI analyses and post-hoc testing of whole-brain findings were conducted with R.
84-1	16732-16735	ROI	_
84-2	16736-16744	analyses	_
84-3	16745-16748	and	_
84-4	16749-16757	post-hoc	_
84-5	16758-16765	testing	_
84-6	16766-16768	of	_
84-7	16769-16780	whole-brain	_
84-8	16781-16789	findings	_
84-9	16790-16794	were	_
84-10	16795-16804	conducted	_
84-11	16805-16809	with	_
84-12	16810-16811	R	_
84-13	16811-16812	.	_

#Text=Post-hoc t tests were applied at a regional level to further investigate the nature of findings in regions demonstrating a main effect of group or an interaction of group by condition.
85-1	16813-16821	Post-hoc	_
85-2	16822-16823	t	_
85-3	16824-16829	tests	_
85-4	16830-16834	were	_
85-5	16835-16842	applied	_
85-6	16843-16845	at	_
85-7	16846-16847	a	_
85-8	16848-16856	regional	_
85-9	16857-16862	level	_
85-10	16863-16865	to	_
85-11	16866-16873	further	_
85-12	16874-16885	investigate	_
85-13	16886-16889	the	_
85-14	16890-16896	nature	_
85-15	16897-16899	of	_
85-16	16900-16908	findings	_
85-17	16909-16911	in	_
85-18	16912-16919	regions	_
85-19	16920-16933	demonstrating	_
85-20	16934-16935	a	_
85-21	16936-16940	main	_
85-22	16941-16947	effect	_
85-23	16948-16950	of	_
85-24	16951-16956	group	_
85-25	16957-16959	or	_
85-26	16960-16962	an	_
85-27	16963-16974	interaction	_
85-28	16975-16977	of	_
85-29	16978-16983	group	_
85-30	16984-16986	by	_
85-31	16987-16996	condition	_
85-32	16996-16997	.	_

#Text=One-way ANOVAs were performed to examine group differences within condition, and paired-samples t tests were performed in each group to assess condition effects.
86-1	16998-17005	One-way	_
86-2	17006-17012	ANOVAs	_
86-3	17013-17017	were	_
86-4	17018-17027	performed	_
86-5	17028-17030	to	_
86-6	17031-17038	examine	_
86-7	17039-17044	group	_
86-8	17045-17056	differences	_
86-9	17057-17063	within	_
86-10	17064-17073	condition	_
86-11	17073-17074	,	_
86-12	17075-17078	and	_
86-13	17079-17093	paired-samples	_
86-14	17094-17095	t	_
86-15	17096-17101	tests	_
86-16	17102-17106	were	_
86-17	17107-17116	performed	_
86-18	17117-17119	in	_
86-19	17120-17124	each	_
86-20	17125-17130	group	_
86-21	17131-17133	to	_
86-22	17134-17140	assess	_
86-23	17141-17150	condition	_
86-24	17151-17158	effects	_
86-25	17158-17159	.	_

#Text=Subsequent analyses including age, education, tobacco use, and alcohol use as covariates were performed.
87-1	17160-17170	Subsequent	_
87-2	17171-17179	analyses	_
87-3	17180-17189	including	_
87-4	17190-17193	age	_
87-5	17193-17194	,	_
87-6	17195-17204	education	_
87-7	17204-17205	,	_
87-8	17206-17213	tobacco	_
87-9	17214-17217	use	_
87-10	17217-17218	,	_
87-11	17219-17222	and	_
87-12	17223-17230	alcohol	_
87-13	17231-17234	use	_
87-14	17235-17237	as	_
87-15	17238-17248	covariates	_
87-16	17249-17253	were	_
87-17	17254-17263	performed	_
87-18	17263-17264	.	_

#Text=Relationships between brain activation and baseline methamphetamine use (i.e., duration [months] of methamphetamine use and dosage [grams] of methamphetamine use) and impulsivity scores were examined using Pearson correlations with a significance threshold of P < .05.
88-1	17265-17278	Relationships	_
88-2	17279-17286	between	_
88-3	17287-17292	brain	_
88-4	17293-17303	activation	_
88-5	17304-17307	and	_
88-6	17308-17316	baseline	_
88-7	17317-17332	methamphetamine	_
88-8	17333-17336	use	_
88-9	17337-17338	(	_
88-10	17338-17341	i.e	_
88-11	17341-17342	.	_
88-12	17342-17343	,	_
88-13	17344-17352	duration	_
88-14	17353-17354	[	_
88-15	17354-17360	months	_
88-16	17360-17361	]	_
88-17	17362-17364	of	_
88-18	17365-17380	methamphetamine	_
88-19	17381-17384	use	_
88-20	17385-17388	and	_
88-21	17389-17395	dosage	_
88-22	17396-17397	[	_
88-23	17397-17402	grams	_
88-24	17402-17403	]	_
88-25	17404-17406	of	_
88-26	17407-17422	methamphetamine	_
88-27	17423-17426	use	_
88-28	17426-17427	)	_
88-29	17428-17431	and	_
88-30	17432-17443	impulsivity	_
88-31	17444-17450	scores	_
88-32	17451-17455	were	_
88-33	17456-17464	examined	_
88-34	17465-17470	using	_
88-35	17471-17478	Pearson	_
88-36	17479-17491	correlations	_
88-37	17492-17496	with	_
88-38	17497-17498	a	_
88-39	17499-17511	significance	_
88-40	17512-17521	threshold	_
88-41	17522-17524	of	_
88-42	17525-17526	P	_
88-43	17527-17528	<	_
88-44	17529-17532	.05	_
88-45	17532-17533	.	_

#Text=A Bonferroni-correction for multiple comparisons threshold of P < (.05/4 = .0125) was applied.
89-1	17534-17535	A	_
89-2	17536-17557	Bonferroni-correction	_
89-3	17558-17561	for	_
89-4	17562-17570	multiple	_
89-5	17571-17582	comparisons	_
89-6	17583-17592	threshold	_
89-7	17593-17595	of	_
89-8	17596-17597	P	_
89-9	17598-17599	<	_
89-10	17600-17601	(	_
89-11	17601-17604	.05	_
89-12	17604-17605	/	_
89-13	17605-17606	4	_
89-14	17607-17608	=	_
89-15	17609-17614	.0125	_
89-16	17614-17615	)	_
89-17	17616-17619	was	_
89-18	17620-17627	applied	_
89-19	17627-17628	.	_

#Text=Results
#Text=Participant Characteristics
#Text=Participant characteristics were summarized (Table 1).
90-1	17629-17636	Results	_
90-2	17637-17648	Participant	_
90-3	17649-17664	Characteristics	_
90-4	17665-17676	Participant	_
90-5	17677-17692	characteristics	_
90-6	17693-17697	were	_
90-7	17698-17708	summarized	_
90-8	17709-17710	(	_
90-9	17710-17715	Table	_
90-10	17716-17717	1	_
90-11	17717-17718	)	_
90-12	17718-17719	.	_

#Text=All STMA and LTMA participants used methamphetamine by smoking the drug.
91-1	17720-17723	All	_
91-2	17724-17728	STMA	_
91-3	17729-17732	and	_
91-4	17733-17737	LTMA	_
91-5	17738-17750	participants	_
91-6	17751-17755	used	_
91-7	17756-17771	methamphetamine	_
91-8	17772-17774	by	_
91-9	17775-17782	smoking	_
91-10	17783-17786	the	_
91-11	17787-17791	drug	_
91-12	17791-17792	.	_

#Text=STMA were younger than HC participants (P = .006).
92-1	17793-17797	STMA	_
92-2	17798-17802	were	_
92-3	17803-17810	younger	_
92-4	17811-17815	than	_
92-5	17816-17818	HC	_
92-6	17819-17831	participants	_
92-7	17832-17833	(	_
92-8	17833-17834	P	_
92-9	17835-17836	=	_
92-10	17837-17841	.006	_
92-11	17841-17842	)	_
92-12	17842-17843	.	_

#Text=STMA participants had the highest education (P < .001), and HC participants reported more education than did LTMA participants (P = .027).
93-1	17844-17848	STMA	_
93-2	17849-17861	participants	_
93-3	17862-17865	had	_
93-4	17866-17869	the	_
93-5	17870-17877	highest	_
93-6	17878-17887	education	_
93-7	17888-17889	(	_
93-8	17889-17890	P	_
93-9	17891-17892	<	_
93-10	17893-17897	.001	_
93-11	17897-17898	)	_
93-12	17898-17899	,	_
93-13	17900-17903	and	_
93-14	17904-17906	HC	_
93-15	17907-17919	participants	_
93-16	17920-17928	reported	_
93-17	17929-17933	more	_
93-18	17934-17943	education	_
93-19	17944-17948	than	_
93-20	17949-17952	did	_
93-21	17953-17957	LTMA	_
93-22	17958-17970	participants	_
93-23	17971-17972	(	_
93-24	17972-17973	P	_
93-25	17974-17975	=	_
93-26	17976-17980	.027	_
93-27	17980-17981	)	_
93-28	17981-17982	.	_

#Text=The duration of methamphetamine abstinence ranged from 1 to 3 months for the STMA group and from 16 to 40 months for the LTMA group.
94-1	17983-17986	The	_
94-2	17987-17995	duration	_
94-3	17996-17998	of	_
94-4	17999-18014	methamphetamine	_
94-5	18015-18025	abstinence	_
94-6	18026-18032	ranged	_
94-7	18033-18037	from	_
94-8	18038-18039	1	_
94-9	18040-18042	to	_
94-10	18043-18044	3	_
94-11	18045-18051	months	_
94-12	18052-18055	for	_
94-13	18056-18059	the	_
94-14	18060-18064	STMA	_
94-15	18065-18070	group	_
94-16	18071-18074	and	_
94-17	18075-18079	from	_
94-18	18080-18082	16	_
94-19	18083-18085	to	_
94-20	18086-18088	40	_
94-21	18089-18095	months	_
94-22	18096-18099	for	_
94-23	18100-18103	the	_
94-24	18104-18108	LTMA	_
94-25	18109-18114	group	_
94-26	18114-18115	.	_

#Text=The 3 groups did not differ in proportions reporting smoking, but HC participants were the least likely to report drinking alcohol among the 3 groups (P = .001).
95-1	18116-18119	The	_
95-2	18120-18121	3	_
95-3	18122-18128	groups	_
95-4	18129-18132	did	_
95-5	18133-18136	not	_
95-6	18137-18143	differ	_
95-7	18144-18146	in	_
95-8	18147-18158	proportions	_
95-9	18159-18168	reporting	_
95-10	18169-18176	smoking	_
95-11	18176-18177	,	_
95-12	18178-18181	but	_
95-13	18182-18184	HC	_
95-14	18185-18197	participants	_
95-15	18198-18202	were	_
95-16	18203-18206	the	_
95-17	18207-18212	least	_
95-18	18213-18219	likely	_
95-19	18220-18222	to	_
95-20	18223-18229	report	_
95-21	18230-18238	drinking	_
95-22	18239-18246	alcohol	_
95-23	18247-18252	among	_
95-24	18253-18256	the	_
95-25	18257-18258	3	_
95-26	18259-18265	groups	_
95-27	18266-18267	(	_
95-28	18267-18268	P	_
95-29	18269-18270	=	_
95-30	18271-18275	.001	_
95-31	18275-18276	)	_
95-32	18276-18277	.	_

#Text=Participant characteristics
#Text=Variable\tHC\tSTMA\tLTMA\tF/χ 2\tdf\tP\t \tn\t47\t49\t50\t–\t–\t–\t \tAge, y (SD)\t34.19 (7.39) \t30.06 (5.51) \t32.54 (6.33)\t5.02\t2, 143\t .008\t \tEducation, y (SD)\t10.06 (2.33) \t11.90 (2.86) \t 8.72 (2.25) \t 20.22\t 2, 143\t <.001\t \tDuration of MA abstinence, mo (SD)\t–\t1.65 (0.84)\t19.58 (3.89)\t−31.88\t1, 97\t<.001\t \tAge of first MA use, y (SD)\t–\t24.59 (5.25)\t25.44 (6.64)\t−0.70\t1, 97\t.483\t \tDuration of MA use, mo (SD)\t–\t66.12 (39.73)\t61.64 (32.60)\t0.61\t1, 97\t.541\t \tTobacco use, N (%)\t41 (87.23)\t42 (85.71)\t49 (98.00)\t5.12\t2\t.077\t \tAlcohol use, N (%)\t7 (14.89)\t24 (48.98)\t22 (44.00)\t13.92\t2\t.001\t \tAttentionala, (SD)\t38.00 (12.89)\t42.30 (16.49)\t51.45 (18.59)\t8.76\t2143\t<.001\t \tMotora, (SD)\t29.09 (15.72)\t39.59 (16.51)\t41.95 (18.18)\t7.91\t2143\t.001\t \tNonplanninga, (SD)\t35.63 (13.76)\t49.80 (17.87)\t63.80 (16.68)\t36.50\t2143\t<.001\t \tImpulsivitya, mean (SD)\t34.24 (8.96)\t43.86 (14.14)\t52.40 (14.68)\t23.94\t2143\t<.001\t \t
#Text=Abbreviations: HC, healthy comparison; LTMA, longer term methamphetamine abstinence; STMA, shorter-term methamphetamine abstinence; F, F-distribution; df, degrees of freedom.
96-1	18278-18289	Participant	_
96-2	18290-18305	characteristics	_
96-3	18306-18314	Variable	_
96-4	18315-18317	HC	_
96-5	18318-18322	STMA	_
96-6	18323-18327	LTMA	_
96-7	18328-18329	F	_
96-8	18329-18330	/	_
96-9	18330-18331	χ	_
96-10	18332-18333	2	_
96-11	18334-18336	df	_
96-12	18337-18338	P	_
96-13	18341-18342	n	_
96-14	18343-18345	47	_
96-15	18346-18348	49	_
96-16	18349-18351	50	_
96-17	18352-18353	–	_
96-18	18354-18355	–	_
96-19	18356-18357	–	_
96-20	18360-18363	Age	_
96-21	18363-18364	,	_
96-22	18365-18366	y	_
96-23	18367-18368	(	_
96-24	18368-18370	SD	_
96-25	18370-18371	)	_
96-26	18372-18377	34.19	_
96-27	18378-18379	(	_
96-28	18379-18383	7.39	_
96-29	18383-18384	)	_
96-30	18386-18391	30.06	_
96-31	18392-18393	(	_
96-32	18393-18397	5.51	_
96-33	18397-18398	)	_
96-34	18400-18405	32.54	_
96-35	18406-18407	(	_
96-36	18407-18411	6.33	_
96-37	18411-18412	)	_
96-38	18413-18417	5.02	_
96-39	18418-18419	2	_
96-40	18419-18420	,	_
96-41	18421-18424	143	_
96-42	18426-18430	.008	_
96-43	18433-18442	Education	_
96-44	18442-18443	,	_
96-45	18444-18445	y	_
96-46	18446-18447	(	_
96-47	18447-18449	SD	_
96-48	18449-18450	)	_
96-49	18451-18456	10.06	_
96-50	18457-18458	(	_
96-51	18458-18462	2.33	_
96-52	18462-18463	)	_
96-53	18465-18470	11.90	_
96-54	18471-18472	(	_
96-55	18472-18476	2.86	_
96-56	18476-18477	)	_
96-57	18480-18484	8.72	_
96-58	18485-18486	(	_
96-59	18486-18490	2.25	_
96-60	18490-18491	)	_
96-61	18494-18499	20.22	_
96-62	18501-18502	2	_
96-63	18502-18503	,	_
96-64	18504-18507	143	_
96-65	18509-18510	<	_
96-66	18510-18514	.001	_
96-67	18517-18525	Duration	_
96-68	18526-18528	of	_
96-69	18529-18531	MA	_
96-70	18532-18542	abstinence	_
96-71	18542-18543	,	_
96-72	18544-18546	mo	_
96-73	18547-18548	(	_
96-74	18548-18550	SD	_
96-75	18550-18551	)	_
96-76	18552-18553	–	_
96-77	18554-18558	1.65	_
96-78	18559-18560	(	_
96-79	18560-18564	0.84	_
96-80	18564-18565	)	_
96-81	18566-18571	19.58	_
96-82	18572-18573	(	_
96-83	18573-18577	3.89	_
96-84	18577-18578	)	_
96-85	18579-18580	−	_
96-86	18580-18585	31.88	_
96-87	18586-18587	1	_
96-88	18587-18588	,	_
96-89	18589-18591	97	_
96-90	18592-18593	<	_
96-91	18593-18597	.001	_
96-92	18600-18603	Age	_
96-93	18604-18606	of	_
96-94	18607-18612	first	_
96-95	18613-18615	MA	_
96-96	18616-18619	use	_
96-97	18619-18620	,	_
96-98	18621-18622	y	_
96-99	18623-18624	(	_
96-100	18624-18626	SD	_
96-101	18626-18627	)	_
96-102	18628-18629	–	_
96-103	18630-18635	24.59	_
96-104	18636-18637	(	_
96-105	18637-18641	5.25	_
96-106	18641-18642	)	_
96-107	18643-18648	25.44	_
96-108	18649-18650	(	_
96-109	18650-18654	6.64	_
96-110	18654-18655	)	_
96-111	18656-18657	−	_
96-112	18657-18661	0.70	_
96-113	18662-18663	1	_
96-114	18663-18664	,	_
96-115	18665-18667	97	_
96-116	18668-18672	.483	_
96-117	18675-18683	Duration	_
96-118	18684-18686	of	_
96-119	18687-18689	MA	_
96-120	18690-18693	use	_
96-121	18693-18694	,	_
96-122	18695-18697	mo	_
96-123	18698-18699	(	_
96-124	18699-18701	SD	_
96-125	18701-18702	)	_
96-126	18703-18704	–	_
96-127	18705-18710	66.12	_
96-128	18711-18712	(	_
96-129	18712-18717	39.73	_
96-130	18717-18718	)	_
96-131	18719-18724	61.64	_
96-132	18725-18726	(	_
96-133	18726-18731	32.60	_
96-134	18731-18732	)	_
96-135	18733-18737	0.61	_
96-136	18738-18739	1	_
96-137	18739-18740	,	_
96-138	18741-18743	97	_
96-139	18744-18748	.541	_
96-140	18751-18758	Tobacco	_
96-141	18759-18762	use	_
96-142	18762-18763	,	_
96-143	18764-18765	N	_
96-144	18766-18767	(	_
96-145	18767-18768	%	_
96-146	18768-18769	)	_
96-147	18770-18772	41	_
96-148	18773-18774	(	_
96-149	18774-18779	87.23	_
96-150	18779-18780	)	_
96-151	18781-18783	42	_
96-152	18784-18785	(	_
96-153	18785-18790	85.71	_
96-154	18790-18791	)	_
96-155	18792-18794	49	_
96-156	18795-18796	(	_
96-157	18796-18801	98.00	_
96-158	18801-18802	)	_
96-159	18803-18807	5.12	_
96-160	18808-18809	2	_
96-161	18810-18814	.077	_
96-162	18817-18824	Alcohol	_
96-163	18825-18828	use	_
96-164	18828-18829	,	_
96-165	18830-18831	N	_
96-166	18832-18833	(	_
96-167	18833-18834	%	_
96-168	18834-18835	)	_
96-169	18836-18837	7	_
96-170	18838-18839	(	_
96-171	18839-18844	14.89	_
96-172	18844-18845	)	_
96-173	18846-18848	24	_
96-174	18849-18850	(	_
96-175	18850-18855	48.98	_
96-176	18855-18856	)	_
96-177	18857-18859	22	_
96-178	18860-18861	(	_
96-179	18861-18866	44.00	_
96-180	18866-18867	)	_
96-181	18868-18873	13.92	_
96-182	18874-18875	2	_
96-183	18876-18880	.001	_
96-184	18883-18895	Attentionala	_
96-185	18895-18896	,	_
96-186	18897-18898	(	_
96-187	18898-18900	SD	_
96-188	18900-18901	)	_
96-189	18902-18907	38.00	_
96-190	18908-18909	(	_
96-191	18909-18914	12.89	_
96-192	18914-18915	)	_
96-193	18916-18921	42.30	_
96-194	18922-18923	(	_
96-195	18923-18928	16.49	_
96-196	18928-18929	)	_
96-197	18930-18935	51.45	_
96-198	18936-18937	(	_
96-199	18937-18942	18.59	_
96-200	18942-18943	)	_
96-201	18944-18948	8.76	_
96-202	18949-18953	2143	_
96-203	18954-18955	<	_
96-204	18955-18959	.001	_
96-205	18962-18968	Motora	_
96-206	18968-18969	,	_
96-207	18970-18971	(	_
96-208	18971-18973	SD	_
96-209	18973-18974	)	_
96-210	18975-18980	29.09	_
96-211	18981-18982	(	_
96-212	18982-18987	15.72	_
96-213	18987-18988	)	_
96-214	18989-18994	39.59	_
96-215	18995-18996	(	_
96-216	18996-19001	16.51	_
96-217	19001-19002	)	_
96-218	19003-19008	41.95	_
96-219	19009-19010	(	_
96-220	19010-19015	18.18	_
96-221	19015-19016	)	_
96-222	19017-19021	7.91	_
96-223	19022-19026	2143	_
96-224	19027-19031	.001	_
96-225	19034-19046	Nonplanninga	_
96-226	19046-19047	,	_
96-227	19048-19049	(	_
96-228	19049-19051	SD	_
96-229	19051-19052	)	_
96-230	19053-19058	35.63	_
96-231	19059-19060	(	_
96-232	19060-19065	13.76	_
96-233	19065-19066	)	_
96-234	19067-19072	49.80	_
96-235	19073-19074	(	_
96-236	19074-19079	17.87	_
96-237	19079-19080	)	_
96-238	19081-19086	63.80	_
96-239	19087-19088	(	_
96-240	19088-19093	16.68	_
96-241	19093-19094	)	_
96-242	19095-19100	36.50	_
96-243	19101-19105	2143	_
96-244	19106-19107	<	_
96-245	19107-19111	.001	_
96-246	19114-19126	Impulsivitya	_
96-247	19126-19127	,	_
96-248	19128-19132	mean	_
96-249	19133-19134	(	_
96-250	19134-19136	SD	_
96-251	19136-19137	)	_
96-252	19138-19143	34.24	_
96-253	19144-19145	(	_
96-254	19145-19149	8.96	_
96-255	19149-19150	)	_
96-256	19151-19156	43.86	_
96-257	19157-19158	(	_
96-258	19158-19163	14.14	_
96-259	19163-19164	)	_
96-260	19165-19170	52.40	_
96-261	19171-19172	(	_
96-262	19172-19177	14.68	_
96-263	19177-19178	)	_
96-264	19179-19184	23.94	_
96-265	19185-19189	2143	_
96-266	19190-19191	<	_
96-267	19191-19195	.001	_
96-268	19199-19212	Abbreviations	_
96-269	19212-19213	:	_
96-270	19214-19216	HC	_
96-271	19216-19217	,	_
96-272	19218-19225	healthy	_
96-273	19226-19236	comparison	_
96-274	19236-19237	;	_
96-275	19238-19242	LTMA	_
96-276	19242-19243	,	_
96-277	19244-19250	longer	_
96-278	19251-19255	term	_
96-279	19256-19271	methamphetamine	_
96-280	19272-19282	abstinence	_
96-281	19282-19283	;	_
96-282	19284-19288	STMA	_
96-283	19288-19289	,	_
96-284	19290-19302	shorter-term	_
96-285	19303-19318	methamphetamine	_
96-286	19319-19329	abstinence	_
96-287	19329-19330	;	_
96-288	19331-19332	F	_
96-289	19332-19333	,	_
96-290	19334-19348	F-distribution	_
96-291	19348-19349	;	_
96-292	19350-19352	df	_
96-293	19352-19353	,	_
96-294	19354-19361	degrees	_
96-295	19362-19364	of	_
96-296	19365-19372	freedom	_
96-297	19372-19373	.	_

#Text=aSubscale and total scores reflect validated transformation of Chinese version of Barratt Impulsiveness Scale-11 onto a 100-point scale.
97-1	19375-19384	aSubscale	_
97-2	19385-19388	and	_
97-3	19389-19394	total	_
97-4	19395-19401	scores	_
97-5	19402-19409	reflect	_
97-6	19410-19419	validated	_
97-7	19420-19434	transformation	_
97-8	19435-19437	of	_
97-9	19438-19445	Chinese	_
97-10	19446-19453	version	_
97-11	19454-19456	of	_
97-12	19457-19464	Barratt	_
97-13	19465-19478	Impulsiveness	_
97-14	19479-19484	Scale	_
97-15	19484-19485	-	_
97-16	19485-19487	11	_
97-17	19488-19492	onto	_
97-18	19493-19494	a	_
97-19	19495-19498	100	_
97-20	19498-19499	-	_
97-21	19499-19504	point	_
97-22	19505-19510	scale	_
97-23	19510-19511	.	_

#Text=Results
#Text=Methamphetamine Cue–Related Activation
#Text=There were no group differences or within-subject effects or group-by-condition interaction of methamphetamine cues relative to neutral cues in the ventral striatum, dorsal striatum, and anterior insula (Figure 2A, B, D).
98-1	19512-19519	Results	_
98-2	19521-19536	Methamphetamine	_
98-3	19537-19548	Cue–Related	_
98-4	19549-19559	Activation	_
98-5	19560-19565	There	_
98-6	19566-19570	were	_
98-7	19571-19573	no	_
98-8	19574-19579	group	_
98-9	19580-19591	differences	_
98-10	19592-19594	or	_
98-11	19595-19609	within-subject	_
98-12	19610-19617	effects	_
98-13	19618-19620	or	_
98-14	19621-19639	group-by-condition	_
98-15	19640-19651	interaction	_
98-16	19652-19654	of	_
98-17	19655-19670	methamphetamine	_
98-18	19671-19675	cues	_
98-19	19676-19684	relative	_
98-20	19685-19687	to	_
98-21	19688-19695	neutral	_
98-22	19696-19700	cues	_
98-23	19701-19703	in	_
98-24	19704-19707	the	_
98-25	19708-19715	ventral	_
98-26	19716-19724	striatum	_
98-27	19724-19725	,	_
98-28	19726-19732	dorsal	_
98-29	19733-19741	striatum	_
98-30	19741-19742	,	_
98-31	19743-19746	and	_
98-32	19747-19755	anterior	_
98-33	19756-19762	insula	_
98-34	19763-19764	(	_
98-35	19764-19770	Figure	_
98-36	19771-19773	2A	_
98-37	19773-19774	,	_
98-38	19775-19776	B	_
98-39	19776-19777	,	_
98-40	19778-19779	D	_
98-41	19779-19780	)	_
98-42	19780-19781	.	_

#Text=ROI analyses revealed a group difference in methamphetamine cue–related activation in the vmPFC (Figure 2C).
99-1	19782-19785	ROI	_
99-2	19786-19794	analyses	_
99-3	19795-19803	revealed	_
99-4	19804-19805	a	_
99-5	19806-19811	group	_
99-6	19812-19822	difference	_
99-7	19823-19825	in	_
99-8	19826-19841	methamphetamine	_
99-9	19842-19853	cue–related	_
99-10	19854-19864	activation	_
99-11	19865-19867	in	_
99-12	19868-19871	the	_
99-13	19872-19877	vmPFC	_
99-14	19878-19879	(	_
99-15	19879-19885	Figure	_
99-16	19886-19888	2C	_
99-17	19888-19889	)	_
99-18	19889-19890	.	_

#Text=The STMA relative to the HC group showed greater methamphetamine cue–related vmPFC activation (P = .003).
100-1	19891-19894	The	_
100-2	19895-19899	STMA	_
100-3	19900-19908	relative	_
100-4	19909-19911	to	_
100-5	19912-19915	the	_
100-6	19916-19918	HC	_
100-7	19919-19924	group	_
100-8	19925-19931	showed	_
100-9	19932-19939	greater	_
100-10	19940-19955	methamphetamine	_
100-11	19956-19967	cue–related	_
100-12	19968-19973	vmPFC	_
100-13	19974-19984	activation	_
100-14	19985-19986	(	_
100-15	19986-19987	P	_
100-16	19988-19989	=	_
100-17	19990-19994	.003	_
100-18	19994-19995	)	_
100-19	19995-19996	.	_

#Text=The LTMA relative to the HC group showed greater methamphetamine cue–related vmPFC activation (P = .020), though this did not survive multiple-comparisons correction.
101-1	19997-20000	The	_
101-2	20001-20005	LTMA	_
101-3	20006-20014	relative	_
101-4	20015-20017	to	_
101-5	20018-20021	the	_
101-6	20022-20024	HC	_
101-7	20025-20030	group	_
101-8	20031-20037	showed	_
101-9	20038-20045	greater	_
101-10	20046-20061	methamphetamine	_
101-11	20062-20073	cue–related	_
101-12	20074-20079	vmPFC	_
101-13	20080-20090	activation	_
101-14	20091-20092	(	_
101-15	20092-20093	P	_
101-16	20094-20095	=	_
101-17	20096-20100	.020	_
101-18	20100-20101	)	_
101-19	20101-20102	,	_
101-20	20103-20109	though	_
101-21	20110-20114	this	_
101-22	20115-20118	did	_
101-23	20119-20122	not	_
101-24	20123-20130	survive	_
101-25	20131-20151	multiple-comparisons	_
101-26	20152-20162	correction	_
101-27	20162-20163	.	_

#Text=The scatterplot and linear relationships between methamphetamine abstinence duration and methamphetamine cue–related vmPFC activations are shown in supplemental Figure 2 for STMA and LTMA separately.
102-1	20164-20167	The	_
102-2	20168-20179	scatterplot	_
102-3	20180-20183	and	_
102-4	20184-20190	linear	_
102-5	20191-20204	relationships	_
102-6	20205-20212	between	_
102-7	20213-20228	methamphetamine	_
102-8	20229-20239	abstinence	_
102-9	20240-20248	duration	_
102-10	20249-20252	and	_
102-11	20253-20268	methamphetamine	_
102-12	20269-20280	cue–related	_
102-13	20281-20286	vmPFC	_
102-14	20287-20298	activations	_
102-15	20299-20302	are	_
102-16	20303-20308	shown	_
102-17	20309-20311	in	_
102-18	20312-20324	supplemental	_
102-19	20325-20331	Figure	_
102-20	20332-20333	2	_
102-21	20334-20337	for	_
102-22	20338-20342	STMA	_
102-23	20343-20346	and	_
102-24	20347-20351	LTMA	_
102-25	20352-20362	separately	_
102-26	20362-20363	.	_

#Text=Within each group, methamphetamine cue–related vmPFC activation was greater than neutral cue–related activation (P < .001).
103-1	20364-20370	Within	_
103-2	20371-20375	each	_
103-3	20376-20381	group	_
103-4	20381-20382	,	_
103-5	20383-20398	methamphetamine	_
103-6	20399-20410	cue–related	_
103-7	20411-20416	vmPFC	_
103-8	20417-20427	activation	_
103-9	20428-20431	was	_
103-10	20432-20439	greater	_
103-11	20440-20444	than	_
103-12	20445-20452	neutral	_
103-13	20453-20464	cue–related	_
103-14	20465-20475	activation	_
103-15	20476-20477	(	_
103-16	20477-20478	P	_
103-17	20479-20480	<	_
103-18	20481-20485	.001	_
103-19	20485-20486	)	_
103-20	20486-20487	.	_

#Text=The group difference of methamphetamine cue–related vmPFC activation survived inclusion of covariates for tobacco use, alcohol use, age, and education (P = .024).
104-1	20488-20491	The	_
104-2	20492-20497	group	_
104-3	20498-20508	difference	_
104-4	20509-20511	of	_
104-5	20512-20527	methamphetamine	_
104-6	20528-20539	cue–related	_
104-7	20540-20545	vmPFC	_
104-8	20546-20556	activation	_
104-9	20557-20565	survived	_
104-10	20566-20575	inclusion	_
104-11	20576-20578	of	_
104-12	20579-20589	covariates	_
104-13	20590-20593	for	_
104-14	20594-20601	tobacco	_
104-15	20602-20605	use	_
104-16	20605-20606	,	_
104-17	20607-20614	alcohol	_
104-18	20615-20618	use	_
104-19	20618-20619	,	_
104-20	20620-20623	age	_
104-21	20623-20624	,	_
104-22	20625-20628	and	_
104-23	20629-20638	education	_
104-24	20639-20640	(	_
104-25	20640-20641	P	_
104-26	20642-20643	=	_
104-27	20644-20648	.024	_
104-28	20648-20649	)	_
104-29	20649-20650	.	_

#Text=Age and education were mean-centered within groups to adjust for group differences, and there was a negative main effect of age on vmPFC activation in response to methamphetamine cues (beta = −0.244, P = .004), and no effects of tobacco use, alcohol use, or education were found (P > .1).
105-1	20651-20654	Age	_
105-2	20655-20658	and	_
105-3	20659-20668	education	_
105-4	20669-20673	were	_
105-5	20674-20687	mean-centered	_
105-6	20688-20694	within	_
105-7	20695-20701	groups	_
105-8	20702-20704	to	_
105-9	20705-20711	adjust	_
105-10	20712-20715	for	_
105-11	20716-20721	group	_
105-12	20722-20733	differences	_
105-13	20733-20734	,	_
105-14	20735-20738	and	_
105-15	20739-20744	there	_
105-16	20745-20748	was	_
105-17	20749-20750	a	_
105-18	20751-20759	negative	_
105-19	20760-20764	main	_
105-20	20765-20771	effect	_
105-21	20772-20774	of	_
105-22	20775-20778	age	_
105-23	20779-20781	on	_
105-24	20782-20787	vmPFC	_
105-25	20788-20798	activation	_
105-26	20799-20801	in	_
105-27	20802-20810	response	_
105-28	20811-20813	to	_
105-29	20814-20829	methamphetamine	_
105-30	20830-20834	cues	_
105-31	20835-20836	(	_
105-32	20836-20840	beta	_
105-33	20841-20842	=	_
105-34	20843-20844	−	_
105-35	20844-20849	0.244	_
105-36	20849-20850	,	_
105-37	20851-20852	P	_
105-38	20853-20854	=	_
105-39	20855-20859	.004	_
105-40	20859-20860	)	_
105-41	20860-20861	,	_
105-42	20862-20865	and	_
105-43	20866-20868	no	_
105-44	20869-20876	effects	_
105-45	20877-20879	of	_
105-46	20880-20887	tobacco	_
105-47	20888-20891	use	_
105-48	20891-20892	,	_
105-49	20893-20900	alcohol	_
105-50	20901-20904	use	_
105-51	20904-20905	,	_
105-52	20906-20908	or	_
105-53	20909-20918	education	_
105-54	20919-20923	were	_
105-55	20924-20929	found	_
105-56	20930-20931	(	_
105-57	20931-20932	P	_
105-58	20933-20934	>	_
105-59	20935-20937	.1	_
105-60	20937-20938	)	_
105-61	20938-20939	.	_

#Text=No group-by-condition interaction of methamphetamine cues relative to neutral cues in the vmPFC was found.
106-1	20940-20942	No	_
106-2	20943-20961	group-by-condition	_
106-3	20962-20973	interaction	_
106-4	20974-20976	of	_
106-5	20977-20992	methamphetamine	_
106-6	20993-20997	cues	_
106-7	20998-21006	relative	_
106-8	21007-21009	to	_
106-9	21010-21017	neutral	_
106-10	21018-21022	cues	_
106-11	21023-21025	in	_
106-12	21026-21029	the	_
106-13	21030-21035	vmPFC	_
106-14	21036-21039	was	_
106-15	21040-21045	found	_
106-16	21045-21046	.	_

#Text=Whole-brain analyses did not identify additional regions with significant methamphetamine cue–related group or condition effects on brain activation.
107-1	21047-21058	Whole-brain	_
107-2	21059-21067	analyses	_
107-3	21068-21071	did	_
107-4	21072-21075	not	_
107-5	21076-21084	identify	_
107-6	21085-21095	additional	_
107-7	21096-21103	regions	_
107-8	21104-21108	with	_
107-9	21109-21120	significant	_
107-10	21121-21136	methamphetamine	_
107-11	21137-21148	cue–related	_
107-12	21149-21154	group	_
107-13	21155-21157	or	_
107-14	21158-21167	condition	_
107-15	21168-21175	effects	_
107-16	21176-21178	on	_
107-17	21179-21184	brain	_
107-18	21185-21195	activation	_
107-19	21195-21196	.	_

#Text=Average regional blood oxygen-level–dependent signal differences between and within groups in the ventral striatum (A), dorsal striatum (B), ventromedial prefrontal cortex (vmPFC) (C), and anterior insula (D).
108-1	21197-21204	Average	_
108-2	21205-21213	regional	_
108-3	21214-21219	blood	_
108-4	21220-21242	oxygen-level–dependent	_
108-5	21243-21249	signal	_
108-6	21250-21261	differences	_
108-7	21262-21269	between	_
108-8	21270-21273	and	_
108-9	21274-21280	within	_
108-10	21281-21287	groups	_
108-11	21288-21290	in	_
108-12	21291-21294	the	_
108-13	21295-21302	ventral	_
108-14	21303-21311	striatum	_
108-15	21312-21313	(	_
108-16	21313-21314	A	_
108-17	21314-21315	)	_
108-18	21315-21316	,	_
108-19	21317-21323	dorsal	_
108-20	21324-21332	striatum	_
108-21	21333-21334	(	_
108-22	21334-21335	B	_
108-23	21335-21336	)	_
108-24	21336-21337	,	_
108-25	21338-21350	ventromedial	_
108-26	21351-21361	prefrontal	_
108-27	21362-21368	cortex	_
108-28	21369-21370	(	_
108-29	21370-21375	vmPFC	_
108-30	21375-21376	)	_
108-31	21377-21378	(	_
108-32	21378-21379	C	_
108-33	21379-21380	)	_
108-34	21380-21381	,	_
108-35	21382-21385	and	_
108-36	21386-21394	anterior	_
108-37	21395-21401	insula	_
108-38	21402-21403	(	_
108-39	21403-21404	D	_
108-40	21404-21405	)	_
108-41	21405-21406	.	_

#Text=Error bars indicate standard error.
109-1	21407-21412	Error	_
109-2	21413-21417	bars	_
109-3	21418-21426	indicate	_
109-4	21427-21435	standard	_
109-5	21436-21441	error	_
109-6	21441-21442	.	_

#Text=HC, healthy comparison; LTMA, longer-term methamphetamine abstinence participants; MA, methamphetamine cue; NE, neutral cue; SE, sexual cue; STMA, shorter term methamphetamine abstinence participants.
110-1	21443-21445	HC	_
110-2	21445-21446	,	_
110-3	21447-21454	healthy	_
110-4	21455-21465	comparison	_
110-5	21465-21466	;	_
110-6	21467-21471	LTMA	_
110-7	21471-21472	,	_
110-8	21473-21484	longer-term	_
110-9	21485-21500	methamphetamine	_
110-10	21501-21511	abstinence	_
110-11	21512-21524	participants	_
110-12	21524-21525	;	_
110-13	21526-21528	MA	_
110-14	21528-21529	,	_
110-15	21530-21545	methamphetamine	_
110-16	21546-21549	cue	_
110-17	21549-21550	;	_
110-18	21551-21553	NE	_
110-19	21553-21554	,	_
110-20	21555-21562	neutral	_
110-21	21563-21566	cue	_
110-22	21566-21567	;	_
110-23	21568-21570	SE	_
110-24	21570-21571	,	_
110-25	21572-21578	sexual	_
110-26	21579-21582	cue	_
110-27	21582-21583	;	_
110-28	21584-21588	STMA	_
110-29	21588-21589	,	_
110-30	21590-21597	shorter	_
110-31	21598-21602	term	_
110-32	21603-21618	methamphetamine	_
110-33	21619-21629	abstinence	_
110-34	21630-21642	participants	_
110-35	21642-21643	.	_

#Text=*P < .05, **P < .01, ***P < .001.
111-1	21644-21645	*	_
111-2	21645-21646	P	_
111-3	21647-21648	<	_
111-4	21649-21652	.05	_
111-5	21652-21653	,	_
111-6	21654-21655	*	_
111-7	21655-21656	*	_
111-8	21656-21657	P	_
111-9	21658-21659	<	_
111-10	21660-21663	.01	_
111-11	21663-21664	,	_
111-12	21665-21666	*	_
111-13	21666-21667	*	_
111-14	21667-21668	*	_
111-15	21668-21669	P	_
111-16	21670-21671	<	_
111-17	21672-21676	.001	_
111-18	21676-21677	.	_

#Text=Sexual Cue–Related Activation
#Text=There were no group differences or group-by-condition interactions in sexual cue–related activation in the ventral striatum, dorsal striatum, or vmPFC.
112-1	21678-21684	Sexual	_
112-2	21685-21696	Cue–Related	_
112-3	21697-21707	Activation	_
112-4	21708-21713	There	_
112-5	21714-21718	were	_
112-6	21719-21721	no	_
112-7	21722-21727	group	_
112-8	21728-21739	differences	_
112-9	21740-21742	or	_
112-10	21743-21761	group-by-condition	_
112-11	21762-21774	interactions	_
112-12	21775-21777	in	_
112-13	21778-21784	sexual	_
112-14	21785-21796	cue–related	_
112-15	21797-21807	activation	_
112-16	21808-21810	in	_
112-17	21811-21814	the	_
112-18	21815-21822	ventral	_
112-19	21823-21831	striatum	_
112-20	21831-21832	,	_
112-21	21833-21839	dorsal	_
112-22	21840-21848	striatum	_
112-23	21848-21849	,	_
112-24	21850-21852	or	_
112-25	21853-21858	vmPFC	_
112-26	21858-21859	.	_

#Text=Within groups, sexual cue–related positive activation was greater than neutral and/or methamphetamine cue–related activation in the ventral striatum, dorsal striatum, and vmPFC (Figure 2A–C).
113-1	21860-21866	Within	_
113-2	21867-21873	groups	_
113-3	21873-21874	,	_
113-4	21875-21881	sexual	_
113-5	21882-21893	cue–related	_
113-6	21894-21902	positive	_
113-7	21903-21913	activation	_
113-8	21914-21917	was	_
113-9	21918-21925	greater	_
113-10	21926-21930	than	_
113-11	21931-21938	neutral	_
113-12	21939-21942	and	_
113-13	21942-21943	/	_
113-14	21943-21945	or	_
113-15	21946-21961	methamphetamine	_
113-16	21962-21973	cue–related	_
113-17	21974-21984	activation	_
113-18	21985-21987	in	_
113-19	21988-21991	the	_
113-20	21992-21999	ventral	_
113-21	22000-22008	striatum	_
113-22	22008-22009	,	_
113-23	22010-22016	dorsal	_
113-24	22017-22025	striatum	_
113-25	22025-22026	,	_
113-26	22027-22030	and	_
113-27	22031-22036	vmPFC	_
113-28	22037-22038	(	_
113-29	22038-22044	Figure	_
113-30	22045-22049	2A–C	_
113-31	22049-22050	)	_
113-32	22050-22051	.	_

#Text=ROI analyses revealed a significant interaction of group and condition in the anterior insula (Figure 2D).
114-1	22052-22055	ROI	_
114-2	22056-22064	analyses	_
114-3	22065-22073	revealed	_
114-4	22074-22075	a	_
114-5	22076-22087	significant	_
114-6	22088-22099	interaction	_
114-7	22100-22102	of	_
114-8	22103-22108	group	_
114-9	22109-22112	and	_
114-10	22113-22122	condition	_
114-11	22123-22125	in	_
114-12	22126-22129	the	_
114-13	22130-22138	anterior	_
114-14	22139-22145	insula	_
114-15	22146-22147	(	_
114-16	22147-22153	Figure	_
114-17	22154-22156	2D	_
114-18	22156-22157	)	_
114-19	22157-22158	.	_

#Text=Relative to HC participants, both STMA and LTMA groups displayed greater sexual cue–related anterior insula activation relative to methamphetamine cues (STMA vs HC: P = .004; LTMA vs HC: P = .016) and neutral cues (STMA vs HC: P = .009; LTMA vs HC: P = .010), and there were no differences between the STMA and LTMA groups in anterior insula responses (P > .5).
115-1	22159-22167	Relative	_
115-2	22168-22170	to	_
115-3	22171-22173	HC	_
115-4	22174-22186	participants	_
115-5	22186-22187	,	_
115-6	22188-22192	both	_
115-7	22193-22197	STMA	_
115-8	22198-22201	and	_
115-9	22202-22206	LTMA	_
115-10	22207-22213	groups	_
115-11	22214-22223	displayed	_
115-12	22224-22231	greater	_
115-13	22232-22238	sexual	_
115-14	22239-22250	cue–related	_
115-15	22251-22259	anterior	_
115-16	22260-22266	insula	_
115-17	22267-22277	activation	_
115-18	22278-22286	relative	_
115-19	22287-22289	to	_
115-20	22290-22305	methamphetamine	_
115-21	22306-22310	cues	_
115-22	22311-22312	(	_
115-23	22312-22316	STMA	_
115-24	22317-22319	vs	_
115-25	22320-22322	HC	_
115-26	22322-22323	:	_
115-27	22324-22325	P	_
115-28	22326-22327	=	_
115-29	22328-22332	.004	_
115-30	22332-22333	;	_
115-31	22334-22338	LTMA	_
115-32	22339-22341	vs	_
115-33	22342-22344	HC	_
115-34	22344-22345	:	_
115-35	22346-22347	P	_
115-36	22348-22349	=	_
115-37	22350-22354	.016	_
115-38	22354-22355	)	_
115-39	22356-22359	and	_
115-40	22360-22367	neutral	_
115-41	22368-22372	cues	_
115-42	22373-22374	(	_
115-43	22374-22378	STMA	_
115-44	22379-22381	vs	_
115-45	22382-22384	HC	_
115-46	22384-22385	:	_
115-47	22386-22387	P	_
115-48	22388-22389	=	_
115-49	22390-22394	.009	_
115-50	22394-22395	;	_
115-51	22396-22400	LTMA	_
115-52	22401-22403	vs	_
115-53	22404-22406	HC	_
115-54	22406-22407	:	_
115-55	22408-22409	P	_
115-56	22410-22411	=	_
115-57	22412-22416	.010	_
115-58	22416-22417	)	_
115-59	22417-22418	,	_
115-60	22419-22422	and	_
115-61	22423-22428	there	_
115-62	22429-22433	were	_
115-63	22434-22436	no	_
115-64	22437-22448	differences	_
115-65	22449-22456	between	_
115-66	22457-22460	the	_
115-67	22461-22465	STMA	_
115-68	22466-22469	and	_
115-69	22470-22474	LTMA	_
115-70	22475-22481	groups	_
115-71	22482-22484	in	_
115-72	22485-22493	anterior	_
115-73	22494-22500	insula	_
115-74	22501-22510	responses	_
115-75	22511-22512	(	_
115-76	22512-22513	P	_
115-77	22514-22515	>	_
115-78	22516-22518	.5	_
115-79	22518-22519	)	_
115-80	22519-22520	.	_

#Text=Whole-brain analysis identified a significant interaction of group and condition on activation in the left superior frontal cortex (SFC) (peak F = 7.14; peak x, y, z coordinates = −27, −22, 32; Brodmann area 6; cluster size 305, pFWE = 0.042) (Figure 3) that was associated with sexual cues.
116-1	22521-22532	Whole-brain	_
116-2	22533-22541	analysis	_
116-3	22542-22552	identified	_
116-4	22553-22554	a	_
116-5	22555-22566	significant	_
116-6	22567-22578	interaction	_
116-7	22579-22581	of	_
116-8	22582-22587	group	_
116-9	22588-22591	and	_
116-10	22592-22601	condition	_
116-11	22602-22604	on	_
116-12	22605-22615	activation	_
116-13	22616-22618	in	_
116-14	22619-22622	the	_
116-15	22623-22627	left	_
116-16	22628-22636	superior	_
116-17	22637-22644	frontal	_
116-18	22645-22651	cortex	_
116-19	22652-22653	(	_
116-20	22653-22656	SFC	_
116-21	22656-22657	)	_
116-22	22658-22659	(	_
116-23	22659-22663	peak	_
116-24	22664-22665	F	_
116-25	22666-22667	=	_
116-26	22668-22672	7.14	_
116-27	22672-22673	;	_
116-28	22674-22678	peak	_
116-29	22679-22680	x	_
116-30	22680-22681	,	_
116-31	22682-22683	y	_
116-32	22683-22684	,	_
116-33	22685-22686	z	_
116-34	22687-22698	coordinates	_
116-35	22699-22700	=	_
116-36	22701-22702	−	_
116-37	22702-22704	27	_
116-38	22704-22705	,	_
116-39	22706-22707	−	_
116-40	22707-22709	22	_
116-41	22709-22710	,	_
116-42	22711-22713	32	_
116-43	22713-22714	;	_
116-44	22715-22723	Brodmann	_
116-45	22724-22728	area	_
116-46	22729-22730	6	_
116-47	22730-22731	;	_
116-48	22732-22739	cluster	_
116-49	22740-22744	size	_
116-50	22745-22748	305	_
116-51	22748-22749	,	_
116-52	22750-22754	pFWE	_
116-53	22755-22756	=	_
116-54	22757-22762	0.042	_
116-55	22762-22763	)	_
116-56	22764-22765	(	_
116-57	22765-22771	Figure	_
116-58	22772-22773	3	_
116-59	22773-22774	)	_
116-60	22775-22779	that	_
116-61	22780-22783	was	_
116-62	22784-22794	associated	_
116-63	22795-22799	with	_
116-64	22800-22806	sexual	_
116-65	22807-22811	cues	_
116-66	22811-22812	.	_

#Text=STMA participants showed greater sexual cue–related SFC activation relative to neutral cue–related negative activity (P < .05).
117-1	22813-22817	STMA	_
117-2	22818-22830	participants	_
117-3	22831-22837	showed	_
117-4	22838-22845	greater	_
117-5	22846-22852	sexual	_
117-6	22853-22864	cue–related	_
117-7	22865-22868	SFC	_
117-8	22869-22879	activation	_
117-9	22880-22888	relative	_
117-10	22889-22891	to	_
117-11	22892-22899	neutral	_
117-12	22900-22911	cue–related	_
117-13	22912-22920	negative	_
117-14	22921-22929	activity	_
117-15	22930-22931	(	_
117-16	22931-22932	P	_
117-17	22933-22934	<	_
117-18	22935-22938	.05	_
117-19	22938-22939	)	_
117-20	22939-22940	.	_

#Text=LTMA participants showed greater sexual cue–related SFC activation relative to neutral and methamphetamine cue–related deactivation (P < .001).
118-1	22941-22945	LTMA	_
118-2	22946-22958	participants	_
118-3	22959-22965	showed	_
118-4	22966-22973	greater	_
118-5	22974-22980	sexual	_
118-6	22981-22992	cue–related	_
118-7	22993-22996	SFC	_
118-8	22997-23007	activation	_
118-9	23008-23016	relative	_
118-10	23017-23019	to	_
118-11	23020-23027	neutral	_
118-12	23028-23031	and	_
118-13	23032-23047	methamphetamine	_
118-14	23048-23059	cue–related	_
118-15	23060-23072	deactivation	_
118-16	23073-23074	(	_
118-17	23074-23075	P	_
118-18	23076-23077	<	_
118-19	23078-23082	.001	_
118-20	23082-23083	)	_
118-21	23083-23084	.	_

#Text=Post-hoc pairwise comparisons revealed LTMA sexual cue–related SFC activation was greater than that in HC participants (P < .001) (Figure 3B).
119-1	23085-23093	Post-hoc	_
119-2	23094-23102	pairwise	_
119-3	23103-23114	comparisons	_
119-4	23115-23123	revealed	_
119-5	23124-23128	LTMA	_
119-6	23129-23135	sexual	_
119-7	23136-23147	cue–related	_
119-8	23148-23151	SFC	_
119-9	23152-23162	activation	_
119-10	23163-23166	was	_
119-11	23167-23174	greater	_
119-12	23175-23179	than	_
119-13	23180-23184	that	_
119-14	23185-23187	in	_
119-15	23188-23190	HC	_
119-16	23191-23203	participants	_
119-17	23204-23205	(	_
119-18	23205-23206	P	_
119-19	23207-23208	<	_
119-20	23209-23213	.001	_
119-21	23213-23214	)	_
119-22	23215-23216	(	_
119-23	23216-23222	Figure	_
119-24	23223-23225	3B	_
119-25	23225-23226	)	_
119-26	23226-23227	.	_

#Text=The scatterplot and linear relationships between methamphetamine abstinence duration and sexual cue–related anterior insula activations, methamphetamine abstinence duration, and sexual cue–related SFC activations are shown in supplemental Figure 3 and supplemental Figure 4 for STMA and LTMA separately.
120-1	23228-23231	The	_
120-2	23232-23243	scatterplot	_
120-3	23244-23247	and	_
120-4	23248-23254	linear	_
120-5	23255-23268	relationships	_
120-6	23269-23276	between	_
120-7	23277-23292	methamphetamine	_
120-8	23293-23303	abstinence	_
120-9	23304-23312	duration	_
120-10	23313-23316	and	_
120-11	23317-23323	sexual	_
120-12	23324-23335	cue–related	_
120-13	23336-23344	anterior	_
120-14	23345-23351	insula	_
120-15	23352-23363	activations	_
120-16	23363-23364	,	_
120-17	23365-23380	methamphetamine	_
120-18	23381-23391	abstinence	_
120-19	23392-23400	duration	_
120-20	23400-23401	,	_
120-21	23402-23405	and	_
120-22	23406-23412	sexual	_
120-23	23413-23424	cue–related	_
120-24	23425-23428	SFC	_
120-25	23429-23440	activations	_
120-26	23441-23444	are	_
120-27	23445-23450	shown	_
120-28	23451-23453	in	_
120-29	23454-23466	supplemental	_
120-30	23467-23473	Figure	_
120-31	23474-23475	3	_
120-32	23476-23479	and	_
120-33	23480-23492	supplemental	_
120-34	23493-23499	Figure	_
120-35	23500-23501	4	_
120-36	23502-23505	for	_
120-37	23506-23510	STMA	_
120-38	23511-23514	and	_
120-39	23515-23519	LTMA	_
120-40	23520-23530	separately	_
120-41	23530-23531	.	_

#Text=The significant interaction of group by condition in the anterior insula survived inclusion of covariates for tobacco use, alcohol use, age, and education (P = .007), the group difference of sexual cue-related SFC activation also survived inclusion of covariates for tobacco use, alcohol use, age, and education (P = .004).
121-1	23532-23535	The	_
121-2	23536-23547	significant	_
121-3	23548-23559	interaction	_
121-4	23560-23562	of	_
121-5	23563-23568	group	_
121-6	23569-23571	by	_
121-7	23572-23581	condition	_
121-8	23582-23584	in	_
121-9	23585-23588	the	_
121-10	23589-23597	anterior	_
121-11	23598-23604	insula	_
121-12	23605-23613	survived	_
121-13	23614-23623	inclusion	_
121-14	23624-23626	of	_
121-15	23627-23637	covariates	_
121-16	23638-23641	for	_
121-17	23642-23649	tobacco	_
121-18	23650-23653	use	_
121-19	23653-23654	,	_
121-20	23655-23662	alcohol	_
121-21	23663-23666	use	_
121-22	23666-23667	,	_
121-23	23668-23671	age	_
121-24	23671-23672	,	_
121-25	23673-23676	and	_
121-26	23677-23686	education	_
121-27	23687-23688	(	_
121-28	23688-23689	P	_
121-29	23690-23691	=	_
121-30	23692-23696	.007	_
121-31	23696-23697	)	_
121-32	23697-23698	,	_
121-33	23699-23702	the	_
121-34	23703-23708	group	_
121-35	23709-23719	difference	_
121-36	23720-23722	of	_
121-37	23723-23729	sexual	_
121-38	23730-23741	cue-related	_
121-39	23742-23745	SFC	_
121-40	23746-23756	activation	_
121-41	23757-23761	also	_
121-42	23762-23770	survived	_
121-43	23771-23780	inclusion	_
121-44	23781-23783	of	_
121-45	23784-23794	covariates	_
121-46	23795-23798	for	_
121-47	23799-23806	tobacco	_
121-48	23807-23810	use	_
121-49	23810-23811	,	_
121-50	23812-23819	alcohol	_
121-51	23820-23823	use	_
121-52	23823-23824	,	_
121-53	23825-23828	age	_
121-54	23828-23829	,	_
121-55	23830-23833	and	_
121-56	23834-23843	education	_
121-57	23844-23845	(	_
121-58	23845-23846	P	_
121-59	23847-23848	=	_
121-60	23849-23853	.004	_
121-61	23853-23854	)	_
121-62	23854-23855	.	_

#Text=Age and education were mean-centered within groups to adjust for group differences, and there were no effects of tobacco use, alcohol use, age, or education on group by condition interaction of anterior insula, or SFC in response to sexual cues (P > .05).
122-1	23856-23859	Age	_
122-2	23860-23863	and	_
122-3	23864-23873	education	_
122-4	23874-23878	were	_
122-5	23879-23892	mean-centered	_
122-6	23893-23899	within	_
122-7	23900-23906	groups	_
122-8	23907-23909	to	_
122-9	23910-23916	adjust	_
122-10	23917-23920	for	_
122-11	23921-23926	group	_
122-12	23927-23938	differences	_
122-13	23938-23939	,	_
122-14	23940-23943	and	_
122-15	23944-23949	there	_
122-16	23950-23954	were	_
122-17	23955-23957	no	_
122-18	23958-23965	effects	_
122-19	23966-23968	of	_
122-20	23969-23976	tobacco	_
122-21	23977-23980	use	_
122-22	23980-23981	,	_
122-23	23982-23989	alcohol	_
122-24	23990-23993	use	_
122-25	23993-23994	,	_
122-26	23995-23998	age	_
122-27	23998-23999	,	_
122-28	24000-24002	or	_
122-29	24003-24012	education	_
122-30	24013-24015	on	_
122-31	24016-24021	group	_
122-32	24022-24024	by	_
122-33	24025-24034	condition	_
122-34	24035-24046	interaction	_
122-35	24047-24049	of	_
122-36	24050-24058	anterior	_
122-37	24059-24065	insula	_
122-38	24065-24066	,	_
122-39	24067-24069	or	_
122-40	24070-24073	SFC	_
122-41	24074-24076	in	_
122-42	24077-24085	response	_
122-43	24086-24088	to	_
122-44	24089-24095	sexual	_
122-45	24096-24100	cues	_
122-46	24101-24102	(	_
122-47	24102-24103	P	_
122-48	24104-24105	>	_
122-49	24106-24109	.05	_
122-50	24109-24110	)	_
122-51	24110-24111	.	_

#Text=Interaction of group and condition in the left SFC (A).
123-1	24112-24123	Interaction	_
123-2	24124-24126	of	_
123-3	24127-24132	group	_
123-4	24133-24136	and	_
123-5	24137-24146	condition	_
123-6	24147-24149	in	_
123-7	24150-24153	the	_
123-8	24154-24158	left	_
123-9	24159-24162	SFC	_
123-10	24163-24164	(	_
123-11	24164-24165	A	_
123-12	24165-24166	)	_
123-13	24166-24167	.	_

#Text=Average regional blood oxygen-level–dependent signal differences between and within groups in the left SFC are shown in (B).
124-1	24168-24175	Average	_
124-2	24176-24184	regional	_
124-3	24185-24190	blood	_
124-4	24191-24213	oxygen-level–dependent	_
124-5	24214-24220	signal	_
124-6	24221-24232	differences	_
124-7	24233-24240	between	_
124-8	24241-24244	and	_
124-9	24245-24251	within	_
124-10	24252-24258	groups	_
124-11	24259-24261	in	_
124-12	24262-24265	the	_
124-13	24266-24270	left	_
124-14	24271-24274	SFC	_
124-15	24275-24278	are	_
124-16	24279-24284	shown	_
124-17	24285-24287	in	_
124-18	24288-24289	(	_
124-19	24289-24290	B	_
124-20	24290-24291	)	_
124-21	24291-24292	.	_

#Text=Error bars indicate standard error.
125-1	24293-24298	Error	_
125-2	24299-24303	bars	_
125-3	24304-24312	indicate	_
125-4	24313-24321	standard	_
125-5	24322-24327	error	_
125-6	24327-24328	.	_

#Text=HC, healthy controls; LTMA, longer term methamphetamine abstinence participants; MA, methamphetamine cue; NE, neutral cue; SE, sexual cue; STMA, shorter term methamphetamine abstinence participants.
126-1	24329-24331	HC	_
126-2	24331-24332	,	_
126-3	24333-24340	healthy	_
126-4	24341-24349	controls	_
126-5	24349-24350	;	_
126-6	24351-24355	LTMA	_
126-7	24355-24356	,	_
126-8	24357-24363	longer	_
126-9	24364-24368	term	_
126-10	24369-24384	methamphetamine	_
126-11	24385-24395	abstinence	_
126-12	24396-24408	participants	_
126-13	24408-24409	;	_
126-14	24410-24412	MA	_
126-15	24412-24413	,	_
126-16	24414-24429	methamphetamine	_
126-17	24430-24433	cue	_
126-18	24433-24434	;	_
126-19	24435-24437	NE	_
126-20	24437-24438	,	_
126-21	24439-24446	neutral	_
126-22	24447-24450	cue	_
126-23	24450-24451	;	_
126-24	24452-24454	SE	_
126-25	24454-24455	,	_
126-26	24456-24462	sexual	_
126-27	24463-24466	cue	_
126-28	24466-24467	;	_
126-29	24468-24472	STMA	_
126-30	24472-24473	,	_
126-31	24474-24481	shorter	_
126-32	24482-24486	term	_
126-33	24487-24502	methamphetamine	_
126-34	24503-24513	abstinence	_
126-35	24514-24526	participants	_
126-36	24526-24527	.	_

#Text=*P < .05, **P < .01, ***P < .001.
127-1	24528-24529	*	_
127-2	24529-24530	P	_
127-3	24531-24532	<	_
127-4	24533-24536	.05	_
127-5	24536-24537	,	_
127-6	24538-24539	*	_
127-7	24539-24540	*	_
127-8	24540-24541	P	_
127-9	24542-24543	<	_
127-10	24544-24547	.01	_
127-11	24547-24548	,	_
127-12	24549-24550	*	_
127-13	24550-24551	*	_
127-14	24551-24552	*	_
127-15	24552-24553	P	_
127-16	24554-24555	<	_
127-17	24556-24560	.001	_
127-18	24560-24561	.	_

#Text=Relationships Between Methamphetamine Use, Impulsivity, and Regional Brain Activations
#Text=LTMA participants reported greater impulsivity relative to HC and STMA participants (P = .001), and STMA participants reported greater impulsivity relative to HC participants (P < .001).
128-1	24562-24575	Relationships	_
128-2	24576-24583	Between	_
128-3	24584-24599	Methamphetamine	_
128-4	24600-24603	Use	_
128-5	24603-24604	,	_
128-6	24605-24616	Impulsivity	_
128-7	24616-24617	,	_
128-8	24618-24621	and	_
128-9	24622-24630	Regional	_
128-10	24631-24636	Brain	_
128-11	24637-24648	Activations	_
128-12	24649-24653	LTMA	_
128-13	24654-24666	participants	_
128-14	24667-24675	reported	_
128-15	24676-24683	greater	_
128-16	24684-24695	impulsivity	_
128-17	24696-24704	relative	_
128-18	24705-24707	to	_
128-19	24708-24710	HC	_
128-20	24711-24714	and	_
128-21	24715-24719	STMA	_
128-22	24720-24732	participants	_
128-23	24733-24734	(	_
128-24	24734-24735	P	_
128-25	24736-24737	=	_
128-26	24738-24742	.001	_
128-27	24742-24743	)	_
128-28	24743-24744	,	_
128-29	24745-24748	and	_
128-30	24749-24753	STMA	_
128-31	24754-24766	participants	_
128-32	24767-24775	reported	_
128-33	24776-24783	greater	_
128-34	24784-24795	impulsivity	_
128-35	24796-24804	relative	_
128-36	24805-24807	to	_
128-37	24808-24810	HC	_
128-38	24811-24823	participants	_
128-39	24824-24825	(	_
128-40	24825-24826	P	_
128-41	24827-24828	<	_
128-42	24829-24833	.001	_
128-43	24833-24834	)	_
128-44	24834-24835	.	_

#Text=In STMA participants, attentional impulsivity negatively correlated with sexual cue–related SFC activation (r = −0.371, P = .009) (Figure 4A) and methamphetamine cue–related SFC activation (r = −0.340, P = .017) (supplemental Figure 5a), nonplanning impulsivity negatively correlated with sexual cue–related SFC activation (r = −0.327, P = .022) (Figure 4B) and methamphetamine cue–related SFC activation (r = −0.308, P = .031) (supplemental Figure 5b), though these findings did not survive Bonferroni correction.
129-1	24836-24838	In	_
129-2	24839-24843	STMA	_
129-3	24844-24856	participants	_
129-4	24856-24857	,	_
129-5	24858-24869	attentional	_
129-6	24870-24881	impulsivity	_
129-7	24882-24892	negatively	_
129-8	24893-24903	correlated	_
129-9	24904-24908	with	_
129-10	24909-24915	sexual	_
129-11	24916-24927	cue–related	_
129-12	24928-24931	SFC	_
129-13	24932-24942	activation	_
129-14	24943-24944	(	_
129-15	24944-24945	r	_
129-16	24946-24947	=	_
129-17	24948-24949	−	_
129-18	24949-24954	0.371	_
129-19	24954-24955	,	_
129-20	24956-24957	P	_
129-21	24958-24959	=	_
129-22	24960-24964	.009	_
129-23	24964-24965	)	_
129-24	24966-24967	(	_
129-25	24967-24973	Figure	_
129-26	24974-24976	4A	_
129-27	24976-24977	)	_
129-28	24978-24981	and	_
129-29	24982-24997	methamphetamine	_
129-30	24998-25009	cue–related	_
129-31	25010-25013	SFC	_
129-32	25014-25024	activation	_
129-33	25025-25026	(	_
129-34	25026-25027	r	_
129-35	25028-25029	=	_
129-36	25030-25031	−	_
129-37	25031-25036	0.340	_
129-38	25036-25037	,	_
129-39	25038-25039	P	_
129-40	25040-25041	=	_
129-41	25042-25046	.017	_
129-42	25046-25047	)	_
129-43	25048-25049	(	_
129-44	25049-25061	supplemental	_
129-45	25062-25068	Figure	_
129-46	25069-25071	5a	_
129-47	25071-25072	)	_
129-48	25072-25073	,	_
129-49	25074-25085	nonplanning	_
129-50	25086-25097	impulsivity	_
129-51	25098-25108	negatively	_
129-52	25109-25119	correlated	_
129-53	25120-25124	with	_
129-54	25125-25131	sexual	_
129-55	25132-25143	cue–related	_
129-56	25144-25147	SFC	_
129-57	25148-25158	activation	_
129-58	25159-25160	(	_
129-59	25160-25161	r	_
129-60	25162-25163	=	_
129-61	25164-25165	−	_
129-62	25165-25170	0.327	_
129-63	25170-25171	,	_
129-64	25172-25173	P	_
129-65	25174-25175	=	_
129-66	25176-25180	.022	_
129-67	25180-25181	)	_
129-68	25182-25183	(	_
129-69	25183-25189	Figure	_
129-70	25190-25192	4B	_
129-71	25192-25193	)	_
129-72	25194-25197	and	_
129-73	25198-25213	methamphetamine	_
129-74	25214-25225	cue–related	_
129-75	25226-25229	SFC	_
129-76	25230-25240	activation	_
129-77	25241-25242	(	_
129-78	25242-25243	r	_
129-79	25244-25245	=	_
129-80	25246-25247	−	_
129-81	25247-25252	0.308	_
129-82	25252-25253	,	_
129-83	25254-25255	P	_
129-84	25256-25257	=	_
129-85	25258-25262	.031	_
129-86	25262-25263	)	_
129-87	25264-25265	(	_
129-88	25265-25277	supplemental	_
129-89	25278-25284	Figure	_
129-90	25285-25287	5b	_
129-91	25287-25288	)	_
129-92	25288-25289	,	_
129-93	25290-25296	though	_
129-94	25297-25302	these	_
129-95	25303-25311	findings	_
129-96	25312-25315	did	_
129-97	25316-25319	not	_
129-98	25320-25327	survive	_
129-99	25328-25338	Bonferroni	_
129-100	25339-25349	correction	_
129-101	25349-25350	.	_

#Text=There were no other relationships between activation in ROI- or whole brain–identified clusters and impulsivity or baseline methamphetamine use.
130-1	25351-25356	There	_
130-2	25357-25361	were	_
130-3	25362-25364	no	_
130-4	25365-25370	other	_
130-5	25371-25384	relationships	_
130-6	25385-25392	between	_
130-7	25393-25403	activation	_
130-8	25404-25406	in	_
130-9	25407-25410	ROI	_
130-10	25410-25411	-	_
130-11	25412-25414	or	_
130-12	25415-25420	whole	_
130-13	25421-25437	brain–identified	_
130-14	25438-25446	clusters	_
130-15	25447-25450	and	_
130-16	25451-25462	impulsivity	_
130-17	25463-25465	or	_
130-18	25466-25474	baseline	_
130-19	25475-25490	methamphetamine	_
130-20	25491-25494	use	_
130-21	25494-25495	.	_

#Text=Scatterplot demonstrating in the shorter term methamphetamine abstinence (STMA) group a negative correlation between attentional impulsivity and activation in the left superior frontal cortex (SFC) relative to sexual cues (A), a negative correlation between nonplanning impulsivity and activation in the left SFC relative to sexual cues (B).
131-1	25496-25507	Scatterplot	_
131-2	25508-25521	demonstrating	_
131-3	25522-25524	in	_
131-4	25525-25528	the	_
131-5	25529-25536	shorter	_
131-6	25537-25541	term	_
131-7	25542-25557	methamphetamine	_
131-8	25558-25568	abstinence	_
131-9	25569-25570	(	_
131-10	25570-25574	STMA	_
131-11	25574-25575	)	_
131-12	25576-25581	group	_
131-13	25582-25583	a	_
131-14	25584-25592	negative	_
131-15	25593-25604	correlation	_
131-16	25605-25612	between	_
131-17	25613-25624	attentional	_
131-18	25625-25636	impulsivity	_
131-19	25637-25640	and	_
131-20	25641-25651	activation	_
131-21	25652-25654	in	_
131-22	25655-25658	the	_
131-23	25659-25663	left	_
131-24	25664-25672	superior	_
131-25	25673-25680	frontal	_
131-26	25681-25687	cortex	_
131-27	25688-25689	(	_
131-28	25689-25692	SFC	_
131-29	25692-25693	)	_
131-30	25694-25702	relative	_
131-31	25703-25705	to	_
131-32	25706-25712	sexual	_
131-33	25713-25717	cues	_
131-34	25718-25719	(	_
131-35	25719-25720	A	_
131-36	25720-25721	)	_
131-37	25721-25722	,	_
131-38	25723-25724	a	_
131-39	25725-25733	negative	_
131-40	25734-25745	correlation	_
131-41	25746-25753	between	_
131-42	25754-25765	nonplanning	_
131-43	25766-25777	impulsivity	_
131-44	25778-25781	and	_
131-45	25782-25792	activation	_
131-46	25793-25795	in	_
131-47	25796-25799	the	_
131-48	25800-25804	left	_
131-49	25805-25808	SFC	_
131-50	25809-25817	relative	_
131-51	25818-25820	to	_
131-52	25821-25827	sexual	_
131-53	25828-25832	cues	_
131-54	25833-25834	(	_
131-55	25834-25835	B	_
131-56	25835-25836	)	_
131-57	25836-25837	.	_

#Text=All significant findings persisted in subsequent analyses excluding 1 LTMA participant with 40 months of abstinence.
132-1	25838-25841	All	_
132-2	25842-25853	significant	_
132-3	25854-25862	findings	_
132-4	25863-25872	persisted	_
132-5	25873-25875	in	_
132-6	25876-25886	subsequent	_
132-7	25887-25895	analyses	_
132-8	25896-25905	excluding	_
132-9	25906-25907	1	_
132-10	25908-25912	LTMA	_
132-11	25913-25924	participant	_
132-12	25925-25929	with	_
132-13	25930-25932	40	_
132-14	25933-25939	months	_
132-15	25940-25942	of	_
132-16	25943-25953	abstinence	_
132-17	25953-25954	.	_

#Text=Discussion
#Text=The present study used a cue-reactivity task involving neutral, methamphetamine, and sexual cues to investigate neurofunctional changes associated with shorter and longer term methamphetamine abstinence.
133-1	25956-25966	Discussion	_
133-2	25967-25970	The	_
133-3	25971-25978	present	_
133-4	25979-25984	study	_
133-5	25985-25989	used	_
133-6	25990-25991	a	_
133-7	25992-26006	cue-reactivity	_
133-8	26007-26011	task	_
133-9	26012-26021	involving	_
133-10	26022-26029	neutral	_
133-11	26029-26030	,	_
133-12	26031-26046	methamphetamine	_
133-13	26046-26047	,	_
133-14	26048-26051	and	_
133-15	26052-26058	sexual	_
133-16	26059-26063	cues	_
133-17	26064-26066	to	_
133-18	26067-26078	investigate	_
133-19	26079-26094	neurofunctional	_
133-20	26095-26102	changes	_
133-21	26103-26113	associated	_
133-22	26114-26118	with	_
133-23	26119-26126	shorter	_
133-24	26127-26130	and	_
133-25	26131-26137	longer	_
133-26	26138-26142	term	_
133-27	26143-26158	methamphetamine	_
133-28	26159-26169	abstinence	_
133-29	26169-26170	.	_

#Text=To our knowledge, this is the first study to compare neural responses with methamphetamine and sexual cues after abstinence of varying durations in a large sample with methamphetamine dependence.
134-1	26171-26173	To	_
134-2	26174-26177	our	_
134-3	26178-26187	knowledge	_
134-4	26187-26188	,	_
134-5	26189-26193	this	_
134-6	26194-26196	is	_
134-7	26197-26200	the	_
134-8	26201-26206	first	_
134-9	26207-26212	study	_
134-10	26213-26215	to	_
134-11	26216-26223	compare	_
134-12	26224-26230	neural	_
134-13	26231-26240	responses	_
134-14	26241-26245	with	_
134-15	26246-26261	methamphetamine	_
134-16	26262-26265	and	_
134-17	26266-26272	sexual	_
134-18	26273-26277	cues	_
134-19	26278-26283	after	_
134-20	26284-26294	abstinence	_
134-21	26295-26297	of	_
134-22	26298-26305	varying	_
134-23	26306-26315	durations	_
134-24	26316-26318	in	_
134-25	26319-26320	a	_
134-26	26321-26326	large	_
134-27	26327-26333	sample	_
134-28	26334-26338	with	_
134-29	26339-26354	methamphetamine	_
134-30	26355-26365	dependence	_
134-31	26365-26366	.	_

#Text=When exposed to methamphetamine cues, both STMA and LTMA groups relative to HCs exhibited increased activation in the vmPFC but not the ventral or dorsal striatum or anterior insula.
135-1	26367-26371	When	_
135-2	26372-26379	exposed	_
135-3	26380-26382	to	_
135-4	26383-26398	methamphetamine	_
135-5	26399-26403	cues	_
135-6	26403-26404	,	_
135-7	26405-26409	both	_
135-8	26410-26414	STMA	_
135-9	26415-26418	and	_
135-10	26419-26423	LTMA	_
135-11	26424-26430	groups	_
135-12	26431-26439	relative	_
135-13	26440-26442	to	_
135-14	26443-26446	HCs	_
135-15	26447-26456	exhibited	_
135-16	26457-26466	increased	_
135-17	26467-26477	activation	_
135-18	26478-26480	in	_
135-19	26481-26484	the	_
135-20	26485-26490	vmPFC	_
135-21	26491-26494	but	_
135-22	26495-26498	not	_
135-23	26499-26502	the	_
135-24	26503-26510	ventral	_
135-25	26511-26513	or	_
135-26	26514-26520	dorsal	_
135-27	26521-26529	striatum	_
135-28	26530-26532	or	_
135-29	26533-26541	anterior	_
135-30	26542-26548	insula	_
135-31	26548-26549	.	_

#Text=Group by condition interaction showed that compared with HCs, sexual cue–related anterior insula activations were greater relative to methamphetamine cues in STMA and LTMA groups, but no anterior insula response differences between STMA and LTMA groups were found.
136-1	26550-26555	Group	_
136-2	26556-26558	by	_
136-3	26559-26568	condition	_
136-4	26569-26580	interaction	_
136-5	26581-26587	showed	_
136-6	26588-26592	that	_
136-7	26593-26601	compared	_
136-8	26602-26606	with	_
136-9	26607-26610	HCs	_
136-10	26610-26611	,	_
136-11	26612-26618	sexual	_
136-12	26619-26630	cue–related	_
136-13	26631-26639	anterior	_
136-14	26640-26646	insula	_
136-15	26647-26658	activations	_
136-16	26659-26663	were	_
136-17	26664-26671	greater	_
136-18	26672-26680	relative	_
136-19	26681-26683	to	_
136-20	26684-26699	methamphetamine	_
136-21	26700-26704	cues	_
136-22	26705-26707	in	_
136-23	26708-26712	STMA	_
136-24	26713-26716	and	_
136-25	26717-26721	LTMA	_
136-26	26722-26728	groups	_
136-27	26728-26729	,	_
136-28	26730-26733	but	_
136-29	26734-26736	no	_
136-30	26737-26745	anterior	_
136-31	26746-26752	insula	_
136-32	26753-26761	response	_
136-33	26762-26773	differences	_
136-34	26774-26781	between	_
136-35	26782-26786	STMA	_
136-36	26787-26790	and	_
136-37	26791-26795	LTMA	_
136-38	26796-26802	groups	_
136-39	26803-26807	were	_
136-40	26808-26813	found	_
136-41	26813-26814	.	_

#Text=LTMA participants exhibited increased activation relative to HCs in the left SFC when exposed to sexual cues; there were no differences in cue-induced brain activation between the STMA and LTMA groups.
137-1	26815-26819	LTMA	_
137-2	26820-26832	participants	_
137-3	26833-26842	exhibited	_
137-4	26843-26852	increased	_
137-5	26853-26863	activation	_
137-6	26864-26872	relative	_
137-7	26873-26875	to	_
137-8	26876-26879	HCs	_
137-9	26880-26882	in	_
137-10	26883-26886	the	_
137-11	26887-26891	left	_
137-12	26892-26895	SFC	_
137-13	26896-26900	when	_
137-14	26901-26908	exposed	_
137-15	26909-26911	to	_
137-16	26912-26918	sexual	_
137-17	26919-26923	cues	_
137-18	26923-26924	;	_
137-19	26925-26930	there	_
137-20	26931-26935	were	_
137-21	26936-26938	no	_
137-22	26939-26950	differences	_
137-23	26951-26953	in	_
137-24	26954-26965	cue-induced	_
137-25	26966-26971	brain	_
137-26	26972-26982	activation	_
137-27	26983-26990	between	_
137-28	26991-26994	the	_
137-29	26995-26999	STMA	_
137-30	27000-27003	and	_
137-31	27004-27008	LTMA	_
137-32	27009-27015	groups	_
137-33	27015-27016	.	_

#Text=However, there was a pattern that the sexual cue–related brain activations in the STMA group appeared intermediate in magnitude between the HC and LTMA groups in the ventral striatum, more so in the SFC.
138-1	27017-27024	However	_
138-2	27024-27025	,	_
138-3	27026-27031	there	_
138-4	27032-27035	was	_
138-5	27036-27037	a	_
138-6	27038-27045	pattern	_
138-7	27046-27050	that	_
138-8	27051-27054	the	_
138-9	27055-27061	sexual	_
138-10	27062-27073	cue–related	_
138-11	27074-27079	brain	_
138-12	27080-27091	activations	_
138-13	27092-27094	in	_
138-14	27095-27098	the	_
138-15	27099-27103	STMA	_
138-16	27104-27109	group	_
138-17	27110-27118	appeared	_
138-18	27119-27131	intermediate	_
138-19	27132-27134	in	_
138-20	27135-27144	magnitude	_
138-21	27145-27152	between	_
138-22	27153-27156	the	_
138-23	27157-27159	HC	_
138-24	27160-27163	and	_
138-25	27164-27168	LTMA	_
138-26	27169-27175	groups	_
138-27	27176-27178	in	_
138-28	27179-27182	the	_
138-29	27183-27190	ventral	_
138-30	27191-27199	striatum	_
138-31	27199-27200	,	_
138-32	27201-27205	more	_
138-33	27206-27208	so	_
138-34	27209-27211	in	_
138-35	27212-27215	the	_
138-36	27216-27219	SFC	_
138-37	27219-27220	.	_

#Text=In this study, when exposed to methamphetamine cues, both STMA and LTMA relative to HC participants exhibited increased activation in the vmPFC, but not the ventral or dorsal striatum or anterior insula, which is partially consistent with our first hypothesis.
139-1	27221-27223	In	_
139-2	27224-27228	this	_
139-3	27229-27234	study	_
139-4	27234-27235	,	_
139-5	27236-27240	when	_
139-6	27241-27248	exposed	_
139-7	27249-27251	to	_
139-8	27252-27267	methamphetamine	_
139-9	27268-27272	cues	_
139-10	27272-27273	,	_
139-11	27274-27278	both	_
139-12	27279-27283	STMA	_
139-13	27284-27287	and	_
139-14	27288-27292	LTMA	_
139-15	27293-27301	relative	_
139-16	27302-27304	to	_
139-17	27305-27307	HC	_
139-18	27308-27320	participants	_
139-19	27321-27330	exhibited	_
139-20	27331-27340	increased	_
139-21	27341-27351	activation	_
139-22	27352-27354	in	_
139-23	27355-27358	the	_
139-24	27359-27364	vmPFC	_
139-25	27364-27365	,	_
139-26	27366-27369	but	_
139-27	27370-27373	not	_
139-28	27374-27377	the	_
139-29	27378-27385	ventral	_
139-30	27386-27388	or	_
139-31	27389-27395	dorsal	_
139-32	27396-27404	striatum	_
139-33	27405-27407	or	_
139-34	27408-27416	anterior	_
139-35	27417-27423	insula	_
139-36	27423-27424	,	_
139-37	27425-27430	which	_
139-38	27431-27433	is	_
139-39	27434-27443	partially	_
139-40	27444-27454	consistent	_
139-41	27455-27459	with	_
139-42	27460-27463	our	_
139-43	27464-27469	first	_
139-44	27470-27480	hypothesis	_
139-45	27480-27481	.	_

#Text=Previous research has demonstrated an important role of the vmPFC in encoding expected value representations, including greater responses when experiencing greater rewards.
140-1	27482-27490	Previous	_
140-2	27491-27499	research	_
140-3	27500-27503	has	_
140-4	27504-27516	demonstrated	_
140-5	27517-27519	an	_
140-6	27520-27529	important	_
140-7	27530-27534	role	_
140-8	27535-27537	of	_
140-9	27538-27541	the	_
140-10	27542-27547	vmPFC	_
140-11	27548-27550	in	_
140-12	27551-27559	encoding	_
140-13	27560-27568	expected	_
140-14	27569-27574	value	_
140-15	27575-27590	representations	_
140-16	27590-27591	,	_
140-17	27592-27601	including	_
140-18	27602-27609	greater	_
140-19	27610-27619	responses	_
140-20	27620-27624	when	_
140-21	27625-27637	experiencing	_
140-22	27638-27645	greater	_
140-23	27646-27653	rewards	_
140-24	27653-27654	.	_

#Text=In patients addicted to methamphetamine, activation of the vmPFC in response to methamphetamine cues may reflect a dysregulation of this region, demonstrated behaviorally as a preference for smaller immediate over larger delayed rewards or for the drug itself given a role for the vmPFC in stimulant craving.
141-1	27655-27657	In	_
141-2	27658-27666	patients	_
141-3	27667-27675	addicted	_
141-4	27676-27678	to	_
141-5	27679-27694	methamphetamine	_
141-6	27694-27695	,	_
141-7	27696-27706	activation	_
141-8	27707-27709	of	_
141-9	27710-27713	the	_
141-10	27714-27719	vmPFC	_
141-11	27720-27722	in	_
141-12	27723-27731	response	_
141-13	27732-27734	to	_
141-14	27735-27750	methamphetamine	_
141-15	27751-27755	cues	_
141-16	27756-27759	may	_
141-17	27760-27767	reflect	_
141-18	27768-27769	a	_
141-19	27770-27783	dysregulation	_
141-20	27784-27786	of	_
141-21	27787-27791	this	_
141-22	27792-27798	region	_
141-23	27798-27799	,	_
141-24	27800-27812	demonstrated	_
141-25	27813-27825	behaviorally	_
141-26	27826-27828	as	_
141-27	27829-27830	a	_
141-28	27831-27841	preference	_
141-29	27842-27845	for	_
141-30	27846-27853	smaller	_
141-31	27854-27863	immediate	_
141-32	27864-27868	over	_
141-33	27869-27875	larger	_
141-34	27876-27883	delayed	_
141-35	27884-27891	rewards	_
141-36	27892-27894	or	_
141-37	27895-27898	for	_
141-38	27899-27902	the	_
141-39	27903-27907	drug	_
141-40	27908-27914	itself	_
141-41	27915-27920	given	_
141-42	27921-27922	a	_
141-43	27923-27927	role	_
141-44	27928-27931	for	_
141-45	27932-27935	the	_
141-46	27936-27941	vmPFC	_
141-47	27942-27944	in	_
141-48	27945-27954	stimulant	_
141-49	27955-27962	craving	_
141-50	27962-27963	.	_

#Text=The vmPFC has also been implicated in the processing and tracking of rewards.
142-1	27964-27967	The	_
142-2	27968-27973	vmPFC	_
142-3	27974-27977	has	_
142-4	27978-27982	also	_
142-5	27983-27987	been	_
142-6	27988-27998	implicated	_
142-7	27999-28001	in	_
142-8	28002-28005	the	_
142-9	28006-28016	processing	_
142-10	28017-28020	and	_
142-11	28021-28029	tracking	_
142-12	28030-28032	of	_
142-13	28033-28040	rewards	_
142-14	28040-28041	.	_

#Text=As such, the STMA and LTMA groups may be demonstrating greater salience at a neural level to drug-related cues after shorter and longer term abstinence, which is consistent with the iRISA model.
143-1	28042-28044	As	_
143-2	28045-28049	such	_
143-3	28049-28050	,	_
143-4	28051-28054	the	_
143-5	28055-28059	STMA	_
143-6	28060-28063	and	_
143-7	28064-28068	LTMA	_
143-8	28069-28075	groups	_
143-9	28076-28079	may	_
143-10	28080-28082	be	_
143-11	28083-28096	demonstrating	_
143-12	28097-28104	greater	_
143-13	28105-28113	salience	_
143-14	28114-28116	at	_
143-15	28117-28118	a	_
143-16	28119-28125	neural	_
143-17	28126-28131	level	_
143-18	28132-28134	to	_
143-19	28135-28147	drug-related	_
143-20	28148-28152	cues	_
143-21	28153-28158	after	_
143-22	28159-28166	shorter	_
143-23	28167-28170	and	_
143-24	28171-28177	longer	_
143-25	28178-28182	term	_
143-26	28183-28193	abstinence	_
143-27	28193-28194	,	_
143-28	28195-28200	which	_
143-29	28201-28203	is	_
143-30	28204-28214	consistent	_
143-31	28215-28219	with	_
143-32	28220-28223	the	_
143-33	28224-28229	iRISA	_
143-34	28230-28235	model	_
143-35	28235-28236	.	_

#Text=The findings also suggest a biological mechanism for recovery in methamphetamine dependence and a need for interventions beyond abstinence (e.g., cognitive behavioral therapies that involve learning new skills and approaches).
144-1	28237-28240	The	_
144-2	28241-28249	findings	_
144-3	28250-28254	also	_
144-4	28255-28262	suggest	_
144-5	28263-28264	a	_
144-6	28265-28275	biological	_
144-7	28276-28285	mechanism	_
144-8	28286-28289	for	_
144-9	28290-28298	recovery	_
144-10	28299-28301	in	_
144-11	28302-28317	methamphetamine	_
144-12	28318-28328	dependence	_
144-13	28329-28332	and	_
144-14	28333-28334	a	_
144-15	28335-28339	need	_
144-16	28340-28343	for	_
144-17	28344-28357	interventions	_
144-18	28358-28364	beyond	_
144-19	28365-28375	abstinence	_
144-20	28376-28377	(	_
144-21	28377-28380	e.g	_
144-22	28380-28381	.	_
144-23	28381-28382	,	_
144-24	28383-28392	cognitive	_
144-25	28393-28403	behavioral	_
144-26	28404-28413	therapies	_
144-27	28414-28418	that	_
144-28	28419-28426	involve	_
144-29	28427-28435	learning	_
144-30	28436-28439	new	_
144-31	28440-28446	skills	_
144-32	28447-28450	and	_
144-33	28451-28461	approaches	_
144-34	28461-28462	)	_
144-35	28462-28463	.	_

#Text=Mixed findings have been reported regarding the ventral striatum, the dorsal striatum, and the processing of drug rewards in drug-abusing individuals, with some studies showing hypoactivity during drug cue exposure ( Klein et al.,), others showing hyperactivity.
145-1	28464-28469	Mixed	_
145-2	28470-28478	findings	_
145-3	28479-28483	have	_
145-4	28484-28488	been	_
145-5	28489-28497	reported	_
145-6	28498-28507	regarding	_
145-7	28508-28511	the	_
145-8	28512-28519	ventral	_
145-9	28520-28528	striatum	_
145-10	28528-28529	,	_
145-11	28530-28533	the	_
145-12	28534-28540	dorsal	_
145-13	28541-28549	striatum	_
145-14	28549-28550	,	_
145-15	28551-28554	and	_
145-16	28555-28558	the	_
145-17	28559-28569	processing	_
145-18	28570-28572	of	_
145-19	28573-28577	drug	_
145-20	28578-28585	rewards	_
145-21	28586-28588	in	_
145-22	28589-28601	drug-abusing	_
145-23	28602-28613	individuals	_
145-24	28613-28614	,	_
145-25	28615-28619	with	_
145-26	28620-28624	some	_
145-27	28625-28632	studies	_
145-28	28633-28640	showing	_
145-29	28641-28653	hypoactivity	_
145-30	28654-28660	during	_
145-31	28661-28665	drug	_
145-32	28666-28669	cue	_
145-33	28670-28678	exposure	_
145-34	28679-28680	(	_
145-35	28681-28686	Klein	_
145-36	28687-28689	et	_
145-37	28690-28692	al	_
145-38	28692-28693	.	_
145-39	28693-28694	,	_
145-40	28694-28695	)	_
145-41	28695-28696	,	_
145-42	28697-28703	others	_
145-43	28704-28711	showing	_
145-44	28712-28725	hyperactivity	_
145-45	28725-28726	.	_

#Text=One possible explanation for seemingly conflicting results may relate to different stages of addiction and abstinence.
146-1	28727-28730	One	_
146-2	28731-28739	possible	_
146-3	28740-28751	explanation	_
146-4	28752-28755	for	_
146-5	28756-28765	seemingly	_
146-6	28766-28777	conflicting	_
146-7	28778-28785	results	_
146-8	28786-28789	may	_
146-9	28790-28796	relate	_
146-10	28797-28799	to	_
146-11	28800-28809	different	_
146-12	28810-28816	stages	_
146-13	28817-28819	of	_
146-14	28820-28829	addiction	_
146-15	28830-28833	and	_
146-16	28834-28844	abstinence	_
146-17	28844-28845	.	_

#Text=The ventral striatum has been implicated in mediating reinforcing effects of stimulant drugs and neural mechanisms of voluntary drug taking; however, the dorsal striatum has been implicated in compulsive drug seeking.
147-1	28846-28849	The	_
147-2	28850-28857	ventral	_
147-3	28858-28866	striatum	_
147-4	28867-28870	has	_
147-5	28871-28875	been	_
147-6	28876-28886	implicated	_
147-7	28887-28889	in	_
147-8	28890-28899	mediating	_
147-9	28900-28911	reinforcing	_
147-10	28912-28919	effects	_
147-11	28920-28922	of	_
147-12	28923-28932	stimulant	_
147-13	28933-28938	drugs	_
147-14	28939-28942	and	_
147-15	28943-28949	neural	_
147-16	28950-28960	mechanisms	_
147-17	28961-28963	of	_
147-18	28964-28973	voluntary	_
147-19	28974-28978	drug	_
147-20	28979-28985	taking	_
147-21	28985-28986	;	_
147-22	28987-28994	however	_
147-23	28994-28995	,	_
147-24	28996-28999	the	_
147-25	29000-29006	dorsal	_
147-26	29007-29015	striatum	_
147-27	29016-29019	has	_
147-28	29020-29024	been	_
147-29	29025-29035	implicated	_
147-30	29036-29038	in	_
147-31	29039-29049	compulsive	_
147-32	29050-29054	drug	_
147-33	29055-29062	seeking	_
147-34	29062-29063	.	_

#Text=How different stages of abstinence may be linked to differences in striatal correlates of reward processing and how such neural correlates of reward processing may in turn impact abstinence warrant further investigation.
148-1	29064-29067	How	_
148-2	29068-29077	different	_
148-3	29078-29084	stages	_
148-4	29085-29087	of	_
148-5	29088-29098	abstinence	_
148-6	29099-29102	may	_
148-7	29103-29105	be	_
148-8	29106-29112	linked	_
148-9	29113-29115	to	_
148-10	29116-29127	differences	_
148-11	29128-29130	in	_
148-12	29131-29139	striatal	_
148-13	29140-29150	correlates	_
148-14	29151-29153	of	_
148-15	29154-29160	reward	_
148-16	29161-29171	processing	_
148-17	29172-29175	and	_
148-18	29176-29179	how	_
148-19	29180-29184	such	_
148-20	29185-29191	neural	_
148-21	29192-29202	correlates	_
148-22	29203-29205	of	_
148-23	29206-29212	reward	_
148-24	29213-29223	processing	_
148-25	29224-29227	may	_
148-26	29228-29230	in	_
148-27	29231-29235	turn	_
148-28	29236-29242	impact	_
148-29	29243-29253	abstinence	_
148-30	29254-29261	warrant	_
148-31	29262-29269	further	_
148-32	29270-29283	investigation	_
148-33	29283-29284	.	_

#Text=Anterior insula activations in response to sexual cues were greater relative to methamphetamine cues and neutral cues in the STMA and LTMA groups compared with HCs in our study, which is consistent with our second hypothesis.
149-1	29285-29293	Anterior	_
149-2	29294-29300	insula	_
149-3	29301-29312	activations	_
149-4	29313-29315	in	_
149-5	29316-29324	response	_
149-6	29325-29327	to	_
149-7	29328-29334	sexual	_
149-8	29335-29339	cues	_
149-9	29340-29344	were	_
149-10	29345-29352	greater	_
149-11	29353-29361	relative	_
149-12	29362-29364	to	_
149-13	29365-29380	methamphetamine	_
149-14	29381-29385	cues	_
149-15	29386-29389	and	_
149-16	29390-29397	neutral	_
149-17	29398-29402	cues	_
149-18	29403-29405	in	_
149-19	29406-29409	the	_
149-20	29410-29414	STMA	_
149-21	29415-29418	and	_
149-22	29419-29423	LTMA	_
149-23	29424-29430	groups	_
149-24	29431-29439	compared	_
149-25	29440-29444	with	_
149-26	29445-29448	HCs	_
149-27	29449-29451	in	_
149-28	29452-29455	our	_
149-29	29456-29461	study	_
149-30	29461-29462	,	_
149-31	29463-29468	which	_
149-32	29469-29471	is	_
149-33	29472-29482	consistent	_
149-34	29483-29487	with	_
149-35	29488-29491	our	_
149-36	29492-29498	second	_
149-37	29499-29509	hypothesis	_
149-38	29509-29510	.	_

#Text=Insula activation in response to sexual stimuli has been reported both in non-drug–using and drug-using individuals.
150-1	29511-29517	Insula	_
150-2	29518-29528	activation	_
150-3	29529-29531	in	_
150-4	29532-29540	response	_
150-5	29541-29543	to	_
150-6	29544-29550	sexual	_
150-7	29551-29558	stimuli	_
150-8	29559-29562	has	_
150-9	29563-29567	been	_
150-10	29568-29576	reported	_
150-11	29577-29581	both	_
150-12	29582-29584	in	_
150-13	29585-29599	non-drug–using	_
150-14	29600-29603	and	_
150-15	29604-29614	drug-using	_
150-16	29615-29626	individuals	_
150-17	29626-29627	.	_

#Text=Our study also found a relationship between anterior insula activation and sexual stimuli.
151-1	29628-29631	Our	_
151-2	29632-29637	study	_
151-3	29638-29642	also	_
151-4	29643-29648	found	_
151-5	29649-29650	a	_
151-6	29651-29663	relationship	_
151-7	29664-29671	between	_
151-8	29672-29680	anterior	_
151-9	29681-29687	insula	_
151-10	29688-29698	activation	_
151-11	29699-29702	and	_
151-12	29703-29709	sexual	_
151-13	29710-29717	stimuli	_
151-14	29717-29718	.	_

#Text=Although the anterior insula may be involved in drug craving and drug seeking under specific conditions, our findings suggest that the anterior insula may also contribute importantly to interoception for specifically survival-related functions, such as sex, hunger, and thirst, but this warrants further investigation.
152-1	29719-29727	Although	_
152-2	29728-29731	the	_
152-3	29732-29740	anterior	_
152-4	29741-29747	insula	_
152-5	29748-29751	may	_
152-6	29752-29754	be	_
152-7	29755-29763	involved	_
152-8	29764-29766	in	_
152-9	29767-29771	drug	_
152-10	29772-29779	craving	_
152-11	29780-29783	and	_
152-12	29784-29788	drug	_
152-13	29789-29796	seeking	_
152-14	29797-29802	under	_
152-15	29803-29811	specific	_
152-16	29812-29822	conditions	_
152-17	29822-29823	,	_
152-18	29824-29827	our	_
152-19	29828-29836	findings	_
152-20	29837-29844	suggest	_
152-21	29845-29849	that	_
152-22	29850-29853	the	_
152-23	29854-29862	anterior	_
152-24	29863-29869	insula	_
152-25	29870-29873	may	_
152-26	29874-29878	also	_
152-27	29879-29889	contribute	_
152-28	29890-29901	importantly	_
152-29	29902-29904	to	_
152-30	29905-29918	interoception	_
152-31	29919-29922	for	_
152-32	29923-29935	specifically	_
152-33	29936-29952	survival-related	_
152-34	29953-29962	functions	_
152-35	29962-29963	,	_
152-36	29964-29968	such	_
152-37	29969-29971	as	_
152-38	29972-29975	sex	_
152-39	29975-29976	,	_
152-40	29977-29983	hunger	_
152-41	29983-29984	,	_
152-42	29985-29988	and	_
152-43	29989-29995	thirst	_
152-44	29995-29996	,	_
152-45	29997-30000	but	_
152-46	30001-30005	this	_
152-47	30006-30014	warrants	_
152-48	30015-30022	further	_
152-49	30023-30036	investigation	_
152-50	30036-30037	.	_

#Text=Contrary to hypotheses, there were no group differences in activation in the ventral striatum, dorsal striatum, and vmPFC when exposed to sexual cues.
153-1	30038-30046	Contrary	_
153-2	30047-30049	to	_
153-3	30050-30060	hypotheses	_
153-4	30060-30061	,	_
153-5	30062-30067	there	_
153-6	30068-30072	were	_
153-7	30073-30075	no	_
153-8	30076-30081	group	_
153-9	30082-30093	differences	_
153-10	30094-30096	in	_
153-11	30097-30107	activation	_
153-12	30108-30110	in	_
153-13	30111-30114	the	_
153-14	30115-30122	ventral	_
153-15	30123-30131	striatum	_
153-16	30131-30132	,	_
153-17	30133-30139	dorsal	_
153-18	30140-30148	striatum	_
153-19	30148-30149	,	_
153-20	30150-30153	and	_
153-21	30154-30159	vmPFC	_
153-22	30160-30164	when	_
153-23	30165-30172	exposed	_
153-24	30173-30175	to	_
153-25	30176-30182	sexual	_
153-26	30183-30187	cues	_
153-27	30187-30188	.	_

#Text=However, within groups, sexual cue–related activation was greater than neutral and/or methamphetamine cue–related activation in the ventral striatum, dorsal striatum, and vmPFC.
154-1	30189-30196	However	_
154-2	30196-30197	,	_
154-3	30198-30204	within	_
154-4	30205-30211	groups	_
154-5	30211-30212	,	_
154-6	30213-30219	sexual	_
154-7	30220-30231	cue–related	_
154-8	30232-30242	activation	_
154-9	30243-30246	was	_
154-10	30247-30254	greater	_
154-11	30255-30259	than	_
154-12	30260-30267	neutral	_
154-13	30268-30271	and	_
154-14	30271-30272	/	_
154-15	30272-30274	or	_
154-16	30275-30290	methamphetamine	_
154-17	30291-30302	cue–related	_
154-18	30303-30313	activation	_
154-19	30314-30316	in	_
154-20	30317-30320	the	_
154-21	30321-30328	ventral	_
154-22	30329-30337	striatum	_
154-23	30337-30338	,	_
154-24	30339-30345	dorsal	_
154-25	30346-30354	striatum	_
154-26	30354-30355	,	_
154-27	30356-30359	and	_
154-28	30360-30365	vmPFC	_
154-29	30365-30366	.	_

#Text=The greater activation to sexual cues in these 3 regions suggests that chronic methamphetamine use may not be associated with blunted sexual reward processing, which is in seeming contrast to the iRISA and reward deficiency models of addiction but is consistent with animal research indicating that chronic methamphetamine exposure impairs sexual performance but not sexual conditioning.
155-1	30367-30370	The	_
155-2	30371-30378	greater	_
155-3	30379-30389	activation	_
155-4	30390-30392	to	_
155-5	30393-30399	sexual	_
155-6	30400-30404	cues	_
155-7	30405-30407	in	_
155-8	30408-30413	these	_
155-9	30414-30415	3	_
155-10	30416-30423	regions	_
155-11	30424-30432	suggests	_
155-12	30433-30437	that	_
155-13	30438-30445	chronic	_
155-14	30446-30461	methamphetamine	_
155-15	30462-30465	use	_
155-16	30466-30469	may	_
155-17	30470-30473	not	_
155-18	30474-30476	be	_
155-19	30477-30487	associated	_
155-20	30488-30492	with	_
155-21	30493-30500	blunted	_
155-22	30501-30507	sexual	_
155-23	30508-30514	reward	_
155-24	30515-30525	processing	_
155-25	30525-30526	,	_
155-26	30527-30532	which	_
155-27	30533-30535	is	_
155-28	30536-30538	in	_
155-29	30539-30546	seeming	_
155-30	30547-30555	contrast	_
155-31	30556-30558	to	_
155-32	30559-30562	the	_
155-33	30563-30568	iRISA	_
155-34	30569-30572	and	_
155-35	30573-30579	reward	_
155-36	30580-30590	deficiency	_
155-37	30591-30597	models	_
155-38	30598-30600	of	_
155-39	30601-30610	addiction	_
155-40	30611-30614	but	_
155-41	30615-30617	is	_
155-42	30618-30628	consistent	_
155-43	30629-30633	with	_
155-44	30634-30640	animal	_
155-45	30641-30649	research	_
155-46	30650-30660	indicating	_
155-47	30661-30665	that	_
155-48	30666-30673	chronic	_
155-49	30674-30689	methamphetamine	_
155-50	30690-30698	exposure	_
155-51	30699-30706	impairs	_
155-52	30707-30713	sexual	_
155-53	30714-30725	performance	_
155-54	30726-30729	but	_
155-55	30730-30733	not	_
155-56	30734-30740	sexual	_
155-57	30741-30753	conditioning	_
155-58	30753-30754	.	_

#Text=However, more research is needed to determine if these sexual cue–related neural responses are a consequence of methamphetamine abstinence (i.e., sexual-reward sensitivity has replaced methamphetamine reward sensitivity after abstaining from methamphetamine) or if these alterations are also present in individuals currently abusing methamphetamine.
156-1	30755-30762	However	_
156-2	30762-30763	,	_
156-3	30764-30768	more	_
156-4	30769-30777	research	_
156-5	30778-30780	is	_
156-6	30781-30787	needed	_
156-7	30788-30790	to	_
156-8	30791-30800	determine	_
156-9	30801-30803	if	_
156-10	30804-30809	these	_
156-11	30810-30816	sexual	_
156-12	30817-30828	cue–related	_
156-13	30829-30835	neural	_
156-14	30836-30845	responses	_
156-15	30846-30849	are	_
156-16	30850-30851	a	_
156-17	30852-30863	consequence	_
156-18	30864-30866	of	_
156-19	30867-30882	methamphetamine	_
156-20	30883-30893	abstinence	_
156-21	30894-30895	(	_
156-22	30895-30898	i.e	_
156-23	30898-30899	.	_
156-24	30899-30900	,	_
156-25	30901-30914	sexual-reward	_
156-26	30915-30926	sensitivity	_
156-27	30927-30930	has	_
156-28	30931-30939	replaced	_
156-29	30940-30955	methamphetamine	_
156-30	30956-30962	reward	_
156-31	30963-30974	sensitivity	_
156-32	30975-30980	after	_
156-33	30981-30991	abstaining	_
156-34	30992-30996	from	_
156-35	30997-31012	methamphetamine	_
156-36	31012-31013	)	_
156-37	31014-31016	or	_
156-38	31017-31019	if	_
156-39	31020-31025	these	_
156-40	31026-31037	alterations	_
156-41	31038-31041	are	_
156-42	31042-31046	also	_
156-43	31047-31054	present	_
156-44	31055-31057	in	_
156-45	31058-31069	individuals	_
156-46	31070-31079	currently	_
156-47	31080-31087	abusing	_
156-48	31088-31103	methamphetamine	_
156-49	31103-31104	.	_

#Text=A whole-brain group-by-condition interaction and post-hoc contrasts indicated that LTMA relative to HC participants showed greater activation of the left SFC in response to sexual cues.
157-1	31105-31106	A	_
157-2	31107-31118	whole-brain	_
157-3	31119-31137	group-by-condition	_
157-4	31138-31149	interaction	_
157-5	31150-31153	and	_
157-6	31154-31162	post-hoc	_
157-7	31163-31172	contrasts	_
157-8	31173-31182	indicated	_
157-9	31183-31187	that	_
157-10	31188-31192	LTMA	_
157-11	31193-31201	relative	_
157-12	31202-31204	to	_
157-13	31205-31207	HC	_
157-14	31208-31220	participants	_
157-15	31221-31227	showed	_
157-16	31228-31235	greater	_
157-17	31236-31246	activation	_
157-18	31247-31249	of	_
157-19	31250-31253	the	_
157-20	31254-31258	left	_
157-21	31259-31262	SFC	_
157-22	31263-31265	in	_
157-23	31266-31274	response	_
157-24	31275-31277	to	_
157-25	31278-31284	sexual	_
157-26	31285-31289	cues	_
157-27	31289-31290	.	_

#Text=The SFC has been implicated in attentional control and in memory and decision-making processes relevant to goal-directed behaviors.
158-1	31291-31294	The	_
158-2	31295-31298	SFC	_
158-3	31299-31302	has	_
158-4	31303-31307	been	_
158-5	31308-31318	implicated	_
158-6	31319-31321	in	_
158-7	31322-31333	attentional	_
158-8	31334-31341	control	_
158-9	31342-31345	and	_
158-10	31346-31348	in	_
158-11	31349-31355	memory	_
158-12	31356-31359	and	_
158-13	31360-31375	decision-making	_
158-14	31376-31385	processes	_
158-15	31386-31394	relevant	_
158-16	31395-31397	to	_
158-17	31398-31411	goal-directed	_
158-18	31412-31421	behaviors	_
158-19	31421-31422	.	_

#Text=As such, the relatively increased SFC activation may reflect increased attention or attentional control in LTMA in response to the sexual stimuli, although this possibility remains speculative.
159-1	31423-31425	As	_
159-2	31426-31430	such	_
159-3	31430-31431	,	_
159-4	31432-31435	the	_
159-5	31436-31446	relatively	_
159-6	31447-31456	increased	_
159-7	31457-31460	SFC	_
159-8	31461-31471	activation	_
159-9	31472-31475	may	_
159-10	31476-31483	reflect	_
159-11	31484-31493	increased	_
159-12	31494-31503	attention	_
159-13	31504-31506	or	_
159-14	31507-31518	attentional	_
159-15	31519-31526	control	_
159-16	31527-31529	in	_
159-17	31530-31534	LTMA	_
159-18	31535-31537	in	_
159-19	31538-31546	response	_
159-20	31547-31549	to	_
159-21	31550-31553	the	_
159-22	31554-31560	sexual	_
159-23	31561-31568	stimuli	_
159-24	31568-31569	,	_
159-25	31570-31578	although	_
159-26	31579-31583	this	_
159-27	31584-31595	possibility	_
159-28	31596-31603	remains	_
159-29	31604-31615	speculative	_
159-30	31615-31616	.	_

#Text=Given that methamphetamine dependence has been associated with cognitive deficits relating to attention and attentional deficits have been linked to sexual risk-taking, it will be important to examine further how such features may relate to sexual behaviors among individuals with LTMA.
160-1	31617-31622	Given	_
160-2	31623-31627	that	_
160-3	31628-31643	methamphetamine	_
160-4	31644-31654	dependence	_
160-5	31655-31658	has	_
160-6	31659-31663	been	_
160-7	31664-31674	associated	_
160-8	31675-31679	with	_
160-9	31680-31689	cognitive	_
160-10	31690-31698	deficits	_
160-11	31699-31707	relating	_
160-12	31708-31710	to	_
160-13	31711-31720	attention	_
160-14	31721-31724	and	_
160-15	31725-31736	attentional	_
160-16	31737-31745	deficits	_
160-17	31746-31750	have	_
160-18	31751-31755	been	_
160-19	31756-31762	linked	_
160-20	31763-31765	to	_
160-21	31766-31772	sexual	_
160-22	31773-31784	risk-taking	_
160-23	31784-31785	,	_
160-24	31786-31788	it	_
160-25	31789-31793	will	_
160-26	31794-31796	be	_
160-27	31797-31806	important	_
160-28	31807-31809	to	_
160-29	31810-31817	examine	_
160-30	31818-31825	further	_
160-31	31826-31829	how	_
160-32	31830-31834	such	_
160-33	31835-31843	features	_
160-34	31844-31847	may	_
160-35	31848-31854	relate	_
160-36	31855-31857	to	_
160-37	31858-31864	sexual	_
160-38	31865-31874	behaviors	_
160-39	31875-31880	among	_
160-40	31881-31892	individuals	_
160-41	31893-31897	with	_
160-42	31898-31902	LTMA	_
160-43	31902-31903	.	_

#Text=Within groups, the greater activation in response to sexual cues in the ventral striatum, dorsal striatum, vmPFC, anterior insula, and left SFC in both STMA and LTMA groups may provide insight into the use of methamphetamine for sexual purposes in individuals with methamphetamine dependence.
161-1	31904-31910	Within	_
161-2	31911-31917	groups	_
161-3	31917-31918	,	_
161-4	31919-31922	the	_
161-5	31923-31930	greater	_
161-6	31931-31941	activation	_
161-7	31942-31944	in	_
161-8	31945-31953	response	_
161-9	31954-31956	to	_
161-10	31957-31963	sexual	_
161-11	31964-31968	cues	_
161-12	31969-31971	in	_
161-13	31972-31975	the	_
161-14	31976-31983	ventral	_
161-15	31984-31992	striatum	_
161-16	31992-31993	,	_
161-17	31994-32000	dorsal	_
161-18	32001-32009	striatum	_
161-19	32009-32010	,	_
161-20	32011-32016	vmPFC	_
161-21	32016-32017	,	_
161-22	32018-32026	anterior	_
161-23	32027-32033	insula	_
161-24	32033-32034	,	_
161-25	32035-32038	and	_
161-26	32039-32043	left	_
161-27	32044-32047	SFC	_
161-28	32048-32050	in	_
161-29	32051-32055	both	_
161-30	32056-32060	STMA	_
161-31	32061-32064	and	_
161-32	32065-32069	LTMA	_
161-33	32070-32076	groups	_
161-34	32077-32080	may	_
161-35	32081-32088	provide	_
161-36	32089-32096	insight	_
161-37	32097-32101	into	_
161-38	32102-32105	the	_
161-39	32106-32109	use	_
161-40	32110-32112	of	_
161-41	32113-32128	methamphetamine	_
161-42	32129-32132	for	_
161-43	32133-32139	sexual	_
161-44	32140-32148	purposes	_
161-45	32149-32151	in	_
161-46	32152-32163	individuals	_
161-47	32164-32168	with	_
161-48	32169-32184	methamphetamine	_
161-49	32185-32195	dependence	_
161-50	32195-32196	.	_

#Text=Methamphetamine use can increase sexual libido, pleasure, and stamina while increasing risk-taking behavior, such as unprotected sexual intercourse and sex with multiple partners.
162-1	32197-32212	Methamphetamine	_
162-2	32213-32216	use	_
162-3	32217-32220	can	_
162-4	32221-32229	increase	_
162-5	32230-32236	sexual	_
162-6	32237-32243	libido	_
162-7	32243-32244	,	_
162-8	32245-32253	pleasure	_
162-9	32253-32254	,	_
162-10	32255-32258	and	_
162-11	32259-32266	stamina	_
162-12	32267-32272	while	_
162-13	32273-32283	increasing	_
162-14	32284-32295	risk-taking	_
162-15	32296-32304	behavior	_
162-16	32304-32305	,	_
162-17	32306-32310	such	_
162-18	32311-32313	as	_
162-19	32314-32325	unprotected	_
162-20	32326-32332	sexual	_
162-21	32333-32344	intercourse	_
162-22	32345-32348	and	_
162-23	32349-32352	sex	_
162-24	32353-32357	with	_
162-25	32358-32366	multiple	_
162-26	32367-32375	partners	_
162-27	32375-32376	.	_

#Text=Understanding how methamphetamine use, and extended abstinence from methamphetamine, may alter responses to sexual cues may provide insight into this population and inform interventions.
163-1	32377-32390	Understanding	_
163-2	32391-32394	how	_
163-3	32395-32410	methamphetamine	_
163-4	32411-32414	use	_
163-5	32414-32415	,	_
163-6	32416-32419	and	_
163-7	32420-32428	extended	_
163-8	32429-32439	abstinence	_
163-9	32440-32444	from	_
163-10	32445-32460	methamphetamine	_
163-11	32460-32461	,	_
163-12	32462-32465	may	_
163-13	32466-32471	alter	_
163-14	32472-32481	responses	_
163-15	32482-32484	to	_
163-16	32485-32491	sexual	_
163-17	32492-32496	cues	_
163-18	32497-32500	may	_
163-19	32501-32508	provide	_
163-20	32509-32516	insight	_
163-21	32517-32521	into	_
163-22	32522-32526	this	_
163-23	32527-32537	population	_
163-24	32538-32541	and	_
163-25	32542-32548	inform	_
163-26	32549-32562	interventions	_
163-27	32562-32563	.	_

#Text=There was a significant negative correlation between attentional impulsivity and left SFC activation to sexual cues in the STMA group, but not among LTMA participants.
164-1	32564-32569	There	_
164-2	32570-32573	was	_
164-3	32574-32575	a	_
164-4	32576-32587	significant	_
164-5	32588-32596	negative	_
164-6	32597-32608	correlation	_
164-7	32609-32616	between	_
164-8	32617-32628	attentional	_
164-9	32629-32640	impulsivity	_
164-10	32641-32644	and	_
164-11	32645-32649	left	_
164-12	32650-32653	SFC	_
164-13	32654-32664	activation	_
164-14	32665-32667	to	_
164-15	32668-32674	sexual	_
164-16	32675-32679	cues	_
164-17	32680-32682	in	_
164-18	32683-32686	the	_
164-19	32687-32691	STMA	_
164-20	32692-32697	group	_
164-21	32697-32698	,	_
164-22	32699-32702	but	_
164-23	32703-32706	not	_
164-24	32707-32712	among	_
164-25	32713-32717	LTMA	_
164-26	32718-32730	participants	_
164-27	32730-32731	.	_

#Text=The findings suggest a complex relationship between SFC activation to methamphetamine and sexual cues, impulsivity, and duration of methamphetamine abstinence among individuals with methamphetamine dependence.
165-1	32732-32735	The	_
165-2	32736-32744	findings	_
165-3	32745-32752	suggest	_
165-4	32753-32754	a	_
165-5	32755-32762	complex	_
165-6	32763-32775	relationship	_
165-7	32776-32783	between	_
165-8	32784-32787	SFC	_
165-9	32788-32798	activation	_
165-10	32799-32801	to	_
165-11	32802-32817	methamphetamine	_
165-12	32818-32821	and	_
165-13	32822-32828	sexual	_
165-14	32829-32833	cues	_
165-15	32833-32834	,	_
165-16	32835-32846	impulsivity	_
165-17	32846-32847	,	_
165-18	32848-32851	and	_
165-19	32852-32860	duration	_
165-20	32861-32863	of	_
165-21	32864-32879	methamphetamine	_
165-22	32880-32890	abstinence	_
165-23	32891-32896	among	_
165-24	32897-32908	individuals	_
165-25	32909-32913	with	_
165-26	32914-32929	methamphetamine	_
165-27	32930-32940	dependence	_
165-28	32940-32941	.	_

#Text=Dysfunction of the PFC has been implicated in poor inhibitory control in addictions, and individuals with SFC damage show poor inhibitory control.
166-1	32942-32953	Dysfunction	_
166-2	32954-32956	of	_
166-3	32957-32960	the	_
166-4	32961-32964	PFC	_
166-5	32965-32968	has	_
166-6	32969-32973	been	_
166-7	32974-32984	implicated	_
166-8	32985-32987	in	_
166-9	32988-32992	poor	_
166-10	32993-33003	inhibitory	_
166-11	33004-33011	control	_
166-12	33012-33014	in	_
166-13	33015-33025	addictions	_
166-14	33025-33026	,	_
166-15	33027-33030	and	_
166-16	33031-33042	individuals	_
166-17	33043-33047	with	_
166-18	33048-33051	SFC	_
166-19	33052-33058	damage	_
166-20	33059-33063	show	_
166-21	33064-33068	poor	_
166-22	33069-33079	inhibitory	_
166-23	33080-33087	control	_
166-24	33087-33088	.	_

#Text=Speculatively, after longer term abstinence, brain function may have partially recovered from impacts of methamphetamine, but shorter term abstinence may not be sufficient for such effects.
167-1	33089-33102	Speculatively	_
167-2	33102-33103	,	_
167-3	33104-33109	after	_
167-4	33110-33116	longer	_
167-5	33117-33121	term	_
167-6	33122-33132	abstinence	_
167-7	33132-33133	,	_
167-8	33134-33139	brain	_
167-9	33140-33148	function	_
167-10	33149-33152	may	_
167-11	33153-33157	have	_
167-12	33158-33167	partially	_
167-13	33168-33177	recovered	_
167-14	33178-33182	from	_
167-15	33183-33190	impacts	_
167-16	33191-33193	of	_
167-17	33194-33209	methamphetamine	_
167-18	33209-33210	,	_
167-19	33211-33214	but	_
167-20	33215-33222	shorter	_
167-21	33223-33227	term	_
167-22	33228-33238	abstinence	_
167-23	33239-33242	may	_
167-24	33243-33246	not	_
167-25	33247-33249	be	_
167-26	33250-33260	sufficient	_
167-27	33261-33264	for	_
167-28	33265-33269	such	_
167-29	33270-33277	effects	_
167-30	33277-33278	.	_

#Text=Previous studies in attention-deficit/hyperactivity disorder (ADHD) and healthy individuals have also reported negative correlations between impulsivity and neural activations, which may suggest a “trait-like” characteristic across different groups.
168-1	33279-33287	Previous	_
168-2	33288-33295	studies	_
168-3	33296-33298	in	_
168-4	33299-33316	attention-deficit	_
168-5	33316-33317	/	_
168-6	33317-33330	hyperactivity	_
168-7	33331-33339	disorder	_
168-8	33340-33341	(	_
168-9	33341-33345	ADHD	_
168-10	33345-33346	)	_
168-11	33347-33350	and	_
168-12	33351-33358	healthy	_
168-13	33359-33370	individuals	_
168-14	33371-33375	have	_
168-15	33376-33380	also	_
168-16	33381-33389	reported	_
168-17	33390-33398	negative	_
168-18	33399-33411	correlations	_
168-19	33412-33419	between	_
168-20	33420-33431	impulsivity	_
168-21	33432-33435	and	_
168-22	33436-33442	neural	_
168-23	33443-33454	activations	_
168-24	33454-33455	,	_
168-25	33456-33461	which	_
168-26	33462-33465	may	_
168-27	33466-33473	suggest	_
168-28	33474-33475	a	_
168-29	33476-33477	“	_
168-30	33477-33487	trait-like	_
168-31	33487-33488	”	_
168-32	33489-33503	characteristic	_
168-33	33504-33510	across	_
168-34	33511-33520	different	_
168-35	33521-33527	groups	_
168-36	33527-33528	.	_

#Text=However, impulsivity as assessed here may also reflect a self-perception of one’s tendencies that may be sensitive to stage of abstinence from methamphetamine.
169-1	33529-33536	However	_
169-2	33536-33537	,	_
169-3	33538-33549	impulsivity	_
169-4	33550-33552	as	_
169-5	33553-33561	assessed	_
169-6	33562-33566	here	_
169-7	33567-33570	may	_
169-8	33571-33575	also	_
169-9	33576-33583	reflect	_
169-10	33584-33585	a	_
169-11	33586-33601	self-perception	_
169-12	33602-33604	of	_
169-13	33605-33608	one	_
169-14	33608-33609	’	_
169-15	33609-33610	s	_
169-16	33611-33621	tendencies	_
169-17	33622-33626	that	_
169-18	33627-33630	may	_
169-19	33631-33633	be	_
169-20	33634-33643	sensitive	_
169-21	33644-33646	to	_
169-22	33647-33652	stage	_
169-23	33653-33655	of	_
169-24	33656-33666	abstinence	_
169-25	33667-33671	from	_
169-26	33672-33687	methamphetamine	_
169-27	33687-33688	.	_

#Text=As such, given stimulant use in ADHD groups, further research is needed to examine whether the current findings may have implications for the understanding of the neurobiology and clinical features of ADHD, especially with respect to stimulant use and sexual behaviors.
170-1	33689-33691	As	_
170-2	33692-33696	such	_
170-3	33696-33697	,	_
170-4	33698-33703	given	_
170-5	33704-33713	stimulant	_
170-6	33714-33717	use	_
170-7	33718-33720	in	_
170-8	33721-33725	ADHD	_
170-9	33726-33732	groups	_
170-10	33732-33733	,	_
170-11	33734-33741	further	_
170-12	33742-33750	research	_
170-13	33751-33753	is	_
170-14	33754-33760	needed	_
170-15	33761-33763	to	_
170-16	33764-33771	examine	_
170-17	33772-33779	whether	_
170-18	33780-33783	the	_
170-19	33784-33791	current	_
170-20	33792-33800	findings	_
170-21	33801-33804	may	_
170-22	33805-33809	have	_
170-23	33810-33822	implications	_
170-24	33823-33826	for	_
170-25	33827-33830	the	_
170-26	33831-33844	understanding	_
170-27	33845-33847	of	_
170-28	33848-33851	the	_
170-29	33852-33864	neurobiology	_
170-30	33865-33868	and	_
170-31	33869-33877	clinical	_
170-32	33878-33886	features	_
170-33	33887-33889	of	_
170-34	33890-33894	ADHD	_
170-35	33894-33895	,	_
170-36	33896-33906	especially	_
170-37	33907-33911	with	_
170-38	33912-33919	respect	_
170-39	33920-33922	to	_
170-40	33923-33932	stimulant	_
170-41	33933-33936	use	_
170-42	33937-33940	and	_
170-43	33941-33947	sexual	_
170-44	33948-33957	behaviors	_
170-45	33957-33958	.	_

#Text=The current findings suggest that brain function may not fully change simply through drug abstinence.
171-1	33959-33962	The	_
171-2	33963-33970	current	_
171-3	33971-33979	findings	_
171-4	33980-33987	suggest	_
171-5	33988-33992	that	_
171-6	33993-33998	brain	_
171-7	33999-34007	function	_
171-8	34008-34011	may	_
171-9	34012-34015	not	_
171-10	34016-34021	fully	_
171-11	34022-34028	change	_
171-12	34029-34035	simply	_
171-13	34036-34043	through	_
171-14	34044-34048	drug	_
171-15	34049-34059	abstinence	_
171-16	34059-34060	.	_

#Text=Some behavioral and medication interventions in treating drug addictions have focused on reducing cue-elicited craving; however, interventions are not uniformly successful.
172-1	34061-34065	Some	_
172-2	34066-34076	behavioral	_
172-3	34077-34080	and	_
172-4	34081-34091	medication	_
172-5	34092-34105	interventions	_
172-6	34106-34108	in	_
172-7	34109-34117	treating	_
172-8	34118-34122	drug	_
172-9	34123-34133	addictions	_
172-10	34134-34138	have	_
172-11	34139-34146	focused	_
172-12	34147-34149	on	_
172-13	34150-34158	reducing	_
172-14	34159-34171	cue-elicited	_
172-15	34172-34179	craving	_
172-16	34179-34180	;	_
172-17	34181-34188	however	_
172-18	34188-34189	,	_
172-19	34190-34203	interventions	_
172-20	34204-34207	are	_
172-21	34208-34211	not	_
172-22	34212-34221	uniformly	_
172-23	34222-34232	successful	_
172-24	34232-34233	.	_

#Text=A recent study suggests that training in selective attentional processing of natural rewards over drug rewards may help alter reward processing networks to be more responsive to natural rewards and reduce drug-related motivations and relapse.
173-1	34234-34235	A	_
173-2	34236-34242	recent	_
173-3	34243-34248	study	_
173-4	34249-34257	suggests	_
173-5	34258-34262	that	_
173-6	34263-34271	training	_
173-7	34272-34274	in	_
173-8	34275-34284	selective	_
173-9	34285-34296	attentional	_
173-10	34297-34307	processing	_
173-11	34308-34310	of	_
173-12	34311-34318	natural	_
173-13	34319-34326	rewards	_
173-14	34327-34331	over	_
173-15	34332-34336	drug	_
173-16	34337-34344	rewards	_
173-17	34345-34348	may	_
173-18	34349-34353	help	_
173-19	34354-34359	alter	_
173-20	34360-34366	reward	_
173-21	34367-34377	processing	_
173-22	34378-34386	networks	_
173-23	34387-34389	to	_
173-24	34390-34392	be	_
173-25	34393-34397	more	_
173-26	34398-34408	responsive	_
173-27	34409-34411	to	_
173-28	34412-34419	natural	_
173-29	34420-34427	rewards	_
173-30	34428-34431	and	_
173-31	34432-34438	reduce	_
173-32	34439-34451	drug-related	_
173-33	34452-34463	motivations	_
173-34	34464-34467	and	_
173-35	34468-34475	relapse	_
173-36	34475-34476	.	_

#Text=However, the current findings suggest that individuals in remission from methamphetamine dependence may exhibit heightened responses to sexual cues, and the extent to which such training may influence responses to sexual rewards warrants consideration and research.
174-1	34477-34484	However	_
174-2	34484-34485	,	_
174-3	34486-34489	the	_
174-4	34490-34497	current	_
174-5	34498-34506	findings	_
174-6	34507-34514	suggest	_
174-7	34515-34519	that	_
174-8	34520-34531	individuals	_
174-9	34532-34534	in	_
174-10	34535-34544	remission	_
174-11	34545-34549	from	_
174-12	34550-34565	methamphetamine	_
174-13	34566-34576	dependence	_
174-14	34577-34580	may	_
174-15	34581-34588	exhibit	_
174-16	34589-34599	heightened	_
174-17	34600-34609	responses	_
174-18	34610-34612	to	_
174-19	34613-34619	sexual	_
174-20	34620-34624	cues	_
174-21	34624-34625	,	_
174-22	34626-34629	and	_
174-23	34630-34633	the	_
174-24	34634-34640	extent	_
174-25	34641-34643	to	_
174-26	34644-34649	which	_
174-27	34650-34654	such	_
174-28	34655-34663	training	_
174-29	34664-34667	may	_
174-30	34668-34677	influence	_
174-31	34678-34687	responses	_
174-32	34688-34690	to	_
174-33	34691-34697	sexual	_
174-34	34698-34705	rewards	_
174-35	34706-34714	warrants	_
174-36	34715-34728	consideration	_
174-37	34729-34732	and	_
174-38	34733-34741	research	_
174-39	34741-34742	.	_

#Text=In the present study, there were no differences in cue-induced brain activation between the STMA and LTMA groups when exposed to both methamphetamine and sexual cues.
175-1	34743-34745	In	_
175-2	34746-34749	the	_
175-3	34750-34757	present	_
175-4	34758-34763	study	_
175-5	34763-34764	,	_
175-6	34765-34770	there	_
175-7	34771-34775	were	_
175-8	34776-34778	no	_
175-9	34779-34790	differences	_
175-10	34791-34793	in	_
175-11	34794-34805	cue-induced	_
175-12	34806-34811	brain	_
175-13	34812-34822	activation	_
175-14	34823-34830	between	_
175-15	34831-34834	the	_
175-16	34835-34839	STMA	_
175-17	34840-34843	and	_
175-18	34844-34848	LTMA	_
175-19	34849-34855	groups	_
175-20	34856-34860	when	_
175-21	34861-34868	exposed	_
175-22	34869-34871	to	_
175-23	34872-34876	both	_
175-24	34877-34892	methamphetamine	_
175-25	34893-34896	and	_
175-26	34897-34903	sexual	_
175-27	34904-34908	cues	_
175-28	34908-34909	.	_

#Text=However, the magnitudes of responses suggested that the brain activation to sexual cues in the STMA group was intermediate (albeit not in a statistically significant fashion) between the HC and LTMA groups in the ventral striatum and the SFC, but not in the dorsal striatum, vmPFC, or anterior insula.
176-1	34910-34917	However	_
176-2	34917-34918	,	_
176-3	34919-34922	the	_
176-4	34923-34933	magnitudes	_
176-5	34934-34936	of	_
176-6	34937-34946	responses	_
176-7	34947-34956	suggested	_
176-8	34957-34961	that	_
176-9	34962-34965	the	_
176-10	34966-34971	brain	_
176-11	34972-34982	activation	_
176-12	34983-34985	to	_
176-13	34986-34992	sexual	_
176-14	34993-34997	cues	_
176-15	34998-35000	in	_
176-16	35001-35004	the	_
176-17	35005-35009	STMA	_
176-18	35010-35015	group	_
176-19	35016-35019	was	_
176-20	35020-35032	intermediate	_
176-21	35033-35034	(	_
176-22	35034-35040	albeit	_
176-23	35041-35044	not	_
176-24	35045-35047	in	_
176-25	35048-35049	a	_
176-26	35050-35063	statistically	_
176-27	35064-35075	significant	_
176-28	35076-35083	fashion	_
176-29	35083-35084	)	_
176-30	35085-35092	between	_
176-31	35093-35096	the	_
176-32	35097-35099	HC	_
176-33	35100-35103	and	_
176-34	35104-35108	LTMA	_
176-35	35109-35115	groups	_
176-36	35116-35118	in	_
176-37	35119-35122	the	_
176-38	35123-35130	ventral	_
176-39	35131-35139	striatum	_
176-40	35140-35143	and	_
176-41	35144-35147	the	_
176-42	35148-35151	SFC	_
176-43	35151-35152	,	_
176-44	35153-35156	but	_
176-45	35157-35160	not	_
176-46	35161-35163	in	_
176-47	35164-35167	the	_
176-48	35168-35174	dorsal	_
176-49	35175-35183	striatum	_
176-50	35183-35184	,	_
176-51	35185-35190	vmPFC	_
176-52	35190-35191	,	_
176-53	35192-35194	or	_
176-54	35195-35203	anterior	_
176-55	35204-35210	insula	_
176-56	35210-35211	.	_

#Text=The ventral striatum has been found to activate in response to methamphetamine in drug-naïve humans and has shown greater activation in individuals with current methamphetamine dependence compared with those without when performing the Balloon Analogue Risk Task.
177-1	35212-35215	The	_
177-2	35216-35223	ventral	_
177-3	35224-35232	striatum	_
177-4	35233-35236	has	_
177-5	35237-35241	been	_
177-6	35242-35247	found	_
177-7	35248-35250	to	_
177-8	35251-35259	activate	_
177-9	35260-35262	in	_
177-10	35263-35271	response	_
177-11	35272-35274	to	_
177-12	35275-35290	methamphetamine	_
177-13	35291-35293	in	_
177-14	35294-35304	drug-naïve	_
177-15	35305-35311	humans	_
177-16	35312-35315	and	_
177-17	35316-35319	has	_
177-18	35320-35325	shown	_
177-19	35326-35333	greater	_
177-20	35334-35344	activation	_
177-21	35345-35347	in	_
177-22	35348-35359	individuals	_
177-23	35360-35364	with	_
177-24	35365-35372	current	_
177-25	35373-35388	methamphetamine	_
177-26	35389-35399	dependence	_
177-27	35400-35408	compared	_
177-28	35409-35413	with	_
177-29	35414-35419	those	_
177-30	35420-35427	without	_
177-31	35428-35432	when	_
177-32	35433-35443	performing	_
177-33	35444-35447	the	_
177-34	35448-35455	Balloon	_
177-35	35456-35464	Analogue	_
177-36	35465-35469	Risk	_
177-37	35470-35474	Task	_
177-38	35474-35475	.	_

#Text=However, the ventral striatum was not implicated in methamphetamine cue responsiveness across groups, although responses to sexual cues were linked to ventral striatal activation.
178-1	35476-35483	However	_
178-2	35483-35484	,	_
178-3	35485-35488	the	_
178-4	35489-35496	ventral	_
178-5	35497-35505	striatum	_
178-6	35506-35509	was	_
178-7	35510-35513	not	_
178-8	35514-35524	implicated	_
178-9	35525-35527	in	_
178-10	35528-35543	methamphetamine	_
178-11	35544-35547	cue	_
178-12	35548-35562	responsiveness	_
178-13	35563-35569	across	_
178-14	35570-35576	groups	_
178-15	35576-35577	,	_
178-16	35578-35586	although	_
178-17	35587-35596	responses	_
178-18	35597-35599	to	_
178-19	35600-35606	sexual	_
178-20	35607-35611	cues	_
178-21	35612-35616	were	_
178-22	35617-35623	linked	_
178-23	35624-35626	to	_
178-24	35627-35634	ventral	_
178-25	35635-35643	striatal	_
178-26	35644-35654	activation	_
178-27	35654-35655	.	_

#Text=The extent to which these findings may relate to functional recovery from drug dependence following extended abstinence (i.e., up to 40 months) warrants investigation in longitudinal studies.
179-1	35656-35659	The	_
179-2	35660-35666	extent	_
179-3	35667-35669	to	_
179-4	35670-35675	which	_
179-5	35676-35681	these	_
179-6	35682-35690	findings	_
179-7	35691-35694	may	_
179-8	35695-35701	relate	_
179-9	35702-35704	to	_
179-10	35705-35715	functional	_
179-11	35716-35724	recovery	_
179-12	35725-35729	from	_
179-13	35730-35734	drug	_
179-14	35735-35745	dependence	_
179-15	35746-35755	following	_
179-16	35756-35764	extended	_
179-17	35765-35775	abstinence	_
179-18	35776-35777	(	_
179-19	35777-35780	i.e	_
179-20	35780-35781	.	_
179-21	35781-35782	,	_
179-22	35783-35785	up	_
179-23	35786-35788	to	_
179-24	35789-35791	40	_
179-25	35792-35798	months	_
179-26	35798-35799	)	_
179-27	35800-35808	warrants	_
179-28	35809-35822	investigation	_
179-29	35823-35825	in	_
179-30	35826-35838	longitudinal	_
179-31	35839-35846	studies	_
179-32	35846-35847	.	_

#Text=Protracted abstinence from methamphetamine may reverse some drug-induced alterations in brain function, and this may explain some findings in the LTMA group relative to the STMA group, although this too warrants additional investigation.
180-1	35848-35858	Protracted	_
180-2	35859-35869	abstinence	_
180-3	35870-35874	from	_
180-4	35875-35890	methamphetamine	_
180-5	35891-35894	may	_
180-6	35895-35902	reverse	_
180-7	35903-35907	some	_
180-8	35908-35920	drug-induced	_
180-9	35921-35932	alterations	_
180-10	35933-35935	in	_
180-11	35936-35941	brain	_
180-12	35942-35950	function	_
180-13	35950-35951	,	_
180-14	35952-35955	and	_
180-15	35956-35960	this	_
180-16	35961-35964	may	_
180-17	35965-35972	explain	_
180-18	35973-35977	some	_
180-19	35978-35986	findings	_
180-20	35987-35989	in	_
180-21	35990-35993	the	_
180-22	35994-35998	LTMA	_
180-23	35999-36004	group	_
180-24	36005-36013	relative	_
180-25	36014-36016	to	_
180-26	36017-36020	the	_
180-27	36021-36025	STMA	_
180-28	36026-36031	group	_
180-29	36031-36032	,	_
180-30	36033-36041	although	_
180-31	36042-36046	this	_
180-32	36047-36050	too	_
180-33	36051-36059	warrants	_
180-34	36060-36070	additional	_
180-35	36071-36084	investigation	_
180-36	36084-36085	.	_

#Text=Several limitations of the present study should be noted.
181-1	36086-36093	Several	_
181-2	36094-36105	limitations	_
181-3	36106-36108	of	_
181-4	36109-36112	the	_
181-5	36113-36120	present	_
181-6	36121-36126	study	_
181-7	36127-36133	should	_
181-8	36134-36136	be	_
181-9	36137-36142	noted	_
181-10	36142-36143	.	_

#Text=First, this was a cross-sectional study.
182-1	36144-36149	First	_
182-2	36149-36150	,	_
182-3	36151-36155	this	_
182-4	36156-36159	was	_
182-5	36160-36161	a	_
182-6	36162-36177	cross-sectional	_
182-7	36178-36183	study	_
182-8	36183-36184	.	_

#Text=Preexisting differences in neural functioning in the LTMA and STMA groups may have been present; hence, future longitudinal studies are indicated.
183-1	36185-36196	Preexisting	_
183-2	36197-36208	differences	_
183-3	36209-36211	in	_
183-4	36212-36218	neural	_
183-5	36219-36230	functioning	_
183-6	36231-36233	in	_
183-7	36234-36237	the	_
183-8	36238-36242	LTMA	_
183-9	36243-36246	and	_
183-10	36247-36251	STMA	_
183-11	36252-36258	groups	_
183-12	36259-36262	may	_
183-13	36263-36267	have	_
183-14	36268-36272	been	_
183-15	36273-36280	present	_
183-16	36280-36281	;	_
183-17	36282-36287	hence	_
183-18	36287-36288	,	_
183-19	36289-36295	future	_
183-20	36296-36308	longitudinal	_
183-21	36309-36316	studies	_
183-22	36317-36320	are	_
183-23	36321-36330	indicated	_
183-24	36330-36331	.	_

#Text=Second, STMA participants were not well matched on age and education to the LTMA or HC participants, as STMA participants tended to be younger and have more education.
184-1	36332-36338	Second	_
184-2	36338-36339	,	_
184-3	36340-36344	STMA	_
184-4	36345-36357	participants	_
184-5	36358-36362	were	_
184-6	36363-36366	not	_
184-7	36367-36371	well	_
184-8	36372-36379	matched	_
184-9	36380-36382	on	_
184-10	36383-36386	age	_
184-11	36387-36390	and	_
184-12	36391-36400	education	_
184-13	36401-36403	to	_
184-14	36404-36407	the	_
184-15	36408-36412	LTMA	_
184-16	36413-36415	or	_
184-17	36416-36418	HC	_
184-18	36419-36431	participants	_
184-19	36431-36432	,	_
184-20	36433-36435	as	_
184-21	36436-36440	STMA	_
184-22	36441-36453	participants	_
184-23	36454-36460	tended	_
184-24	36461-36463	to	_
184-25	36464-36466	be	_
184-26	36467-36474	younger	_
184-27	36475-36478	and	_
184-28	36479-36483	have	_
184-29	36484-36488	more	_
184-30	36489-36498	education	_
184-31	36498-36499	.	_

#Text=HC participants were not well matched on alcohol use to the STMA or LTMA participants, as HC participants were the least likely to report drinking alcohol among the 3 groups.
185-1	36500-36502	HC	_
185-2	36503-36515	participants	_
185-3	36516-36520	were	_
185-4	36521-36524	not	_
185-5	36525-36529	well	_
185-6	36530-36537	matched	_
185-7	36538-36540	on	_
185-8	36541-36548	alcohol	_
185-9	36549-36552	use	_
185-10	36553-36555	to	_
185-11	36556-36559	the	_
185-12	36560-36564	STMA	_
185-13	36565-36567	or	_
185-14	36568-36572	LTMA	_
185-15	36573-36585	participants	_
185-16	36585-36586	,	_
185-17	36587-36589	as	_
185-18	36590-36592	HC	_
185-19	36593-36605	participants	_
185-20	36606-36610	were	_
185-21	36611-36614	the	_
185-22	36615-36620	least	_
185-23	36621-36627	likely	_
185-24	36628-36630	to	_
185-25	36631-36637	report	_
185-26	36638-36646	drinking	_
185-27	36647-36654	alcohol	_
185-28	36655-36660	among	_
185-29	36661-36664	the	_
185-30	36665-36666	3	_
185-31	36667-36673	groups	_
185-32	36673-36674	.	_

#Text=However, when including age, education, and alcohol use as covariates, the main findings persisted.
186-1	36675-36682	However	_
186-2	36682-36683	,	_
186-3	36684-36688	when	_
186-4	36689-36698	including	_
186-5	36699-36702	age	_
186-6	36702-36703	,	_
186-7	36704-36713	education	_
186-8	36713-36714	,	_
186-9	36715-36718	and	_
186-10	36719-36726	alcohol	_
186-11	36727-36730	use	_
186-12	36731-36733	as	_
186-13	36734-36744	covariates	_
186-14	36744-36745	,	_
186-15	36746-36749	the	_
186-16	36750-36754	main	_
186-17	36755-36763	findings	_
186-18	36764-36773	persisted	_
186-19	36773-36774	.	_

#Text=Third, STMA and LTMA participants were recruited from voluntary and compulsory drug rehabilitation centers, respectively.
187-1	36775-36780	Third	_
187-2	36780-36781	,	_
187-3	36782-36786	STMA	_
187-4	36787-36790	and	_
187-5	36791-36795	LTMA	_
187-6	36796-36808	participants	_
187-7	36809-36813	were	_
187-8	36814-36823	recruited	_
187-9	36824-36828	from	_
187-10	36829-36838	voluntary	_
187-11	36839-36842	and	_
187-12	36843-36853	compulsory	_
187-13	36854-36858	drug	_
187-14	36859-36873	rehabilitation	_
187-15	36874-36881	centers	_
187-16	36881-36882	,	_
187-17	36883-36895	respectively	_
187-18	36895-36896	.	_

#Text=As such, differences in motivations for treatment and the abstention from sexual activities may have influenced neural responses to methamphetamine and sexual cues.
188-1	36897-36899	As	_
188-2	36900-36904	such	_
188-3	36904-36905	,	_
188-4	36906-36917	differences	_
188-5	36918-36920	in	_
188-6	36921-36932	motivations	_
188-7	36933-36936	for	_
188-8	36937-36946	treatment	_
188-9	36947-36950	and	_
188-10	36951-36954	the	_
188-11	36955-36965	abstention	_
188-12	36966-36970	from	_
188-13	36971-36977	sexual	_
188-14	36978-36988	activities	_
188-15	36989-36992	may	_
188-16	36993-36997	have	_
188-17	36998-37008	influenced	_
188-18	37009-37015	neural	_
188-19	37016-37025	responses	_
188-20	37026-37028	to	_
188-21	37029-37044	methamphetamine	_
188-22	37045-37048	and	_
188-23	37049-37055	sexual	_
188-24	37056-37060	cues	_
188-25	37060-37061	.	_

#Text=Hence, future studies should gather information on motivations for treatment and other domains that may differ in voluntary vs compulsory treatment programs.
189-1	37062-37067	Hence	_
189-2	37067-37068	,	_
189-3	37069-37075	future	_
189-4	37076-37083	studies	_
189-5	37084-37090	should	_
189-6	37091-37097	gather	_
189-7	37098-37109	information	_
189-8	37110-37112	on	_
189-9	37113-37124	motivations	_
189-10	37125-37128	for	_
189-11	37129-37138	treatment	_
189-12	37139-37142	and	_
189-13	37143-37148	other	_
189-14	37149-37156	domains	_
189-15	37157-37161	that	_
189-16	37162-37165	may	_
189-17	37166-37172	differ	_
189-18	37173-37175	in	_
189-19	37176-37185	voluntary	_
189-20	37186-37188	vs	_
189-21	37189-37199	compulsory	_
189-22	37200-37209	treatment	_
189-23	37210-37218	programs	_
189-24	37218-37219	.	_

#Text=Fourth, due to a limited number of methamphetamine-dependent females completing study procedures (n = 3), the current analyses were limited to males, and it will be important to examine neurofunctioning in women with methamphetamine dependence in future studies given gender-related differences noted in studies of stimulant dependence.
190-1	37220-37226	Fourth	_
190-2	37226-37227	,	_
190-3	37228-37231	due	_
190-4	37232-37234	to	_
190-5	37235-37236	a	_
190-6	37237-37244	limited	_
190-7	37245-37251	number	_
190-8	37252-37254	of	_
190-9	37255-37280	methamphetamine-dependent	_
190-10	37281-37288	females	_
190-11	37289-37299	completing	_
190-12	37300-37305	study	_
190-13	37306-37316	procedures	_
190-14	37317-37318	(	_
190-15	37318-37319	n	_
190-16	37320-37321	=	_
190-17	37322-37323	3	_
190-18	37323-37324	)	_
190-19	37324-37325	,	_
190-20	37326-37329	the	_
190-21	37330-37337	current	_
190-22	37338-37346	analyses	_
190-23	37347-37351	were	_
190-24	37352-37359	limited	_
190-25	37360-37362	to	_
190-26	37363-37368	males	_
190-27	37368-37369	,	_
190-28	37370-37373	and	_
190-29	37374-37376	it	_
190-30	37377-37381	will	_
190-31	37382-37384	be	_
190-32	37385-37394	important	_
190-33	37395-37397	to	_
190-34	37398-37405	examine	_
190-35	37406-37422	neurofunctioning	_
190-36	37423-37425	in	_
190-37	37426-37431	women	_
190-38	37432-37436	with	_
190-39	37437-37452	methamphetamine	_
190-40	37453-37463	dependence	_
190-41	37464-37466	in	_
190-42	37467-37473	future	_
190-43	37474-37481	studies	_
190-44	37482-37487	given	_
190-45	37488-37502	gender-related	_
190-46	37503-37514	differences	_
190-47	37515-37520	noted	_
190-48	37521-37523	in	_
190-49	37524-37531	studies	_
190-50	37532-37534	of	_
190-51	37535-37544	stimulant	_
190-52	37545-37555	dependence	_
190-53	37555-37556	.	_

#Text=Fifth, we did not evaluate participants’ craving or other subjective responses to the sexual and methamphetamine cues, such as their use of methamphetamine for sexual purposes.
191-1	37557-37562	Fifth	_
191-2	37562-37563	,	_
191-3	37564-37566	we	_
191-4	37567-37570	did	_
191-5	37571-37574	not	_
191-6	37575-37583	evaluate	_
191-7	37584-37596	participants	_
191-8	37596-37597	’	_
191-9	37598-37605	craving	_
191-10	37606-37608	or	_
191-11	37609-37614	other	_
191-12	37615-37625	subjective	_
191-13	37626-37635	responses	_
191-14	37636-37638	to	_
191-15	37639-37642	the	_
191-16	37643-37649	sexual	_
191-17	37650-37653	and	_
191-18	37654-37669	methamphetamine	_
191-19	37670-37674	cues	_
191-20	37674-37675	,	_
191-21	37676-37680	such	_
191-22	37681-37683	as	_
191-23	37684-37689	their	_
191-24	37690-37693	use	_
191-25	37694-37696	of	_
191-26	37697-37712	methamphetamine	_
191-27	37713-37716	for	_
191-28	37717-37723	sexual	_
191-29	37724-37732	purposes	_
191-30	37732-37733	.	_

#Text=This may have been relevant to the current study in that SFC activation has been related to cravings for drug and responses to drug-related cues.
192-1	37734-37738	This	_
192-2	37739-37742	may	_
192-3	37743-37747	have	_
192-4	37748-37752	been	_
192-5	37753-37761	relevant	_
192-6	37762-37764	to	_
192-7	37765-37768	the	_
192-8	37769-37776	current	_
192-9	37777-37782	study	_
192-10	37783-37785	in	_
192-11	37786-37790	that	_
192-12	37791-37794	SFC	_
192-13	37795-37805	activation	_
192-14	37806-37809	has	_
192-15	37810-37814	been	_
192-16	37815-37822	related	_
192-17	37823-37825	to	_
192-18	37826-37834	cravings	_
192-19	37835-37838	for	_
192-20	37839-37843	drug	_
192-21	37844-37847	and	_
192-22	37848-37857	responses	_
192-23	37858-37860	to	_
192-24	37861-37873	drug-related	_
192-25	37874-37878	cues	_
192-26	37878-37879	.	_

#Text=Sixth, we did not test the lateralized effects in the ROI analyses; further study could consider exploring each region for effects of laterality.
193-1	37880-37885	Sixth	_
193-2	37885-37886	,	_
193-3	37887-37889	we	_
193-4	37890-37893	did	_
193-5	37894-37897	not	_
193-6	37898-37902	test	_
193-7	37903-37906	the	_
193-8	37907-37918	lateralized	_
193-9	37919-37926	effects	_
193-10	37927-37929	in	_
193-11	37930-37933	the	_
193-12	37934-37937	ROI	_
193-13	37938-37946	analyses	_
193-14	37946-37947	;	_
193-15	37948-37955	further	_
193-16	37956-37961	study	_
193-17	37962-37967	could	_
193-18	37968-37976	consider	_
193-19	37977-37986	exploring	_
193-20	37987-37991	each	_
193-21	37992-37998	region	_
193-22	37999-38002	for	_
193-23	38003-38010	effects	_
193-24	38011-38013	of	_
193-25	38014-38024	laterality	_
193-26	38024-38025	.	_

#Text=Seventh, the whole-brain analysis was performed without covariates to adjust for group differences in age, education, and alcohol use.
194-1	38026-38033	Seventh	_
194-2	38033-38034	,	_
194-3	38035-38038	the	_
194-4	38039-38050	whole-brain	_
194-5	38051-38059	analysis	_
194-6	38060-38063	was	_
194-7	38064-38073	performed	_
194-8	38074-38081	without	_
194-9	38082-38092	covariates	_
194-10	38093-38095	to	_
194-11	38096-38102	adjust	_
194-12	38103-38106	for	_
194-13	38107-38112	group	_
194-14	38113-38124	differences	_
194-15	38125-38127	in	_
194-16	38128-38131	age	_
194-17	38131-38132	,	_
194-18	38133-38142	education	_
194-19	38142-38143	,	_
194-20	38144-38147	and	_
194-21	38148-38155	alcohol	_
194-22	38156-38159	use	_
194-23	38159-38160	.	_

#Text=It is possible that analysis incorporating these covariates may have resulted in an altered pattern of regional group differences.
195-1	38161-38163	It	_
195-2	38164-38166	is	_
195-3	38167-38175	possible	_
195-4	38176-38180	that	_
195-5	38181-38189	analysis	_
195-6	38190-38203	incorporating	_
195-7	38204-38209	these	_
195-8	38210-38220	covariates	_
195-9	38221-38224	may	_
195-10	38225-38229	have	_
195-11	38230-38238	resulted	_
195-12	38239-38241	in	_
195-13	38242-38244	an	_
195-14	38245-38252	altered	_
195-15	38253-38260	pattern	_
195-16	38261-38263	of	_
195-17	38264-38272	regional	_
195-18	38273-38278	group	_
195-19	38279-38290	differences	_
195-20	38290-38291	.	_

#Text=Another limitation was the absence of the use of urine screening tests to confirm absence of psychoactive drug use in all participants.
196-1	38292-38299	Another	_
196-2	38300-38310	limitation	_
196-3	38311-38314	was	_
196-4	38315-38318	the	_
196-5	38319-38326	absence	_
196-6	38327-38329	of	_
196-7	38330-38333	the	_
196-8	38334-38337	use	_
196-9	38338-38340	of	_
196-10	38341-38346	urine	_
196-11	38347-38356	screening	_
196-12	38357-38362	tests	_
196-13	38363-38365	to	_
196-14	38366-38373	confirm	_
196-15	38374-38381	absence	_
196-16	38382-38384	of	_
196-17	38385-38397	psychoactive	_
196-18	38398-38402	drug	_
196-19	38403-38406	use	_
196-20	38407-38409	in	_
196-21	38410-38413	all	_
196-22	38414-38426	participants	_
196-23	38426-38427	.	_

#Text=Duration of abstinence may impact responses to sexual cues more so than to methamphetamine cues in individuals with methamphetamine dependence.
197-1	38428-38436	Duration	_
197-2	38437-38439	of	_
197-3	38440-38450	abstinence	_
197-4	38451-38454	may	_
197-5	38455-38461	impact	_
197-6	38462-38471	responses	_
197-7	38472-38474	to	_
197-8	38475-38481	sexual	_
197-9	38482-38486	cues	_
197-10	38487-38491	more	_
197-11	38492-38494	so	_
197-12	38495-38499	than	_
197-13	38500-38502	to	_
197-14	38503-38518	methamphetamine	_
197-15	38519-38523	cues	_
197-16	38524-38526	in	_
197-17	38527-38538	individuals	_
197-18	38539-38543	with	_
197-19	38544-38559	methamphetamine	_
197-20	38560-38570	dependence	_
197-21	38570-38571	.	_

#Text=Greater vmPFC activation to methamphetamine cues was observed in both the STMA and LTMA groups relative to HC participants, but our approach identified no differences in methamphetamine cue–related activation between STMA and LTMA groups.
198-1	38572-38579	Greater	_
198-2	38580-38585	vmPFC	_
198-3	38586-38596	activation	_
198-4	38597-38599	to	_
198-5	38600-38615	methamphetamine	_
198-6	38616-38620	cues	_
198-7	38621-38624	was	_
198-8	38625-38633	observed	_
198-9	38634-38636	in	_
198-10	38637-38641	both	_
198-11	38642-38645	the	_
198-12	38646-38650	STMA	_
198-13	38651-38654	and	_
198-14	38655-38659	LTMA	_
198-15	38660-38666	groups	_
198-16	38667-38675	relative	_
198-17	38676-38678	to	_
198-18	38679-38681	HC	_
198-19	38682-38694	participants	_
198-20	38694-38695	,	_
198-21	38696-38699	but	_
198-22	38700-38703	our	_
198-23	38704-38712	approach	_
198-24	38713-38723	identified	_
198-25	38724-38726	no	_
198-26	38727-38738	differences	_
198-27	38739-38741	in	_
198-28	38742-38757	methamphetamine	_
198-29	38758-38769	cue–related	_
198-30	38770-38780	activation	_
198-31	38781-38788	between	_
198-32	38789-38793	STMA	_
198-33	38794-38797	and	_
198-34	38798-38802	LTMA	_
198-35	38803-38809	groups	_
198-36	38809-38810	.	_

#Text=Greater anterior insula activations in response to sexual cues relative to methamphetamine cues and neutral cues in STMA and LTMA groups compared with HCs were observed.
199-1	38811-38818	Greater	_
199-2	38819-38827	anterior	_
199-3	38828-38834	insula	_
199-4	38835-38846	activations	_
199-5	38847-38849	in	_
199-6	38850-38858	response	_
199-7	38859-38861	to	_
199-8	38862-38868	sexual	_
199-9	38869-38873	cues	_
199-10	38874-38882	relative	_
199-11	38883-38885	to	_
199-12	38886-38901	methamphetamine	_
199-13	38902-38906	cues	_
199-14	38907-38910	and	_
199-15	38911-38918	neutral	_
199-16	38919-38923	cues	_
199-17	38924-38926	in	_
199-18	38927-38931	STMA	_
199-19	38932-38935	and	_
199-20	38936-38940	LTMA	_
199-21	38941-38947	groups	_
199-22	38948-38956	compared	_
199-23	38957-38961	with	_
199-24	38962-38965	HCs	_
199-25	38966-38970	were	_
199-26	38971-38979	observed	_
199-27	38979-38980	.	_

#Text=Greater SFC activation to sexual cues was observed in LTMA but not STMA participants compared with HCs.
200-1	38981-38988	Greater	_
200-2	38989-38992	SFC	_
200-3	38993-39003	activation	_
200-4	39004-39006	to	_
200-5	39007-39013	sexual	_
200-6	39014-39018	cues	_
200-7	39019-39022	was	_
200-8	39023-39031	observed	_
200-9	39032-39034	in	_
200-10	39035-39039	LTMA	_
200-11	39040-39043	but	_
200-12	39044-39047	not	_
200-13	39048-39052	STMA	_
200-14	39053-39065	participants	_
200-15	39066-39074	compared	_
200-16	39075-39079	with	_
200-17	39080-39083	HCs	_
200-18	39083-39084	.	_

#Text=Activation in the ventral striatum, dorsal striatum, vmPFC, anterior insula, and SFC in response to sexual cues was greater than responses to neutral and/or methamphetamine cues both in STMA and LTMA participants.
201-1	39085-39095	Activation	_
201-2	39096-39098	in	_
201-3	39099-39102	the	_
201-4	39103-39110	ventral	_
201-5	39111-39119	striatum	_
201-6	39119-39120	,	_
201-7	39121-39127	dorsal	_
201-8	39128-39136	striatum	_
201-9	39136-39137	,	_
201-10	39138-39143	vmPFC	_
201-11	39143-39144	,	_
201-12	39145-39153	anterior	_
201-13	39154-39160	insula	_
201-14	39160-39161	,	_
201-15	39162-39165	and	_
201-16	39166-39169	SFC	_
201-17	39170-39172	in	_
201-18	39173-39181	response	_
201-19	39182-39184	to	_
201-20	39185-39191	sexual	_
201-21	39192-39196	cues	_
201-22	39197-39200	was	_
201-23	39201-39208	greater	_
201-24	39209-39213	than	_
201-25	39214-39223	responses	_
201-26	39224-39226	to	_
201-27	39227-39234	neutral	_
201-28	39235-39238	and	_
201-29	39238-39239	/	_
201-30	39239-39241	or	_
201-31	39242-39257	methamphetamine	_
201-32	39258-39262	cues	_
201-33	39263-39267	both	_
201-34	39268-39270	in	_
201-35	39271-39275	STMA	_
201-36	39276-39279	and	_
201-37	39280-39284	LTMA	_
201-38	39285-39297	participants	_
201-39	39297-39298	.	_

#Text=These findings may have clinical relevance given the use of methamphetamine for sexual purposes and the relevance of neural and behavioral responses to natural vs drug rewards for addiction recovery.
202-1	39299-39304	These	_
202-2	39305-39313	findings	_
202-3	39314-39317	may	_
202-4	39318-39322	have	_
202-5	39323-39331	clinical	_
202-6	39332-39341	relevance	_
202-7	39342-39347	given	_
202-8	39348-39351	the	_
202-9	39352-39355	use	_
202-10	39356-39358	of	_
202-11	39359-39374	methamphetamine	_
202-12	39375-39378	for	_
202-13	39379-39385	sexual	_
202-14	39386-39394	purposes	_
202-15	39395-39398	and	_
202-16	39399-39402	the	_
202-17	39403-39412	relevance	_
202-18	39413-39415	of	_
202-19	39416-39422	neural	_
202-20	39423-39426	and	_
202-21	39427-39437	behavioral	_
202-22	39438-39447	responses	_
202-23	39448-39450	to	_
202-24	39451-39458	natural	_
202-25	39459-39461	vs	_
202-26	39462-39466	drug	_
202-27	39467-39474	rewards	_
202-28	39475-39478	for	_
202-29	39479-39488	addiction	_
202-30	39489-39497	recovery	_
202-31	39497-39498	.	_

#Text=Future studies investigating individuals at multiple stages of addiction and abstinence could help clarify functional alterations that may represent preexisting features, consequences of chronic methamphetamine exposure, and recovery from methamphetamine dependence.
203-1	39499-39505	Future	_
203-2	39506-39513	studies	_
203-3	39514-39527	investigating	_
203-4	39528-39539	individuals	_
203-5	39540-39542	at	_
203-6	39543-39551	multiple	_
203-7	39552-39558	stages	_
203-8	39559-39561	of	_
203-9	39562-39571	addiction	_
203-10	39572-39575	and	_
203-11	39576-39586	abstinence	_
203-12	39587-39592	could	_
203-13	39593-39597	help	_
203-14	39598-39605	clarify	_
203-15	39606-39616	functional	_
203-16	39617-39628	alterations	_
203-17	39629-39633	that	_
203-18	39634-39637	may	_
203-19	39638-39647	represent	_
203-20	39648-39659	preexisting	_
203-21	39660-39668	features	_
203-22	39668-39669	,	_
203-23	39670-39682	consequences	_
203-24	39683-39685	of	_
203-25	39686-39693	chronic	_
203-26	39694-39709	methamphetamine	_
203-27	39710-39718	exposure	_
203-28	39718-39719	,	_
203-29	39720-39723	and	_
203-30	39724-39732	recovery	_
203-31	39733-39737	from	_
203-32	39738-39753	methamphetamine	_
203-33	39754-39764	dependence	_
203-34	39764-39765	.	_

#Text=Supplementary Material
#Text=This work was supported by National Key R and D Program of China (no. 2017YFC1310400), National Natural Science Foundation of China (no. 81571307, no. 81371465 and no. 81671324), Fundamental Research Funds for Central Universities of the Central South University (no. 2016zzts148), National Basic Research Program of China (973 Program) (no. 2015CB553504), National Key R and D Program of China (no. 2016YFC0800908-Z02), and the National Institutes of Health (K01 DA042998, R01 DA039136).
204-1	39766-39779	Supplementary	_
204-2	39780-39788	Material	_
204-3	39789-39793	This	_
204-4	39794-39798	work	_
204-5	39799-39802	was	_
204-6	39803-39812	supported	_
204-7	39813-39815	by	_
204-8	39816-39824	National	_
204-9	39825-39828	Key	_
204-10	39829-39830	R	_
204-11	39831-39834	and	_
204-12	39835-39836	D	_
204-13	39837-39844	Program	_
204-14	39845-39847	of	_
204-15	39848-39853	China	_
204-16	39854-39855	(	_
204-17	39855-39857	no	_
204-18	39857-39858	.	_
204-19	39859-39873	2017YFC1310400	_
204-20	39873-39874	)	_
204-21	39874-39875	,	_
204-22	39876-39884	National	_
204-23	39885-39892	Natural	_
204-24	39893-39900	Science	_
204-25	39901-39911	Foundation	_
204-26	39912-39914	of	_
204-27	39915-39920	China	_
204-28	39921-39922	(	_
204-29	39922-39924	no	_
204-30	39924-39925	.	_
204-31	39926-39934	81571307	_
204-32	39934-39935	,	_
204-33	39936-39938	no	_
204-34	39938-39939	.	_
204-35	39940-39948	81371465	_
204-36	39949-39952	and	_
204-37	39953-39955	no	_
204-38	39955-39956	.	_
204-39	39957-39965	81671324	_
204-40	39965-39966	)	_
204-41	39966-39967	,	_
204-42	39968-39979	Fundamental	_
204-43	39980-39988	Research	_
204-44	39989-39994	Funds	_
204-45	39995-39998	for	_
204-46	39999-40006	Central	_
204-47	40007-40019	Universities	_
204-48	40020-40022	of	_
204-49	40023-40026	the	_
204-50	40027-40034	Central	_
204-51	40035-40040	South	_
204-52	40041-40051	University	_
204-53	40052-40053	(	_
204-54	40053-40055	no	_
204-55	40055-40056	.	_
204-56	40057-40068	2016zzts148	_
204-57	40068-40069	)	_
204-58	40069-40070	,	_
204-59	40071-40079	National	_
204-60	40080-40085	Basic	_
204-61	40086-40094	Research	_
204-62	40095-40102	Program	_
204-63	40103-40105	of	_
204-64	40106-40111	China	_
204-65	40112-40113	(	_
204-66	40113-40116	973	_
204-67	40117-40124	Program	_
204-68	40124-40125	)	_
204-69	40126-40127	(	_
204-70	40127-40129	no	_
204-71	40129-40130	.	_
204-72	40131-40143	2015CB553504	_
204-73	40143-40144	)	_
204-74	40144-40145	,	_
204-75	40146-40154	National	_
204-76	40155-40158	Key	_
204-77	40159-40160	R	_
204-78	40161-40164	and	_
204-79	40165-40166	D	_
204-80	40167-40174	Program	_
204-81	40175-40177	of	_
204-82	40178-40183	China	_
204-83	40184-40185	(	_
204-84	40185-40187	no	_
204-85	40187-40188	.	_
204-86	40189-40203	2016YFC0800908	_
204-87	40203-40204	-	_
204-88	40204-40207	Z02	_
204-89	40207-40208	)	_
204-90	40208-40209	,	_
204-91	40210-40213	and	_
204-92	40214-40217	the	_
204-93	40218-40226	National	_
204-94	40227-40237	Institutes	_
204-95	40238-40240	of	_
204-96	40241-40247	Health	_
204-97	40248-40249	(	_
204-98	40249-40252	K01	_
204-99	40253-40261	DA042998	_
204-100	40261-40262	,	_
204-101	40263-40266	R01	_
204-102	40267-40275	DA039136	_
204-103	40275-40276	)	_
204-104	40276-40277	.	_

#Text=Statement of Interest
#Text=The authors declare no conflicts of interest with the content of the manuscript.
205-1	40278-40287	Statement	_
205-2	40288-40290	of	_
205-3	40291-40299	Interest	_
205-4	40301-40304	The	_
205-5	40305-40312	authors	_
205-6	40313-40320	declare	_
205-7	40321-40323	no	_
205-8	40324-40333	conflicts	_
205-9	40334-40336	of	_
205-10	40337-40345	interest	_
205-11	40346-40350	with	_
205-12	40351-40354	the	_
205-13	40355-40362	content	_
205-14	40363-40365	of	_
205-15	40366-40369	the	_
205-16	40370-40380	manuscript	_
205-17	40380-40381	.	_

#Text=Dr Potenza has consulted for Rivermend Health, Opiant/Lightlake Therapeutics, Addiction Policy Forum, Jazz Pharmaceuticals, and Game Day Data, LLC; has received research support from the Mohegan Sun Casino and the National Center for Responsible Gaming; and has consulted for and/or advised gambling and legal entities on issues related to impulse-control/addictive disorders.
206-1	40382-40384	Dr	_
206-2	40385-40392	Potenza	_
206-3	40393-40396	has	_
206-4	40397-40406	consulted	_
206-5	40407-40410	for	_
206-6	40411-40420	Rivermend	_
206-7	40421-40427	Health	_
206-8	40427-40428	,	_
206-9	40429-40435	Opiant	_
206-10	40435-40436	/	_
206-11	40436-40445	Lightlake	_
206-12	40446-40458	Therapeutics	_
206-13	40458-40459	,	_
206-14	40460-40469	Addiction	_
206-15	40470-40476	Policy	_
206-16	40477-40482	Forum	_
206-17	40482-40483	,	_
206-18	40484-40488	Jazz	_
206-19	40489-40504	Pharmaceuticals	_
206-20	40504-40505	,	_
206-21	40506-40509	and	_
206-22	40510-40514	Game	_
206-23	40515-40518	Day	_
206-24	40519-40523	Data	_
206-25	40523-40524	,	_
206-26	40525-40528	LLC	_
206-27	40528-40529	;	_
206-28	40530-40533	has	_
206-29	40534-40542	received	_
206-30	40543-40551	research	_
206-31	40552-40559	support	_
206-32	40560-40564	from	_
206-33	40565-40568	the	_
206-34	40569-40576	Mohegan	_
206-35	40577-40580	Sun	_
206-36	40581-40587	Casino	_
206-37	40588-40591	and	_
206-38	40592-40595	the	_
206-39	40596-40604	National	_
206-40	40605-40611	Center	_
206-41	40612-40615	for	_
206-42	40616-40627	Responsible	_
206-43	40628-40634	Gaming	_
206-44	40634-40635	;	_
206-45	40636-40639	and	_
206-46	40640-40643	has	_
206-47	40644-40653	consulted	_
206-48	40654-40657	for	_
206-49	40658-40661	and	_
206-50	40661-40662	/	_
206-51	40662-40664	or	_
206-52	40665-40672	advised	_
206-53	40673-40681	gambling	_
206-54	40682-40685	and	_
206-55	40686-40691	legal	_
206-56	40692-40700	entities	_
206-57	40701-40703	on	_
206-58	40704-40710	issues	_
206-59	40711-40718	related	_
206-60	40719-40721	to	_
206-61	40722-40737	impulse-control	_
206-62	40737-40738	/	_
206-63	40738-40747	addictive	_
206-64	40748-40757	disorders	_
206-65	40757-40758	.	_

#Text=References
#Text=Neurofunctional reward processing changes in cocaine dependence during recovery
#Text=Acquired personality disturbances associated with bilateral damage to the ventromedial prefrontal region
#Text=Decision-making deficits, linked to a dysfunctional ventromedial prefrontal cortex, revealed in alcohol and stimulant abusers
#Text=Choosing the lesser of two evils, the better of two goods: specifying the roles of ventromedial prefrontal cortex and dorsal anterior cingulate in object choice
#Text=Chronic pre-exposure to methamphetamine following 31 days of withdrawal impairs sexual performance but not sexual conditioning in male Japanese quail
#Text=Substance use disorders and sexual behavior; the effects of alcohol and drugs on patients’ sexual thoughts, feelings and behavior
#Text=Cognitive behavioral interventions for alcohol and drug use disorders: through the stage model and back again
#Text=Applying extinction research and theory to cue-exposure addiction treatments
#Text=A universal role of the ventral striatum in reward-based learning: evidence from human studies
#Text=Associative processes in addiction and reward.
207-1	40759-40769	References	_
207-2	40770-40785	Neurofunctional	_
207-3	40786-40792	reward	_
207-4	40793-40803	processing	_
207-5	40804-40811	changes	_
207-6	40812-40814	in	_
207-7	40815-40822	cocaine	_
207-8	40823-40833	dependence	_
207-9	40834-40840	during	_
207-10	40841-40849	recovery	_
207-11	40850-40858	Acquired	_
207-12	40859-40870	personality	_
207-13	40871-40883	disturbances	_
207-14	40884-40894	associated	_
207-15	40895-40899	with	_
207-16	40900-40909	bilateral	_
207-17	40910-40916	damage	_
207-18	40917-40919	to	_
207-19	40920-40923	the	_
207-20	40924-40936	ventromedial	_
207-21	40937-40947	prefrontal	_
207-22	40948-40954	region	_
207-23	40955-40970	Decision-making	_
207-24	40971-40979	deficits	_
207-25	40979-40980	,	_
207-26	40981-40987	linked	_
207-27	40988-40990	to	_
207-28	40991-40992	a	_
207-29	40993-41006	dysfunctional	_
207-30	41007-41019	ventromedial	_
207-31	41020-41030	prefrontal	_
207-32	41031-41037	cortex	_
207-33	41037-41038	,	_
207-34	41039-41047	revealed	_
207-35	41048-41050	in	_
207-36	41051-41058	alcohol	_
207-37	41059-41062	and	_
207-38	41063-41072	stimulant	_
207-39	41073-41080	abusers	_
207-40	41081-41089	Choosing	_
207-41	41090-41093	the	_
207-42	41094-41100	lesser	_
207-43	41101-41103	of	_
207-44	41104-41107	two	_
207-45	41108-41113	evils	_
207-46	41113-41114	,	_
207-47	41115-41118	the	_
207-48	41119-41125	better	_
207-49	41126-41128	of	_
207-50	41129-41132	two	_
207-51	41133-41138	goods	_
207-52	41138-41139	:	_
207-53	41140-41150	specifying	_
207-54	41151-41154	the	_
207-55	41155-41160	roles	_
207-56	41161-41163	of	_
207-57	41164-41176	ventromedial	_
207-58	41177-41187	prefrontal	_
207-59	41188-41194	cortex	_
207-60	41195-41198	and	_
207-61	41199-41205	dorsal	_
207-62	41206-41214	anterior	_
207-63	41215-41224	cingulate	_
207-64	41225-41227	in	_
207-65	41228-41234	object	_
207-66	41235-41241	choice	_
207-67	41242-41249	Chronic	_
207-68	41250-41262	pre-exposure	_
207-69	41263-41265	to	_
207-70	41266-41281	methamphetamine	_
207-71	41282-41291	following	_
207-72	41292-41294	31	_
207-73	41295-41299	days	_
207-74	41300-41302	of	_
207-75	41303-41313	withdrawal	_
207-76	41314-41321	impairs	_
207-77	41322-41328	sexual	_
207-78	41329-41340	performance	_
207-79	41341-41344	but	_
207-80	41345-41348	not	_
207-81	41349-41355	sexual	_
207-82	41356-41368	conditioning	_
207-83	41369-41371	in	_
207-84	41372-41376	male	_
207-85	41377-41385	Japanese	_
207-86	41386-41391	quail	_
207-87	41392-41401	Substance	_
207-88	41402-41405	use	_
207-89	41406-41415	disorders	_
207-90	41416-41419	and	_
207-91	41420-41426	sexual	_
207-92	41427-41435	behavior	_
207-93	41435-41436	;	_
207-94	41437-41440	the	_
207-95	41441-41448	effects	_
207-96	41449-41451	of	_
207-97	41452-41459	alcohol	_
207-98	41460-41463	and	_
207-99	41464-41469	drugs	_
207-100	41470-41472	on	_
207-101	41473-41481	patients	_
207-102	41481-41482	’	_
207-103	41483-41489	sexual	_
207-104	41490-41498	thoughts	_
207-105	41498-41499	,	_
207-106	41500-41508	feelings	_
207-107	41509-41512	and	_
207-108	41513-41521	behavior	_
207-109	41522-41531	Cognitive	_
207-110	41532-41542	behavioral	_
207-111	41543-41556	interventions	_
207-112	41557-41560	for	_
207-113	41561-41568	alcohol	_
207-114	41569-41572	and	_
207-115	41573-41577	drug	_
207-116	41578-41581	use	_
207-117	41582-41591	disorders	_
207-118	41591-41592	:	_
207-119	41593-41600	through	_
207-120	41601-41604	the	_
207-121	41605-41610	stage	_
207-122	41611-41616	model	_
207-123	41617-41620	and	_
207-124	41621-41625	back	_
207-125	41626-41631	again	_
207-126	41632-41640	Applying	_
207-127	41641-41651	extinction	_
207-128	41652-41660	research	_
207-129	41661-41664	and	_
207-130	41665-41671	theory	_
207-131	41672-41674	to	_
207-132	41675-41687	cue-exposure	_
207-133	41688-41697	addiction	_
207-134	41698-41708	treatments	_
207-135	41709-41710	A	_
207-136	41711-41720	universal	_
207-137	41721-41725	role	_
207-138	41726-41728	of	_
207-139	41729-41732	the	_
207-140	41733-41740	ventral	_
207-141	41741-41749	striatum	_
207-142	41750-41752	in	_
207-143	41753-41765	reward-based	_
207-144	41766-41774	learning	_
207-145	41774-41775	:	_
207-146	41776-41784	evidence	_
207-147	41785-41789	from	_
207-148	41790-41795	human	_
207-149	41796-41803	studies	_
207-150	41804-41815	Associative	_
207-151	41816-41825	processes	_
207-152	41826-41828	in	_
207-153	41829-41838	addiction	_
207-154	41839-41842	and	_
207-155	41843-41849	reward	_
207-156	41849-41850	.	_

#Text=The role of amygdala-ventral striatal subsystems
#Text=From the ventral to the dorsal striatum: devolving views of their roles in drug addiction
#Text=The activation of attentional networks
#Text=Inhibitory control is slowed in patients with right superior medial frontal damage
#Text=Mixing pleasures: review of the effects of drugs on sex behavior in humans and animal models
#Text=Methamphetamine acts on subpopulations of neurons regulating sexual behavior in male rats
#Text=Concurrent exposure to methamphetamine and sexual behavior enhances subsequent drug reward and causes compulsive sexual behavior in male rats
#Text=Sexual HIV risk among gay and bisexual male methamphetamine abusers
#Text=Insula and drug cravings
#Text=Cue-induced cocaine craving: neuroanatomical specificity for drug users and drug stimuli
#Text=Effects of mindfulness-oriented recovery enhancement on reward responsiveness and opioid cue-reactivity
#Text=Activation of prefrontal cortex and anterior thalamus in alcoholic subjects on exposure to alcohol-specific cues
#Text=Determining a role for ventromedial prefrontal cortex in encoding action-based value signals during reward-related decision making
#Text=Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex
#Text=Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications
#Text=Bidirectional modulation of goal-directed actions by prefrontal cortical dopamine
#Text=The neural mechanisms of top-down attentional control
#Text=Response inhibition and impulsivity: an fMRI study
#Text=Craving responses to methamphetamine and sexual visual cues in individuals with methamphetamine use disorder after long-term drug rehabilitation
#Text=The danger of being inattentive - ADHD symptoms and risky sexual behaviour in Russian adolescents
#Text=Brain fMRI reactivity to smoking-related images before and during extended smoking abstinence
#Text=Brain reactivity to smoking cues prior to smoking cessation predicts ability to maintain tobacco abstinence
#Text=Increased self-reported impulsivity in methamphetamine users maintaining drug abstinence
#Text=The neural basis of addiction: a pathology of motivation and choice
#Text=A region of mesial prefrontal cortex tracks monetarily rewarding outcomes: characterization with rapid event-related fMRI
#Text=Brain activity during cocaine craving and gambling urges: an fMRI study
#Text=Risky decision making, prefrontal cortex, and mesocorticolimbic functional connectivity in methamphetamine dependence
#Text=Similarities and differences between pathological gambling and substance use disorders: a focus on impulsivity and compulsivity
#Text=Relationships among impulsive, addictive and sexual tendencies and behaviours: a systematic review of experimental and prospective studies in humans
#Text=Reliability and validity of an adapted Chinese version of Barratt Impulsiveness Scale
#Text=Abstinence-induced changes in self-report craving correlate with event-related FMRI responses to smoking cues
#Text=Modelling group-level repeated measures of neuroimaging data using the univariate general linear model
#Text=“I use weed for my ADHD”: a qualitative analysis of online forum discussions on cannabis use and ADHD
#Text=Methamphetamine use and sexual and injection risk behaviors among out-of-treatment injection drug users
#Text=Differential brain activity in alcoholics and social drinkers to alcohol cues: relationship to craving
#Text=The insula: a critical neural substrate for craving and drug seeking under conflict and risk
#Text=The effect of repeated exposure to virtual gambling cues on the urge to gamble
#Text=Factor structure of the Barratt impulsiveness scale
#Text=Behavioral and functional neuroimaging evidence for prefrontal dysfunction in methamphetamine-dependent subjects
#Text=The finding of casual sex partners on the internet, methamphetamine use for sexual pleasure, and incidence of HIV infection among men who have sex with men in Bangkok, Thailand: an observational cohort study
#Text=Cocaine self-administration produces a progressive involvement of limbic, association, and sensorimotor striatal domains
#Text=Neural correlates of stress-induced and cue-induced drug craving: influences of sex and cocaine dependence
#Text=Cognitive deficits in individuals with methamphetamine use disorder: a meta-analysis
#Text=The relationship between years of cocaine use and brain activation to cocaine and response inhibition cues
#Text=
#Text=Drugs and sexual effects: role of drug type and gender
#Text=Repetitive transcranial magnetic stimulation of the superior frontal gyrus modulates craving for cigarettes
#Text=Action sets and decisions in the medial frontal cortex
#Text=Neural correlates of sexual arousal in homosexual and heterosexual men
#Text=Impaired prefrontal cortical function and disrupted adaptive cognitive control in methamphetamine abusers: a functional magnetic resonance imaging study
#Text=Impairment of fronto-striatal and parietal cerebral networks correlates with attention deficit hyperactivity disorder (ADHD) psychopathology in adults - a functional magnetic resonance imaging (fMRI) study
#Text=The role of dorsal vs ventral striatal pathways in cocaine-seeking behavior after prolonged abstinence in rats
#Text=Motivations associated with methamphetamine use among HIV+ men who have sex with men
#Text=Female methamphetamine users: social characteristics and sexual risk behavior
#Text=Targeting extinction and reconsolidation mechanisms to combat the impact of drug cues on addiction
#Text=Effect of drug use and influence of abstinence on sexual functioning in a Spanish male drug‐dependent sample: a multisite study
#Text=Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence
#Text=The addicted human brain: insights from imaging studies
#Text=Neurobiologic advances from the brain disease model of addiction
#Text=Methamphetamine activates reward circuitry in drug naïve human subjects
#Text=Initial, habitual and compulsive alcohol use is characterized by a shift of cue processing from ventral to dorsal striatum
#Text=Effects of cue-exposure treatment on neural cue reactivity in alcohol dependence: a randomized trial
#Text=Partial recovery of brain metabolism in methamphetamine abusers after protracted abstinence
#Text=Functional magnetic resonance imaging of cocaine craving
#Text=Do individuals with ADHD self-medicate with cigarettes and substances of abuse?
208-1	41851-41854	The	_
208-2	41855-41859	role	_
208-3	41860-41862	of	_
208-4	41863-41879	amygdala-ventral	_
208-5	41880-41888	striatal	_
208-6	41889-41899	subsystems	_
208-7	41900-41904	From	_
208-8	41905-41908	the	_
208-9	41909-41916	ventral	_
208-10	41917-41919	to	_
208-11	41920-41923	the	_
208-12	41924-41930	dorsal	_
208-13	41931-41939	striatum	_
208-14	41939-41940	:	_
208-15	41941-41950	devolving	_
208-16	41951-41956	views	_
208-17	41957-41959	of	_
208-18	41960-41965	their	_
208-19	41966-41971	roles	_
208-20	41972-41974	in	_
208-21	41975-41979	drug	_
208-22	41980-41989	addiction	_
208-23	41990-41993	The	_
208-24	41994-42004	activation	_
208-25	42005-42007	of	_
208-26	42008-42019	attentional	_
208-27	42020-42028	networks	_
208-28	42029-42039	Inhibitory	_
208-29	42040-42047	control	_
208-30	42048-42050	is	_
208-31	42051-42057	slowed	_
208-32	42058-42060	in	_
208-33	42061-42069	patients	_
208-34	42070-42074	with	_
208-35	42075-42080	right	_
208-36	42081-42089	superior	_
208-37	42090-42096	medial	_
208-38	42097-42104	frontal	_
208-39	42105-42111	damage	_
208-40	42112-42118	Mixing	_
208-41	42119-42128	pleasures	_
208-42	42128-42129	:	_
208-43	42130-42136	review	_
208-44	42137-42139	of	_
208-45	42140-42143	the	_
208-46	42144-42151	effects	_
208-47	42152-42154	of	_
208-48	42155-42160	drugs	_
208-49	42161-42163	on	_
208-50	42164-42167	sex	_
208-51	42168-42176	behavior	_
208-52	42177-42179	in	_
208-53	42180-42186	humans	_
208-54	42187-42190	and	_
208-55	42191-42197	animal	_
208-56	42198-42204	models	_
208-57	42205-42220	Methamphetamine	_
208-58	42221-42225	acts	_
208-59	42226-42228	on	_
208-60	42229-42243	subpopulations	_
208-61	42244-42246	of	_
208-62	42247-42254	neurons	_
208-63	42255-42265	regulating	_
208-64	42266-42272	sexual	_
208-65	42273-42281	behavior	_
208-66	42282-42284	in	_
208-67	42285-42289	male	_
208-68	42290-42294	rats	_
208-69	42295-42305	Concurrent	_
208-70	42306-42314	exposure	_
208-71	42315-42317	to	_
208-72	42318-42333	methamphetamine	_
208-73	42334-42337	and	_
208-74	42338-42344	sexual	_
208-75	42345-42353	behavior	_
208-76	42354-42362	enhances	_
208-77	42363-42373	subsequent	_
208-78	42374-42378	drug	_
208-79	42379-42385	reward	_
208-80	42386-42389	and	_
208-81	42390-42396	causes	_
208-82	42397-42407	compulsive	_
208-83	42408-42414	sexual	_
208-84	42415-42423	behavior	_
208-85	42424-42426	in	_
208-86	42427-42431	male	_
208-87	42432-42436	rats	_
208-88	42437-42443	Sexual	_
208-89	42444-42447	HIV	_
208-90	42448-42452	risk	_
208-91	42453-42458	among	_
208-92	42459-42462	gay	_
208-93	42463-42466	and	_
208-94	42467-42475	bisexual	_
208-95	42476-42480	male	_
208-96	42481-42496	methamphetamine	_
208-97	42497-42504	abusers	_
208-98	42505-42511	Insula	_
208-99	42512-42515	and	_
208-100	42516-42520	drug	_
208-101	42521-42529	cravings	_
208-102	42530-42541	Cue-induced	_
208-103	42542-42549	cocaine	_
208-104	42550-42557	craving	_
208-105	42557-42558	:	_
208-106	42559-42574	neuroanatomical	_
208-107	42575-42586	specificity	_
208-108	42587-42590	for	_
208-109	42591-42595	drug	_
208-110	42596-42601	users	_
208-111	42602-42605	and	_
208-112	42606-42610	drug	_
208-113	42611-42618	stimuli	_
208-114	42619-42626	Effects	_
208-115	42627-42629	of	_
208-116	42630-42650	mindfulness-oriented	_
208-117	42651-42659	recovery	_
208-118	42660-42671	enhancement	_
208-119	42672-42674	on	_
208-120	42675-42681	reward	_
208-121	42682-42696	responsiveness	_
208-122	42697-42700	and	_
208-123	42701-42707	opioid	_
208-124	42708-42722	cue-reactivity	_
208-125	42723-42733	Activation	_
208-126	42734-42736	of	_
208-127	42737-42747	prefrontal	_
208-128	42748-42754	cortex	_
208-129	42755-42758	and	_
208-130	42759-42767	anterior	_
208-131	42768-42776	thalamus	_
208-132	42777-42779	in	_
208-133	42780-42789	alcoholic	_
208-134	42790-42798	subjects	_
208-135	42799-42801	on	_
208-136	42802-42810	exposure	_
208-137	42811-42813	to	_
208-138	42814-42830	alcohol-specific	_
208-139	42831-42835	cues	_
208-140	42836-42847	Determining	_
208-141	42848-42849	a	_
208-142	42850-42854	role	_
208-143	42855-42858	for	_
208-144	42859-42871	ventromedial	_
208-145	42872-42882	prefrontal	_
208-146	42883-42889	cortex	_
208-147	42890-42892	in	_
208-148	42893-42901	encoding	_
208-149	42902-42914	action-based	_
208-150	42915-42920	value	_
208-151	42921-42928	signals	_
208-152	42929-42935	during	_
208-153	42936-42950	reward-related	_
208-154	42951-42959	decision	_
208-155	42960-42966	making	_
208-156	42967-42971	Drug	_
208-157	42972-42981	addiction	_
208-158	42982-42985	and	_
208-159	42986-42989	its	_
208-160	42990-43000	underlying	_
208-161	43001-43016	neurobiological	_
208-162	43017-43022	basis	_
208-163	43022-43023	:	_
208-164	43024-43036	neuroimaging	_
208-165	43037-43045	evidence	_
208-166	43046-43049	for	_
208-167	43050-43053	the	_
208-168	43054-43065	involvement	_
208-169	43066-43068	of	_
208-170	43069-43072	the	_
208-171	43073-43080	frontal	_
208-172	43081-43087	cortex	_
208-173	43088-43099	Dysfunction	_
208-174	43100-43102	of	_
208-175	43103-43106	the	_
208-176	43107-43117	prefrontal	_
208-177	43118-43124	cortex	_
208-178	43125-43127	in	_
208-179	43128-43137	addiction	_
208-180	43137-43138	:	_
208-181	43139-43151	neuroimaging	_
208-182	43152-43160	findings	_
208-183	43161-43164	and	_
208-184	43165-43173	clinical	_
208-185	43174-43186	implications	_
208-186	43187-43200	Bidirectional	_
208-187	43201-43211	modulation	_
208-188	43212-43214	of	_
208-189	43215-43228	goal-directed	_
208-190	43229-43236	actions	_
208-191	43237-43239	by	_
208-192	43240-43250	prefrontal	_
208-193	43251-43259	cortical	_
208-194	43260-43268	dopamine	_
208-195	43269-43272	The	_
208-196	43273-43279	neural	_
208-197	43280-43290	mechanisms	_
208-198	43291-43293	of	_
208-199	43294-43302	top-down	_
208-200	43303-43314	attentional	_
208-201	43315-43322	control	_
208-202	43323-43331	Response	_
208-203	43332-43342	inhibition	_
208-204	43343-43346	and	_
208-205	43347-43358	impulsivity	_
208-206	43358-43359	:	_
208-207	43360-43362	an	_
208-208	43363-43367	fMRI	_
208-209	43368-43373	study	_
208-210	43374-43381	Craving	_
208-211	43382-43391	responses	_
208-212	43392-43394	to	_
208-213	43395-43410	methamphetamine	_
208-214	43411-43414	and	_
208-215	43415-43421	sexual	_
208-216	43422-43428	visual	_
208-217	43429-43433	cues	_
208-218	43434-43436	in	_
208-219	43437-43448	individuals	_
208-220	43449-43453	with	_
208-221	43454-43469	methamphetamine	_
208-222	43470-43473	use	_
208-223	43474-43482	disorder	_
208-224	43483-43488	after	_
208-225	43489-43498	long-term	_
208-226	43499-43503	drug	_
208-227	43504-43518	rehabilitation	_
208-228	43519-43522	The	_
208-229	43523-43529	danger	_
208-230	43530-43532	of	_
208-231	43533-43538	being	_
208-232	43539-43550	inattentive	_
208-233	43551-43552	-	_
208-234	43553-43557	ADHD	_
208-235	43558-43566	symptoms	_
208-236	43567-43570	and	_
208-237	43571-43576	risky	_
208-238	43577-43583	sexual	_
208-239	43584-43593	behaviour	_
208-240	43594-43596	in	_
208-241	43597-43604	Russian	_
208-242	43605-43616	adolescents	_
208-243	43617-43622	Brain	_
208-244	43623-43627	fMRI	_
208-245	43628-43638	reactivity	_
208-246	43639-43641	to	_
208-247	43642-43657	smoking-related	_
208-248	43658-43664	images	_
208-249	43665-43671	before	_
208-250	43672-43675	and	_
208-251	43676-43682	during	_
208-252	43683-43691	extended	_
208-253	43692-43699	smoking	_
208-254	43700-43710	abstinence	_
208-255	43711-43716	Brain	_
208-256	43717-43727	reactivity	_
208-257	43728-43730	to	_
208-258	43731-43738	smoking	_
208-259	43739-43743	cues	_
208-260	43744-43749	prior	_
208-261	43750-43752	to	_
208-262	43753-43760	smoking	_
208-263	43761-43770	cessation	_
208-264	43771-43779	predicts	_
208-265	43780-43787	ability	_
208-266	43788-43790	to	_
208-267	43791-43799	maintain	_
208-268	43800-43807	tobacco	_
208-269	43808-43818	abstinence	_
208-270	43819-43828	Increased	_
208-271	43829-43842	self-reported	_
208-272	43843-43854	impulsivity	_
208-273	43855-43857	in	_
208-274	43858-43873	methamphetamine	_
208-275	43874-43879	users	_
208-276	43880-43891	maintaining	_
208-277	43892-43896	drug	_
208-278	43897-43907	abstinence	_
208-279	43908-43911	The	_
208-280	43912-43918	neural	_
208-281	43919-43924	basis	_
208-282	43925-43927	of	_
208-283	43928-43937	addiction	_
208-284	43937-43938	:	_
208-285	43939-43940	a	_
208-286	43941-43950	pathology	_
208-287	43951-43953	of	_
208-288	43954-43964	motivation	_
208-289	43965-43968	and	_
208-290	43969-43975	choice	_
208-291	43976-43977	A	_
208-292	43978-43984	region	_
208-293	43985-43987	of	_
208-294	43988-43994	mesial	_
208-295	43995-44005	prefrontal	_
208-296	44006-44012	cortex	_
208-297	44013-44019	tracks	_
208-298	44020-44030	monetarily	_
208-299	44031-44040	rewarding	_
208-300	44041-44049	outcomes	_
208-301	44049-44050	:	_
208-302	44051-44067	characterization	_
208-303	44068-44072	with	_
208-304	44073-44078	rapid	_
208-305	44079-44092	event-related	_
208-306	44093-44097	fMRI	_
208-307	44098-44103	Brain	_
208-308	44104-44112	activity	_
208-309	44113-44119	during	_
208-310	44120-44127	cocaine	_
208-311	44128-44135	craving	_
208-312	44136-44139	and	_
208-313	44140-44148	gambling	_
208-314	44149-44154	urges	_
208-315	44154-44155	:	_
208-316	44156-44158	an	_
208-317	44159-44163	fMRI	_
208-318	44164-44169	study	_
208-319	44170-44175	Risky	_
208-320	44176-44184	decision	_
208-321	44185-44191	making	_
208-322	44191-44192	,	_
208-323	44193-44203	prefrontal	_
208-324	44204-44210	cortex	_
208-325	44210-44211	,	_
208-326	44212-44215	and	_
208-327	44216-44233	mesocorticolimbic	_
208-328	44234-44244	functional	_
208-329	44245-44257	connectivity	_
208-330	44258-44260	in	_
208-331	44261-44276	methamphetamine	_
208-332	44277-44287	dependence	_
208-333	44288-44300	Similarities	_
208-334	44301-44304	and	_
208-335	44305-44316	differences	_
208-336	44317-44324	between	_
208-337	44325-44337	pathological	_
208-338	44338-44346	gambling	_
208-339	44347-44350	and	_
208-340	44351-44360	substance	_
208-341	44361-44364	use	_
208-342	44365-44374	disorders	_
208-343	44374-44375	:	_
208-344	44376-44377	a	_
208-345	44378-44383	focus	_
208-346	44384-44386	on	_
208-347	44387-44398	impulsivity	_
208-348	44399-44402	and	_
208-349	44403-44415	compulsivity	_
208-350	44416-44429	Relationships	_
208-351	44430-44435	among	_
208-352	44436-44445	impulsive	_
208-353	44445-44446	,	_
208-354	44447-44456	addictive	_
208-355	44457-44460	and	_
208-356	44461-44467	sexual	_
208-357	44468-44478	tendencies	_
208-358	44479-44482	and	_
208-359	44483-44493	behaviours	_
208-360	44493-44494	:	_
208-361	44495-44496	a	_
208-362	44497-44507	systematic	_
208-363	44508-44514	review	_
208-364	44515-44517	of	_
208-365	44518-44530	experimental	_
208-366	44531-44534	and	_
208-367	44535-44546	prospective	_
208-368	44547-44554	studies	_
208-369	44555-44557	in	_
208-370	44558-44564	humans	_
208-371	44565-44576	Reliability	_
208-372	44577-44580	and	_
208-373	44581-44589	validity	_
208-374	44590-44592	of	_
208-375	44593-44595	an	_
208-376	44596-44603	adapted	_
208-377	44604-44611	Chinese	_
208-378	44612-44619	version	_
208-379	44620-44622	of	_
208-380	44623-44630	Barratt	_
208-381	44631-44644	Impulsiveness	_
208-382	44645-44650	Scale	_
208-383	44651-44669	Abstinence-induced	_
208-384	44670-44677	changes	_
208-385	44678-44680	in	_
208-386	44681-44692	self-report	_
208-387	44693-44700	craving	_
208-388	44701-44710	correlate	_
208-389	44711-44715	with	_
208-390	44716-44729	event-related	_
208-391	44730-44734	FMRI	_
208-392	44735-44744	responses	_
208-393	44745-44747	to	_
208-394	44748-44755	smoking	_
208-395	44756-44760	cues	_
208-396	44761-44770	Modelling	_
208-397	44771-44782	group-level	_
208-398	44783-44791	repeated	_
208-399	44792-44800	measures	_
208-400	44801-44803	of	_
208-401	44804-44816	neuroimaging	_
208-402	44817-44821	data	_
208-403	44822-44827	using	_
208-404	44828-44831	the	_
208-405	44832-44842	univariate	_
208-406	44843-44850	general	_
208-407	44851-44857	linear	_
208-408	44858-44863	model	_
208-409	44864-44865	“	_
208-410	44865-44866	I	_
208-411	44867-44870	use	_
208-412	44871-44875	weed	_
208-413	44876-44879	for	_
208-414	44880-44882	my	_
208-415	44883-44887	ADHD	_
208-416	44887-44888	”	_
208-417	44888-44889	:	_
208-418	44890-44891	a	_
208-419	44892-44903	qualitative	_
208-420	44904-44912	analysis	_
208-421	44913-44915	of	_
208-422	44916-44922	online	_
208-423	44923-44928	forum	_
208-424	44929-44940	discussions	_
208-425	44941-44943	on	_
208-426	44944-44952	cannabis	_
208-427	44953-44956	use	_
208-428	44957-44960	and	_
208-429	44961-44965	ADHD	_
208-430	44966-44981	Methamphetamine	_
208-431	44982-44985	use	_
208-432	44986-44989	and	_
208-433	44990-44996	sexual	_
208-434	44997-45000	and	_
208-435	45001-45010	injection	_
208-436	45011-45015	risk	_
208-437	45016-45025	behaviors	_
208-438	45026-45031	among	_
208-439	45032-45048	out-of-treatment	_
208-440	45049-45058	injection	_
208-441	45059-45063	drug	_
208-442	45064-45069	users	_
208-443	45070-45082	Differential	_
208-444	45083-45088	brain	_
208-445	45089-45097	activity	_
208-446	45098-45100	in	_
208-447	45101-45111	alcoholics	_
208-448	45112-45115	and	_
208-449	45116-45122	social	_
208-450	45123-45131	drinkers	_
208-451	45132-45134	to	_
208-452	45135-45142	alcohol	_
208-453	45143-45147	cues	_
208-454	45147-45148	:	_
208-455	45149-45161	relationship	_
208-456	45162-45164	to	_
208-457	45165-45172	craving	_
208-458	45173-45176	The	_
208-459	45177-45183	insula	_
208-460	45183-45184	:	_
208-461	45185-45186	a	_
208-462	45187-45195	critical	_
208-463	45196-45202	neural	_
208-464	45203-45212	substrate	_
208-465	45213-45216	for	_
208-466	45217-45224	craving	_
208-467	45225-45228	and	_
208-468	45229-45233	drug	_
208-469	45234-45241	seeking	_
208-470	45242-45247	under	_
208-471	45248-45256	conflict	_
208-472	45257-45260	and	_
208-473	45261-45265	risk	_
208-474	45266-45269	The	_
208-475	45270-45276	effect	_
208-476	45277-45279	of	_
208-477	45280-45288	repeated	_
208-478	45289-45297	exposure	_
208-479	45298-45300	to	_
208-480	45301-45308	virtual	_
208-481	45309-45317	gambling	_
208-482	45318-45322	cues	_
208-483	45323-45325	on	_
208-484	45326-45329	the	_
208-485	45330-45334	urge	_
208-486	45335-45337	to	_
208-487	45338-45344	gamble	_
208-488	45345-45351	Factor	_
208-489	45352-45361	structure	_
208-490	45362-45364	of	_
208-491	45365-45368	the	_
208-492	45369-45376	Barratt	_
208-493	45377-45390	impulsiveness	_
208-494	45391-45396	scale	_
208-495	45397-45407	Behavioral	_
208-496	45408-45411	and	_
208-497	45412-45422	functional	_
208-498	45423-45435	neuroimaging	_
208-499	45436-45444	evidence	_
208-500	45445-45448	for	_
208-501	45449-45459	prefrontal	_
208-502	45460-45471	dysfunction	_
208-503	45472-45474	in	_
208-504	45475-45500	methamphetamine-dependent	_
208-505	45501-45509	subjects	_
208-506	45510-45513	The	_
208-507	45514-45521	finding	_
208-508	45522-45524	of	_
208-509	45525-45531	casual	_
208-510	45532-45535	sex	_
208-511	45536-45544	partners	_
208-512	45545-45547	on	_
208-513	45548-45551	the	_
208-514	45552-45560	internet	_
208-515	45560-45561	,	_
208-516	45562-45577	methamphetamine	_
208-517	45578-45581	use	_
208-518	45582-45585	for	_
208-519	45586-45592	sexual	_
208-520	45593-45601	pleasure	_
208-521	45601-45602	,	_
208-522	45603-45606	and	_
208-523	45607-45616	incidence	_
208-524	45617-45619	of	_
208-525	45620-45623	HIV	_
208-526	45624-45633	infection	_
208-527	45634-45639	among	_
208-528	45640-45643	men	_
208-529	45644-45647	who	_
208-530	45648-45652	have	_
208-531	45653-45656	sex	_
208-532	45657-45661	with	_
208-533	45662-45665	men	_
208-534	45666-45668	in	_
208-535	45669-45676	Bangkok	_
208-536	45676-45677	,	_
208-537	45678-45686	Thailand	_
208-538	45686-45687	:	_
208-539	45688-45690	an	_
208-540	45691-45704	observational	_
208-541	45705-45711	cohort	_
208-542	45712-45717	study	_
208-543	45718-45725	Cocaine	_
208-544	45726-45745	self-administration	_
208-545	45746-45754	produces	_
208-546	45755-45756	a	_
208-547	45757-45768	progressive	_
208-548	45769-45780	involvement	_
208-549	45781-45783	of	_
208-550	45784-45790	limbic	_
208-551	45790-45791	,	_
208-552	45792-45803	association	_
208-553	45803-45804	,	_
208-554	45805-45808	and	_
208-555	45809-45821	sensorimotor	_
208-556	45822-45830	striatal	_
208-557	45831-45838	domains	_
208-558	45839-45845	Neural	_
208-559	45846-45856	correlates	_
208-560	45857-45859	of	_
208-561	45860-45874	stress-induced	_
208-562	45875-45878	and	_
208-563	45879-45890	cue-induced	_
208-564	45891-45895	drug	_
208-565	45896-45903	craving	_
208-566	45903-45904	:	_
208-567	45905-45915	influences	_
208-568	45916-45918	of	_
208-569	45919-45922	sex	_
208-570	45923-45926	and	_
208-571	45927-45934	cocaine	_
208-572	45935-45945	dependence	_
208-573	45946-45955	Cognitive	_
208-574	45956-45964	deficits	_
208-575	45965-45967	in	_
208-576	45968-45979	individuals	_
208-577	45980-45984	with	_
208-578	45985-46000	methamphetamine	_
208-579	46001-46004	use	_
208-580	46005-46013	disorder	_
208-581	46013-46014	:	_
208-582	46015-46016	a	_
208-583	46017-46030	meta-analysis	_
208-584	46031-46034	The	_
208-585	46035-46047	relationship	_
208-586	46048-46055	between	_
208-587	46056-46061	years	_
208-588	46062-46064	of	_
208-589	46065-46072	cocaine	_
208-590	46073-46076	use	_
208-591	46077-46080	and	_
208-592	46081-46086	brain	_
208-593	46087-46097	activation	_
208-594	46098-46100	to	_
208-595	46101-46108	cocaine	_
208-596	46109-46112	and	_
208-597	46113-46121	response	_
208-598	46122-46132	inhibition	_
208-599	46133-46137	cues	_
208-600	46139-46144	Drugs	_
208-601	46145-46148	and	_
208-602	46149-46155	sexual	_
208-603	46156-46163	effects	_
208-604	46163-46164	:	_
208-605	46165-46169	role	_
208-606	46170-46172	of	_
208-607	46173-46177	drug	_
208-608	46178-46182	type	_
208-609	46183-46186	and	_
208-610	46187-46193	gender	_
208-611	46194-46204	Repetitive	_
208-612	46205-46217	transcranial	_
208-613	46218-46226	magnetic	_
208-614	46227-46238	stimulation	_
208-615	46239-46241	of	_
208-616	46242-46245	the	_
208-617	46246-46254	superior	_
208-618	46255-46262	frontal	_
208-619	46263-46268	gyrus	_
208-620	46269-46278	modulates	_
208-621	46279-46286	craving	_
208-622	46287-46290	for	_
208-623	46291-46301	cigarettes	_
208-624	46302-46308	Action	_
208-625	46309-46313	sets	_
208-626	46314-46317	and	_
208-627	46318-46327	decisions	_
208-628	46328-46330	in	_
208-629	46331-46334	the	_
208-630	46335-46341	medial	_
208-631	46342-46349	frontal	_
208-632	46350-46356	cortex	_
208-633	46357-46363	Neural	_
208-634	46364-46374	correlates	_
208-635	46375-46377	of	_
208-636	46378-46384	sexual	_
208-637	46385-46392	arousal	_
208-638	46393-46395	in	_
208-639	46396-46406	homosexual	_
208-640	46407-46410	and	_
208-641	46411-46423	heterosexual	_
208-642	46424-46427	men	_
208-643	46428-46436	Impaired	_
208-644	46437-46447	prefrontal	_
208-645	46448-46456	cortical	_
208-646	46457-46465	function	_
208-647	46466-46469	and	_
208-648	46470-46479	disrupted	_
208-649	46480-46488	adaptive	_
208-650	46489-46498	cognitive	_
208-651	46499-46506	control	_
208-652	46507-46509	in	_
208-653	46510-46525	methamphetamine	_
208-654	46526-46533	abusers	_
208-655	46533-46534	:	_
208-656	46535-46536	a	_
208-657	46537-46547	functional	_
208-658	46548-46556	magnetic	_
208-659	46557-46566	resonance	_
208-660	46567-46574	imaging	_
208-661	46575-46580	study	_
208-662	46581-46591	Impairment	_
208-663	46592-46594	of	_
208-664	46595-46610	fronto-striatal	_
208-665	46611-46614	and	_
208-666	46615-46623	parietal	_
208-667	46624-46632	cerebral	_
208-668	46633-46641	networks	_
208-669	46642-46652	correlates	_
208-670	46653-46657	with	_
208-671	46658-46667	attention	_
208-672	46668-46675	deficit	_
208-673	46676-46689	hyperactivity	_
208-674	46690-46698	disorder	_
208-675	46699-46700	(	_
208-676	46700-46704	ADHD	_
208-677	46704-46705	)	_
208-678	46706-46721	psychopathology	_
208-679	46722-46724	in	_
208-680	46725-46731	adults	_
208-681	46732-46733	-	_
208-682	46734-46735	a	_
208-683	46736-46746	functional	_
208-684	46747-46755	magnetic	_
208-685	46756-46765	resonance	_
208-686	46766-46773	imaging	_
208-687	46774-46775	(	_
208-688	46775-46779	fMRI	_
208-689	46779-46780	)	_
208-690	46781-46786	study	_
208-691	46787-46790	The	_
208-692	46791-46795	role	_
208-693	46796-46798	of	_
208-694	46799-46805	dorsal	_
208-695	46806-46808	vs	_
208-696	46809-46816	ventral	_
208-697	46817-46825	striatal	_
208-698	46826-46834	pathways	_
208-699	46835-46837	in	_
208-700	46838-46853	cocaine-seeking	_
208-701	46854-46862	behavior	_
208-702	46863-46868	after	_
208-703	46869-46878	prolonged	_
208-704	46879-46889	abstinence	_
208-705	46890-46892	in	_
208-706	46893-46897	rats	_
208-707	46898-46909	Motivations	_
208-708	46910-46920	associated	_
208-709	46921-46925	with	_
208-710	46926-46941	methamphetamine	_
208-711	46942-46945	use	_
208-712	46946-46951	among	_
208-713	46952-46955	HIV	_
208-714	46955-46956	+	_
208-715	46957-46960	men	_
208-716	46961-46964	who	_
208-717	46965-46969	have	_
208-718	46970-46973	sex	_
208-719	46974-46978	with	_
208-720	46979-46982	men	_
208-721	46983-46989	Female	_
208-722	46990-47005	methamphetamine	_
208-723	47006-47011	users	_
208-724	47011-47012	:	_
208-725	47013-47019	social	_
208-726	47020-47035	characteristics	_
208-727	47036-47039	and	_
208-728	47040-47046	sexual	_
208-729	47047-47051	risk	_
208-730	47052-47060	behavior	_
208-731	47061-47070	Targeting	_
208-732	47071-47081	extinction	_
208-733	47082-47085	and	_
208-734	47086-47101	reconsolidation	_
208-735	47102-47112	mechanisms	_
208-736	47113-47115	to	_
208-737	47116-47122	combat	_
208-738	47123-47126	the	_
208-739	47127-47133	impact	_
208-740	47134-47136	of	_
208-741	47137-47141	drug	_
208-742	47142-47146	cues	_
208-743	47147-47149	on	_
208-744	47150-47159	addiction	_
208-745	47160-47166	Effect	_
208-746	47167-47169	of	_
208-747	47170-47174	drug	_
208-748	47175-47178	use	_
208-749	47179-47182	and	_
208-750	47183-47192	influence	_
208-751	47193-47195	of	_
208-752	47196-47206	abstinence	_
208-753	47207-47209	on	_
208-754	47210-47216	sexual	_
208-755	47217-47228	functioning	_
208-756	47229-47231	in	_
208-757	47232-47233	a	_
208-758	47234-47241	Spanish	_
208-759	47242-47246	male	_
208-760	47247-47261	drug‐dependent	_
208-761	47262-47268	sample	_
208-762	47268-47269	:	_
208-763	47270-47271	a	_
208-764	47272-47281	multisite	_
208-765	47282-47287	study	_
208-766	47288-47292	Loss	_
208-767	47293-47295	of	_
208-768	47296-47304	dopamine	_
208-769	47305-47317	transporters	_
208-770	47318-47320	in	_
208-771	47321-47336	methamphetamine	_
208-772	47337-47344	abusers	_
208-773	47345-47353	recovers	_
208-774	47354-47358	with	_
208-775	47359-47369	protracted	_
208-776	47370-47380	abstinence	_
208-777	47381-47384	The	_
208-778	47385-47393	addicted	_
208-779	47394-47399	human	_
208-780	47400-47405	brain	_
208-781	47405-47406	:	_
208-782	47407-47415	insights	_
208-783	47416-47420	from	_
208-784	47421-47428	imaging	_
208-785	47429-47436	studies	_
208-786	47437-47450	Neurobiologic	_
208-787	47451-47459	advances	_
208-788	47460-47464	from	_
208-789	47465-47468	the	_
208-790	47469-47474	brain	_
208-791	47475-47482	disease	_
208-792	47483-47488	model	_
208-793	47489-47491	of	_
208-794	47492-47501	addiction	_
208-795	47502-47517	Methamphetamine	_
208-796	47518-47527	activates	_
208-797	47528-47534	reward	_
208-798	47535-47544	circuitry	_
208-799	47545-47547	in	_
208-800	47548-47552	drug	_
208-801	47553-47558	naïve	_
208-802	47559-47564	human	_
208-803	47565-47573	subjects	_
208-804	47574-47581	Initial	_
208-805	47581-47582	,	_
208-806	47583-47591	habitual	_
208-807	47592-47595	and	_
208-808	47596-47606	compulsive	_
208-809	47607-47614	alcohol	_
208-810	47615-47618	use	_
208-811	47619-47621	is	_
208-812	47622-47635	characterized	_
208-813	47636-47638	by	_
208-814	47639-47640	a	_
208-815	47641-47646	shift	_
208-816	47647-47649	of	_
208-817	47650-47653	cue	_
208-818	47654-47664	processing	_
208-819	47665-47669	from	_
208-820	47670-47677	ventral	_
208-821	47678-47680	to	_
208-822	47681-47687	dorsal	_
208-823	47688-47696	striatum	_
208-824	47697-47704	Effects	_
208-825	47705-47707	of	_
208-826	47708-47720	cue-exposure	_
208-827	47721-47730	treatment	_
208-828	47731-47733	on	_
208-829	47734-47740	neural	_
208-830	47741-47744	cue	_
208-831	47745-47755	reactivity	_
208-832	47756-47758	in	_
208-833	47759-47766	alcohol	_
208-834	47767-47777	dependence	_
208-835	47777-47778	:	_
208-836	47779-47780	a	_
208-837	47781-47791	randomized	_
208-838	47792-47797	trial	_
208-839	47798-47805	Partial	_
208-840	47806-47814	recovery	_
208-841	47815-47817	of	_
208-842	47818-47823	brain	_
208-843	47824-47834	metabolism	_
208-844	47835-47837	in	_
208-845	47838-47853	methamphetamine	_
208-846	47854-47861	abusers	_
208-847	47862-47867	after	_
208-848	47868-47878	protracted	_
208-849	47879-47889	abstinence	_
208-850	47890-47900	Functional	_
208-851	47901-47909	magnetic	_
208-852	47910-47919	resonance	_
208-853	47920-47927	imaging	_
208-854	47928-47930	of	_
208-855	47931-47938	cocaine	_
208-856	47939-47946	craving	_
208-857	47947-47949	Do	_
208-858	47950-47961	individuals	_
208-859	47962-47966	with	_
208-860	47967-47971	ADHD	_
208-861	47972-47985	self-medicate	_
208-862	47986-47990	with	_
208-863	47991-48001	cigarettes	_
208-864	48002-48005	and	_
208-865	48006-48016	substances	_
208-866	48017-48019	of	_
208-867	48020-48025	abuse	_
208-868	48025-48026	?	_

#Text=Results from a controlled family study of ADHD
#Text=Dopamine, learning and motivation
209-1	48027-48034	Results	_
209-2	48035-48039	from	_
209-3	48040-48041	a	_
209-4	48042-48052	controlled	_
209-5	48053-48059	family	_
209-6	48060-48065	study	_
209-7	48066-48068	of	_
209-8	48069-48073	ADHD	_
209-9	48074-48082	Dopamine	_
209-10	48082-48083	,	_
209-11	48084-48092	learning	_
209-12	48093-48096	and	_
209-13	48097-48107	motivation	_
